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ABSTRACT 
 The clinical management of cancer has principally relied upon surgery, radiation therapy, and 
chemotherapy for many decades. Despite recent advances in molecularly-targeted diagnostic and therapeutic agents, 
the long-term survival rates in patients with solid malignancies including ovarian cancer have improved only 
incrementally. Nanotechnologies designed to locally interrogate and modulate the tumor microenvironment offer a 
promising opportunity to enhance existing treatment modalities and establish new therapeutic paradigms. By virtue 
of their elemental composition, geometry, and surface chemistry, nanomaterials can be engineered with optical and 
pharmacokinetic properties which permit these agents to localize, fluoresce, and deposit energy within tumors. 
Nanomaterials therefore provide a clear route towards future approaches for sensitive diagnosis and imaging of 
tumors and targeted therapeutic delivery.  
This thesis describes the development and application of optically-active nanomaterials for non-invasive 
imaging, localized heating of deep tumors, and enhanced therapeutic delivery, each explored in the context of 
ovarian cancer. Because effective cytoreduction of ovarian tumors remains one of the most significant prognostic 
factors for long-term survival, the first part of this thesis explores a nanomaterial-inspired imaging approach for 
guiding cytoreductive surgery. Single-walled carbon nanotubes are shown to selectively target deep ovarian tumors 
and through their fluorescence in the second near-infrared window, guide cytoreduction of sub-millimeter tumors. 
The second component of the thesis focuses on the application of plasmonic gold nanorods for locally heating 
tumors in clinically-relevant anatomical contexts, including photothermal ablation of a genetically-engineered 
sarcoma model and milder heating of orthotopic ovarian xenografts using an implanted near-infrared source. Lastly, 
because therapeutic delivery to solid tumors can be enhanced by heating, the final section of the thesis explores the 
effects of gold nanorod-mediated heating on therapeutic delivery in ovarian tumor models. In the clinic, 
chemotherapy is administered in multiple cycles spanning weeks to months, so we investigated multiple exposures 
to gold nanorod heating; a transient period of thermotolerance was observed and a role for the endothelial heat shock 
response identified. Collectively, this work demonstrates how next-generation nanomaterials may prove useful in the 
clinic for diverse applications in cancer management ranging from imaging to drug delivery.  
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EPIGRAPH 
 
 
 
 
 
“What would the properties of materials be if we could really arrange the atoms the way we want 
them? […] I can hardly doubt that when we have some control of the arrangement of things on a 
small scale we will get an enormously greater range of possible properties that substances can 
have, and of different things that we can do.”  
– Richard Feynman, “Plenty of Room at the Bottom” (1959) 
 
 
 
“Much has been written about the nature of scientific discovery. […] Originality and simplicity 
are certainly crucial elements. Even more important are the intellectual fearlessness and emotional 
drive to put it all together, step forward, do the right experiment, promulgate it to the world, defend 
the new insights, and go forward to further innovation.”  
 
– Solomon Snyder, “The Audacity Principle in Science” (2005) 
 
 
 
 
“To see the world in a grain of sand,  
And a heaven in a wild flower,  
Hold infinity in the palm of your hand,  
And eternity in an hour.”  
 
– William Blake (1863) 
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CHAPTER 1. BACKGROUND AND SIGNIFICANCE  
1.0   Ovarian Cancer 
1.0.1 Epidemiology 
Ovarian cancer is one of the most lethal malignancies for women in the United States and 
worldwide. In 2014, approximately 22,000 new cases will be diagnosed and more than 14,000 
deaths will result from this disease.[1] The majority of women present with ovarian cancer in the 
fifth and sixth decades of life, with an overall lifetime risk of developing ovarian cancer of 1 in 
70.[2] While screening for ovarian cancer in the general population is not currently 
recommended, women who have a family history of breast or ovarian cancer, infertility, 
endometriosis, or are at an otherwise increased risk may benefit from disease screening in certain 
cases. Epidemiological studies suggest that women who have been pregnant, breastfeed, or use 
oral contraception are at a reduced risk of developing ovarian cancer.   
For patients deemed to be at high risk for developing ovarian cancer, several screening 
methods have been proposed. Genetic mutations in the DNA repair genes BRCA1 and BRCA2 
confer significantly increased risk; women with mutant alleles in these genes have a 15 to 40 
percent chance of being diagnosed with ovarian cancer during their lifetime, which is 
substantially higher than the rate in the general population. The prevalence of certain mutant 
BRCA alleles in Ashkenazi Jewish populations is 2.5 percent compared with a population 
prevalence of 0.2 percent.[3] Other genetic mutations and syndromes that may predispose 
patients to ovarian cancer include the DNA mismatch repair genes MSH2 and MLH1 associated 
with Lynch syndrome or HNPCC. Blood biomarkers, most notably CA-125 which is elevated in 
half of women with early stage ovarian cancer, have been investigated but have low specificity 
for disease detection.[4] While CA-125 is useful for diagnosing recurrent disease in patients who 
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have undergone treatment, it is not useful for general population screening.[2] Non-invasive 
imaging methods including transvaginal and abdominal ultrasound can be useful for 
differentiating between simple and complex cysts, and this can guide the decision to pursue the 
diagnosis further or monitor in an outpatient setting.  
Despite gradual advances in the diagnosis and clinical management of ovarian cancer, 
long-term survival rates of 20-40% have remained static for several decades (Fig. 1.1).[5, 6] The 
majority of women present with advanced stage disease (Stage III/IV) in which tumors are 
disseminated throughout the peritoneal cavity.[2, 7, 8] These patients typically undergo a 
rigorous treatment regimen consisting of surgical resection (cytoreduction) and chemotherapy, 
but eventual relapse of drug-resistant disease is common, leading to an average overall survival 
of approximately one year. Clinical evidence has established that two important criteria for 
extending overall survival are the effectiveness of cytoreduction (i.e., how much tumor is 
resected during surgery) and intraperitoneal (versus intravenous) administration of 
chemotherapy. [2, 5, 8-17] These clinical findings point to specific areas in which technological 
innovations could yield benefits to ovarian cancer patients.    
 
 
Figure 1.1. Rates of new diagnosed cases and deaths from ovarian cancer. (From SEER 
9 Incidence & U.S. Mortality 1975-2010) 
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1.0.2 Clinical Management 
1.0.2.1 Diagnostic Imaging 
Several imaging modalities are currently used for diagnosis and management of ovarian 
cancer. Broadly, these imaging studies are used to distinguish between cancerous lesions and 
benign cysts, determine the extent of disease and necessity of cytoreduction, and monitor 
response to chemotherapy and disease progression. The primary imaging modalities include 
ultrasound, computed tomography (CT), positron emission tomography (PET), and magnetic 
resonance imaging (MRI). More recently, optical imaging probes in the visible and near- infrared 
(NIR) spectral regimes have been investigated for intraoperative utility.  
Pelvic and abdominal ultrasound is commonly used for screening procedures to 
distinguish benign cystic lesions from tumors. Ultrasound transmits acoustic waves with 
frequencies on the order of 1 MHz into the body where they interact with and reveal structural 
and pathologic features of soft tissues. Ultrasound offers a fast, inexpensive, safe, and non-
invasive method for obtaining structural information in the pelvis. The technique is limited by 
comparatively lower spatial resolution, and while it is effective at distinguishing liquid from 
solid structures, it is less capable of distinguishing between solid tumors and soft tissues in the 
peritoneum. Nevertheless, because ultrasound offers roughly equivalent predictive qualities for 
less cost, it is the recommended method for an initial diagnostic evaluation. For monitoring 
disease recurrence, transvaginal ultrasound may have utility in combination with CA-125 and 
physical examination as well.[18] 
Computed tomography (CT) offers another method for obtaining structural information in 
the peritoneum. CT imaging involves a series of x-ray images that are reconstructed into a three-
dimensional representation of the region of interest. CT offers excellent spatial resolution, and 
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when used with vascular contrast agents, can be helpful in delineating tumor from normal tissue 
in the peritoneum. CT imaging is widely used for cancer diagnosis in diverse tissue sites. One 
anatomic region where CT has proven particularly useful is the lung because the air-tissue 
interface provides a direct way to distinguish solid tumor from background with high contrast. 
CT subjects patients to a significant amount of ionizing radiation so it is undesirable for patients 
to undergo CT scanning unless there is a strong clinical rationale for doing so. Additionally, 
allergic reactions and nephropathy induced by vascular contrast agents represents a finite risk to 
patients. Finally, the lengthy period of image processing required to generate a three-dimensional 
representations is not particularly well-suited for intraoperative procedures where rapid feedback 
is more desirable. For ovarian cancer, the sensitivity of CT imaging for monitoring disease 
recurrence varies widely (32-84%) based on the anatomic location and size of the tumors and is 
therefore not ideally suited for diagnostic applications in this disease.[19, 20] 
More recently, CT imaging has been combined with positron emission tomography 
(PET). PET imaging relies of the use of functional imaging probes containing radioactive 
isotopes. Many PET tracers have been developed to probe various biological and pathological 
processes, with fluorodeoxyglucose (18F-FDG) as the prototypical agent to visualize glucose 
metabolism in metabolically active tissues including tumors and the brain. PET offers excellent 
sensitivity for larger tumors, but sensitivity decreases significantly for smaller tumor nodules less 
than 1 centimeter.[18, 21-23] Because many of these radioactive probes have half-lives on the 
order of minutes to hours, PET-CT facilities typically require a cyclotron on site to synthesize 
the imaging probes immediately prior to use. This creates a logistical barrier for PET and PET-
CT imaging that limits its widespread adoption and particularly its use in operating room 
settings. However, in the past decade, PET-CT has proven very useful for the field of oncology 
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where it has helped to guide surgery and radiation, as well as monitor disease progression during 
and after chemotherapy.  
Magnetic resonance imaging (MRI) offers yet another approach to non-invasively 
visualize soft tissues with excellent spatial resolution and without exposing patients to ionizing 
radiation. During MRI procedures, a large, uniform magnetic field is generated around the 
patient, leading to dipole alignment in the hydrogen atoms present in water molecules. By 
varying the magnetic field gradients and positions with time, structural information may be 
deduced by the differences in the frequency and relaxation times of the water molecules, as 
tissues contain varying water content and therefore will respond differently to the applied 
magnetic fields. MRI requires significant instrumentation including a magnet with a field 
strength on the order of 1 Tesla, uses vascular contrast agents like CT, and is not ideally suited 
for the operating room. Furthermore, MRI, while superior to CT or ultrasound at resolving soft 
tissue structure, can still be inefficient and not sensitive at distinguishing ovarian tumor nodules 
from healthy tissues in the peritoneum. For ovarian cancer recurrence, as with CT imaging, the 
reported sensitivities for detecting tumors by MRI vary widely based on tumor size (35% for < 2 
cm; 82% for larger tumors) and anatomic location (83% for abdominal wall tumors; 67% for 
upper abdominal disease and lymph nodes).[24, 25] 
Optical imaging approaches have gained increasing attention for applications in medicine 
due to the development of optically-active probes with molecular specificity for ligands present 
in healthy and diseased tissues. NIR light at wavelengths of 700-950 nm is relatively transparent 
to tissues in the body. The major sources of light absorption and scattering in vivo include 
hemoglobin in erythrocytes, lipids, and water. Between these spectral regions, however, there 
6 
 
 
exist optical ‘windows’ where light can pass through tissue relatively unimpeded.[26] Many 
reagents which emit light in these regions are being explored for a variety of imaging 
applications. These reagents often have low toxicity, provide real-time imaging capabilities, and 
the instrumentation including light sources and photodetectors is generally safe and does not 
expose patients to ionizing radiation. Probes that emit light in the visible spectrum (400-700nm) 
such as fluorescein are already in clinical use and being explored for real-time intraoperative 
imaging.[27] However, visible dyes have comparatively low tissue transmittance, making them 
less useful for non-invasive imaging applications such as monitoring tumor progression during 
chemotherapy. Visible dyes are also susceptible to photobleaching, rendering them less useful 
for scenarios required extending periods of excitation such as cytoreductive surgery, which could 
last for several hours or longer. Intrinsic tissue autofluorescence creates additional difficulty for 
dyes in the visible regime by reducing signal-to-noise ratios in vivo. NIR imaging agents such as 
indocyanine green (ICG) have been used in the clinic for ophthalmic, cardiovascular, and hepatic 
applications for decades.[26, 28, 29] These NIR agents offer superior tissue penetration and 
sensitivity to visible dyes, but are still limited to a centimeter or less for tissue penetrance.  
At wavelengths beyond the first near-infrared window between wavelengths of 950-1400 
nm, the second near-infrared window (NIR2) offers great promise for non-invasive optical 
imaging (Fig. 1.2). Theoretical simulations predict that fluorescent agents emitting light in the 
second near-infrared window can have up to 10 cm tissue penetration depth, which would be 
sufficient for many procedures in human patients.[30] Furthermore, the signal-to-noise ratio in 
the second near-infrared window would be considerably higher than in the ‘first window’ 
regime. One challenge for imaging in the second near-infrared window has been the availability 
of imaging probes that retain their fluorescence in vivo. 
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One material with emission in the second near-infrared window is the single-walled carbon 
nanotube (SWNT), a rolled-up sheet of graphene, whose fluorescent properties are dictated by 
the chirality and layers of bundling in the structure. Based on the chirality, SWNTs can be either 
metallic or semiconducting, and only semiconducting carbon nanotubes fluoresce in the second 
near-infrared window. SWNTs have been explored in a number of pre-clinical imaging studies, 
although there has been reported concern about the clearance and toxicity of this material 
particularly involving entrapment and irritation in the lungs.[31-33] Clinical trials are currently 
underway to assess the safety of these materials in humans, but their potential as imaging probes 
has been well-established in pre-clinical models.   
One translational challenge for the development of carbon nanotubes as a new class of 
imaging agents has been the ability to target carbon nanotubes to tissues of interest in a manner 
 
 Figure 1.2. Optical attenuation in tissues due to absorption and scattering of light with 
primarily blood, skin, and fat tissue. Two optical windows (NIR1 and NIR2) exist at 
wavelengths of 650nm-950nm for NIR1 and 950nm-1,400nm for NIR2. Adapted with 
permission from [26].  
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that preserves their fluorescence. Stabilizing carbon nanotubes with biocompatible lipids such as 
sodium cholate or proteins such as the p8 coat protein of the M13 bacteriophage virus have been 
two methods that have been adopted to successfully prevent aggregation and loss of fluorescence 
of carbon nanotubes in living systems.[33-36] Additionally, bacteriophage have been engineered 
to express peptides from the p3 protein at the proximal tip of the bacteriophage. Libraries of 
distinct bacteriophage expressing unique targeting peptides have been used for in vivo phage 
display to identify peptides that target specific biological structures such as tumor extracellular 
matrix proteins.[37-40] Bacteriophage therefore represent suitable carriers for carbon nanotubes 
because of their ability to stabilize carbon nanotubes along their coat protein surface to preserve 
fluorescence and provide molecular targeting to deliver carbon nanotubes to the tumor site and 
reveal the tumor’s location. 
1.0.2.2 Cytoreduction 
When complex ovarian cysts are identified by diagnostic imaging and the patient is 
deemed to be a good surgical candidate, cytoreductive surgery (cytoreduction) is performed as 
the initial step of therapy. Cytoreduction, or tumor debulking, serves at least two important roles. 
First, cytoreduction allows for precise staging of disease and this can in turn guide subsequent 
therapeutic decisions involving chemotherapy. Second, cytoreduction allows for the debulking of 
tumors disseminated throughout the peritoneal cavity. The process of tumor spread in this 
setting, known as peritoneal carcinomatosis, is distinct from traditional metastasis because the 
route of spread is not initially hematogenous, but rather via shedding of the primary ovarian 
tumor and implantation on organ and tissue surfaces throughout the peritoneum. In advanced 
stage disease, the number of tumor nodules can number in the hundreds, and these nodules may 
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not be easily palpable or visible to surgeons exploring the complex and crowded anatomical 
space of the peritoneum. 
The maximal removal of tumors in advanced ovarian cancer has been shown to have a 
significant survival benefit for patients.[41] Over three decades of clinical evidence have 
revealed that patients who receive ‘optimal’ cytoreduction experience a 20 month improvement 
in median overall survival.[9, 11-13, 16, 17, 42, 43] In a meta-analysis of outcomes following 
optimal versus sub-optimal cytoreduction, it was observed that every 10% increase in maximal 
cytoreduction was associated with a 5.5% improvement in overall survival, making “maximal 
cytoreduction [one of the] most powerful determinants of cohort survival among patients with 
Stage III or IV ovarian carcinoma.”[8] 
By the current guidelines of the Gynecologic Oncology Group, ‘optimal’ cytoreduction is 
defined as the removal of all tumors with a maximum diameter of 1 centimeter or larger.[44] 
 
Figure 1.3. Kaplan-Meier overall survival curves for ovarian cancer patients based on amount 
of residual disease present after surgical cytoreduction. Adapted with permission from [41].  
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However, there is emerging evidence that more aggressive surgical interventions seeking to 
remove all visible tumor burden and leave no apparent residual disease may lead to improved 
patient outcomes.[45] The reasons behind this clinical observation are still being understood, but 
there are several leading explanations. First, a smaller residual tumor burden may be more 
effectively eradicated by adjuvant chemotherapies leading to increased cure rates and limited 
recurrence of disease. Second, by removing more tumor burden while it is still confined to the 
peritoneum, this reduces the likelihood of residual tumor from metastasizing to distant organs 
and increase mortality. Third, removing more tumor burden can decrease the incidence of 
secondary effects such as intestinal blockage, ascites formation, and hemorrhage which can 
directly increase morbidity and mortality in patients. Finally, patients who are able to undergo 
optimal cytoreduction may represent a unique patient population that responds more effectively 
to chemotherapy and has increased survival independent of the surgical procedure itself.[44, 45]  
The high rate of disease recurrence following therapy (95% within 5 years) suggests that 
although surgeons may identify the majority of tumors by traditional approaches, a population of 
tumor implants remains in the peritoneum that is left unidentified, either because they are too 
small to be detected by eye, indistinguishable from normal tissues, or are located in anatomically 
privileged sites. Given the significant survival benefit of effective surgery and the high rates of 
disease recurrence following surgery, it is clear that improved methods of detecting disease 
burden in the peritoneum could be advantageous for achieving optimal cytoreduction and thereby 
improve patient survival (Fig. 1.3).  
1.0.2.3 Chemotherapy 
Following cytoreduction, patients receive adjuvant chemotherapy to treat residual disease 
burden. Patients initially receive platinum-based chemotherapeutics such as cisplatin or 
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carboplatin either alone or in combination with taxanes, including paclitaxel and docetaxel. 
While most patients receive multiple cycles of chemotherapy often lasting months, the optimal 
dosing regimens are dependent on the drug combination, disease stage, and the patient’s overall 
health. The mechanisms of action of platinum-based chemotherapies and taxanes are non-
overlapping and therefore exert complementary effects. Platinum-based chemotherapy leads to 
intrastrand DNA cross-linking, whereas taxanes stabilize tubulin and inhibit mitosis in cancer 
cells. In one trial, when taxanes were included alongside platinum-based chemotherapy, survival 
was increased significantly by 25 to 37 months.[46] For patients treated by cytoreduction and 
chemotherapy when diagnosed an advanced stage of disease, the median survival is 5 years and 
about half of patients achieve complete remission as determined by examination, imaging 
studies, and clinical biomarkers such as CA-125.[2] However, these patients ultimately have a 
70-90% rate of recurrence. When disease is recurrent, first-line chemotherapy agents are often no 
longer effective because the tumors develop drug resistance. The high rate of recurrence 
underscores the need for effective initial treatment of residual disease to minimize the 
development of drug resistance and disease relapse.  
Interestingly, for ovarian cancer there is clinical evidence that intraperitoneal 
administration of chemotherapies is more effective at eradicating residual disease than 
intravenous administration (Fig. 1.4).[5] This suggests that vascular transport limitations in 
ovarian tumors may be limiting the efficacy of intravenously administered chemotherapeutics. 
Intravenous administration requires higher dosages that can lead to hematologic, gastrointestinal, 
and neurologic toxicities. By circumventing these barriers through intraperitoneal delivery, a 
significantly higher concentration of drug becomes accessible to residual tumors. Furthermore, 
small tumor nodules may be hypovascularized and unable to receive intravenously administered 
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chemotherapeutics at concentrations sufficient to be cytotoxic. Although survival was improved 
with intraperitoneal administration, however, patients reported lower qualities of life and higher 
toxicities during treatment. These findings were attributed to factors including the catheter used 
to deliver chemotherapy and the higher dosages of chemotherapy administered.[5] More efficient 
approaches to deliver chemotherapies to ovarian tumors would be expected to provide similar 
therapeutic benefits with reductions in systemic toxicities. 
 
An experimental delivery method known as hyperthermic intraperitoneal chemotherapy 
(HIPEC) or intraperitoneal hyperthermic chemoperfusion (IPHC) has been used in patients, often 
immediately following cytoreduction.[47, 48] During HIPEC procedures, a heated solution 
containing chemotherapy is infused directly into the peritoneal cavity and spread throughout the 
 
Figure 1.4. Kaplan-Meier overall survival curves for stage III ovarian cancer patients 
randomly assigned to receive intravenous chemotherapy or intraperitoneal chemotherapy (with 
intravenous paclitaxel). Adapted from [5].  Reproduced with permission from New England 
Journal of Medicine, Copyright Massachusetts Medical Society.   
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cavity by physical manipulation techniques. Because the mode of delivery is confined to the 
peritoneal cavity, a substantially higher concentration of chemotherapy can be tolerated in 
comparison to intravenous administration. However, the penetration depth of chemotherapy into 
tumors has been estimated to be less than 5 mm from the tumor surface.[49] In addition, the 
sensitivity of intraperitoneal organs such as the small intestine to diffusely elevated temperatures 
increases the risk of complications during HIPEC procedures and has led to debates of the 
relative merits of the approach.[50]  
1.1   Drug Transport in Solid Tumors 
Over the past decade, our understanding of the genomic complexity of ovarian and other 
cancers has greatly expanded. Tumors previously identified by their tissue of origin or pathologic 
appearance are increasingly being classified based on their underlying genetic mutational 
patterns. This molecular classification of cancer has been brought about largely by the ability to 
rapidly sequence cancer genomes in a more cost-efficient manner than was possible a decade 
ago. The hope of such efforts is that by capturing the full compendium of mutations that 
contribute to cancer, we will be better able to diagnose patients, provide more personalized 
therapeutic options, design smarter clinical trials, and understand the key molecular drivers for 
this disease. The success of molecularly-targeted cancer therapeutics such as vemurafenib for 
BRAF-mutant melanoma and imatinib for BCR-ABL-mutant chronic myelogenous leukemia 
(CML) at temporarily slowing the growth or completely curing these cancers has provided hope 
to patients and the biomedical community that similar approaches will be discovered for many 
other types of cancer.[51-54]  
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The success of imatinib, or Gleevec, at transforming CML from a fatal to a chronic or 
cured disease is often cited as a harbinger of future successes of molecular therapeutics. 
However, at least part of its success may be attributed to the high bioavailability of the drug to 
the leukemia cells, as both are present in the circulating blood and bone marrow, increasing the 
likelihood that this small molecule therapy will reach its intended target. For many solid tumors, 
however, the accessibility of systemically administered chemotherapeutics to tumor cells is 
limiting (Fig. 1.5). This low accessibility can be attributed to several transport bottlenecks or 
barriers that impede the delivery of therapeutics to tumors: (1) blood flow, (2) transvascular 
transport, (3) interstitial diffusion, and (4) cellular uptake.[55-59]  
 
 
Figure 1.5. Barriers to drug delivery in solid tumors for nanomedicines and conventional 
diagnostic or therapeutic agents include vascular supply, transvascular transport, and 
interstitial diffusion. Strategies to actively modulate these delivery barriers are being explored 
to improve the delivery of nanotherapeutic agents into tumors with greater sensitivity and 
potency. Adapted with permission from [55].  
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1.1.1 Blood Flow 
Adequate blood flow in the tumor is a prerequisite for systemically delivered therapeutics 
to reach tumor cells. In tumors, blood flow is impaired by irregular vascular structure, variable 
flow rates, and impaired lymphatic drainage. The process of angiogenesis creates a tortuous 
network of microvessels in the tumor with variable lengths and diameters. This disorganized, 
heterogeneous arrangement leads some regions of tumors to receive adequate blood flow, 
whereas other regions may experience poor or absent blood flow.[56] In addition to limiting drug 
transport, poor blood flow creates hypoxic, acidic conditions within tumors that facilitate drug 
resistance, cellular transformation to malignancy, and metastatic progression.[56] The irregular 
architecture contributes to one form of resistance that impedes blood flow. In addition, blood 
flow rates in tumors are reduced by increased blood viscosity. The leakage of plasma and 
proteins across permeable tumor vessels results in an increased hematocrit and apparent 
viscosity, thereby decreasing tumor blood flow.[60] Finally, impaired lymphatic drainage in 
solid tumors caused by compression of lymphatic vessels by proliferating tumor cells creates an 
increased interstitial pressure which can directly compromise blood flow.[61]    
The concept of vascular ‘normalization’ was conceived as a strategy to improve the 
overall blood flow in tumors.[57, 62-70] To normalize the tumor vasculature, anti-angiogenic 
antibodies such as bevacizumab, traztuzumab, and cediranib have been used to prune angiogenic 
neovasculature and decrease vascular permeability, thereby decreasing the structural and viscous 
resistance and increasing overall blood flow to tumors.[62, 66, 71] Small molecule and 
endogenous angiogenesis inhibitors such as endostatin and the VEGFR inhibitor AZD2171 have 
demonstrated similar behavior in pre-clinical and clinical studies.[63, 72] This approach has been 
shown to improve delivery of multiple therapeutic agents to solid tumors and correlates with 
16 
 
 
improved survival in pre-clinical tumor models. Emerging evidence in small-scale clinical trials 
indicates that this approach may have both diagnostic and therapeutic utility in humans as 
well.[62] The corresponding reduction in vascular permeability by this method, however, 
suggests that it may be most useful for small molecule chemotherapeutics that are not as limited 
by movement across the vessel wall or diffusion through the interstitium.[59]  
Physical stimuli including heat have also been explored as methods to modulate blood 
flow in tumors. Normal tissues respond to heat with increased blood flow when the temperature 
does not exceed 45°C, and blood flow returns to baseline levels within hours.[73] Previous 
studies have reported that from basal flow rates of 3-5 mL/min per 100 grams of tissue, heating 
induced 15-fold and 10-fold increases in blood flow in the skin and muscle, respectively.[73] 
The reported effects of heating on tumor blood flow are more variable, however, with studies 
reporting both positive and negative effects based on the tumor model, heating regimen, and 
heating method employed. For instance, localized heating induced by high-intensity focused 
ultrasound (HIFU) generates a smaller increase in tumor blood flow versus heated water bath 
methods because of differing boundary conditions and thermal gradients generated at air-skin 
and water-skin interfaces, respectively.[73] One group examined the effects of multiple rounds 
of heating on tumor blood flow by exposing tumors to five cycles of heating with intervals 
between heating of 1-3 days.[74] They observed a roughly 2-fold increase in blood flow with the 
initial heating cycle at 43.5°C, but no subsequent changes to blood flow with further heating 
cycles applied in one day intervals.[74] This finding is suggestive of a vascular adaptation to 
heating referred to as vascular thermotolerance.  
1.1.2 Transvascular Transport 
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The second primary barrier to therapeutic delivery in tumors is transvascular transport. 
Although tumor blood vessels are typically more permeable than normal vessels, transport across 
the endothelium is often rate-limiting for larger therapeutics such as antibodies and nanoparticle 
formulations.[59, 75] Transvascular transport is governed by a combination of convection and 
diffusion reactions that depend on the vessel structure, microenvironmental variables, and 
properties of the therapeutic itself. Several of the key relevant parameters include intravascular 
and interstitial concentrations of the drug, hydrostatic and osmotic pressure gradients, effective 
endothelial pore size, and the molecular properties of the therapeutic including charge, size, and 
geometry. A consequence of both the increased vessel permeability in tumors and diminished 
lymphatic drainage, elevated interstitial fluid pressure (IFP) poses a significant challenge for 
transvascular transport.[56] Additionally, just as the blood flow in tumors is heterogeneous, the 
effective vascular pore sizes in vessels and permeability varies significantly throughout the 
tumor from several nanometers to one micrometer or larger. Therefore, while certain regions of 
the tumor including the periphery may have highly permeable vasculature, other regions in the 
same tumor such as the core regions may be significantly less permeable, leading to spatially 
different patterns of accumulation of therapeutics within individual tumors.  
To understand the mechanisms for transvascular transport in tumors, it is helpful to first 
consider the cellular structure and composition of blood vessels. A normal blood vessel is 
composed of endothelial cells, smooth muscle cells, and extracellular matrix proteins arranged in 
three concentric layers called the intima, media, and adventitia.[76] The intima is the innermost 
layer in contact with the circulating blood and is composed of an endothelial cells. The internal 
elastic lamina separates the intima from the media, and the media is composed of smooth muscle 
cells, which provide vessel stability and contract or dilate in response to chemical stimuli or 
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input from the nervous system. The outermost layer of a blood vessel, the adventitia, consists of 
connective tissue, nerves, and the vasa vasorum, a network of vessels that provides oxygen and 
nutrients to the outermost layers of the vessels themselves. Vessels span a wide range in 
diameters, and the structure is dictated largely by the physiological demands of the particular 
vessel. Large arteries like the aorta have high elasticity, and give rise to smaller, more muscular 
arteries. These arteries in turn branch into smaller arteries, arterioles, and capillaries. Capillaries, 
which exhibit slow blood flow and are the site of oxygen transfer into tissues, consist of an 
endothelial monolayer on a basement membrane. Endothelial cells are not simply passive 
barriers to nutrient, oxygen, and macromolecular diffusion, but instead play an important 
physiological role in regulating processes such as coagulation and leukocyte trafficking.[76]  
Transvascular transport in tumors occurs most prominently in capillary and post-capillary 
venule networks. Several classes of tumor capillaries have been identified in tumors and include 
continuous, fenestrated, and discontinuous capillaries.[75] The distinction between these 
structures is largely based on extent of coverage of their endothelial linings. Continuous 
capillaries are characterized by a functionally intact endothelial barrier and have been previously 
identified in pre-clinical tumor models.[75, 77] Fenestrated capillaries such as those found in 
renal glomeruli have also been observed in tumor models; these capillaries contain 
interendothelial fenestrations, or openings, that contribute to vascular permeability. 
Discontinuous, or sinusoidal, capillaries represent a more extreme variation of fenestrated 
capillaries and are found not only in tumors, but also in the liver and spleen. With larger pore 
sizes between adjacent endothelial cells and diminished basement membrane accumulation, 
discontinuous capillaries also contribute to the enhanced vascular permeability observed in 
tumors. These capillary networks ultimately converge into post-capillary venules, which are 
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typically between 20-60 µm in diameter, possess weak interendothelial cell junctions, and are 
therefore the principal site of exudation of fluids and leukocytes in tumors.[75, 76] 
While transvascular transport occurs across each type of capillary and post-capillary 
venule network, the relevant transport pathways vary for each type of vascular structure and 
molecule being transported. In general, the mechanisms for transvascular transport can be 
categorized as endothelial cell diffusion, lateral membrane diffusion, interendothelial junctions, 
fenestrations, and vesicle transport.[75] Small molecules, water, and lipophilic solutes diffuse 
through endothelial cells or via lateral membrane diffusion, whereas transport through 
interendothelial junctions or fenestrations occurs for larger macromolecules including many 
nanoparticle therapeutics. Transport across continuous capillaries occurs primarily through 
endothelial cell diffusion, lateral membrane diffusion, narrow interendothelial junctions, and 
vesicular transport. Fenestrated capillary transport shares these mechanisms, but additionally 
involves transport through closed and open fenestrations across the endothelium. Discontinuous 
capillary transport involves the mechanisms of continuous capillaries as well as large 
interendothelial cell junctions.[75]  
The mechanisms of vascular permeability, in particular during inflammatory responses to 
a variety of chemical, physical, and microbial insults, have been well documented and have 
served as a framework for strategies to overcome transvascular transport limitations in tumors. 
The primary consequence during an acute inflammatory response is the extravasation of fluid, 
proteins, and cells from the vessel lumen into the injured tissue.[76] The mechanisms responsible 
for these effects have provided specific areas to mimic as therapeutic strategies. In the immediate 
aftermath of a tissue injury, degranulation of mast cells releases the vasoactive agents such as 
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histamine, which within minutes induce endothelial cell contraction and increased vascular 
permeability primarily in post-capillary venules.[78-80] Additionally, inflammatory cytokines 
such as tumor necrosis factor (TNF) and interleukin-1 (IL-1) can induce endothelial cell 
contraction, although the effects of these cytokines may occur after several hours in contrast to 
the rapid action of vasoactive compounds. Hours after injury to a tissue, leukocytes recruited to 
sites of inflammation can also act upon the endothelium to increase the effective vascular 
permeability. In the context of tumor vasculature, permeability is governed by mediators such as 
vascular endothelial growth factor (VEGF) that promote the formation of angiogenic vessels 
with increased permeability relative to normal vasculature. Importantly, the lack of significant 
pericyte coverage in angiogenic vessels plays an important role in the permeability of 
macromolecules across the endothelium.   
1.1.3 Diffusion 
Upon extravasation from the blood vessels, macromolecular compounds must diffuse 
through the interstitial space of the tumor. The tumor interstitium is composed of a dense 
extracellular matrix of collagen fibers and charged glycosaminoglycans (GAGs), along with non-
malignant cells recruited to the tumor site such as macrophages, leukocytes, and fibroblasts. 
While the prevalence of specific matrix proteins or cell populations varies significantly based on 
the tumor type, site of disease, and tumor stage, these factors collectively pose a large hurdle for 
diagnostic or therapeutic nanoparticle formulations of large hydrodynamic radius or surface 
charge. Particles may become sequestered within dense regions of extracellular matrix or 
engulfed by macrophages through processes such as phagocytosis or macropinocytosis. These 
factors effectively reduce the concentration of free therapeutic compound that is available to 
target tumor cells directly.  
21 
 
 
Several proof-of-concept studies in pre-clinical models have demonstrated that reductions 
in ECM density or macrophage populations can enhance therapeutic diffusion in solid tumors. 
Groups have used matrix-degrading enzymes and hormones such as collagenase, matrix 
metalloproteinases (MMPs), and relaxin to decrease the collagen concentration in tumors and 
demonstrated superior distribution of therapeutic particles in regions with reduced collagen 
concentration.[81-85] However, given the abundance of collagen in the body, the inability to 
target this matrix-degrading enzymatic activity specifically to tumors creates a narrow 
therapeutic window for approaches involving collagenase. Pharmacologic strategies using the 
FDA-approved angiotensin receptor blocker losartan have also demonstrated that antagonism of 
transforming growth factor beta 1 (TGFβ1) activity in cancer-associated fibroblasts reduces the 
collagen density in tumors and improves diffusion of both oxygen and therapeutic molecules.[86, 
87] To deplete phagocyte cell populations that may sequester diffusing therapeutics, studies have 
examined the effect of co-administration of therapeutic compounds with clodronate liposomes, 
which deplete peripheral phagocytic CD68+ and CD163+ cells. In one study, this strategy led to 
five- to ten-fold improvements in intratumoral therapeutic concentrations of oncolytic 
viruses.[88] Finally, more recent reports have described tumor-penetrating peptides such as 
iRGD that when co-administered with a variety of therapeutics can significantly increase the 
penetration of compounds into solid tumors.[89]  
1.1.4 Cellular Uptake 
A final barrier for diagnostic and therapeutic agents with intracellular mechanisms of 
action is the transport across cellular membranes and release from endocytic vesicles. Certain 
molecules such as the PET imaging probe fluorodeoxyglucose (FDG) are not limited by blood 
flow, transvascular transport, or diffusion, but rather by cellular binding and intracellular 
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reactions.[59] In addition, emerging classes of therapeutics such as siRNAs must act in the 
cytoplasm and therefore escape from endocytic vesicles in order to demonstrate therapeutic 
utility. Pathogens that must co-opt eukaryotic cellular machinery to proliferate have evolved 
mechanisms to penetrate cell membranes and escape from acidified endocytic vesicles. Typically 
cationically charged, cell-penetrating peptides isolated from these pathogens such as transportan 
have been incorporated into nanotherapeutic carrier complexes as a strategy for penetrating 
cellular and vesicular membranes with higher efficiency.[90]  
While there is reason for considerable hope and excitement with the identification of 
highly specific and potent molecular therapeutics for cancer, it is important to consider the 
physical transport barriers, which greatly diminish the therapeutic efficacy of these compounds 
in solid tumors and fuel the development of drug resistance. Advances in overcoming these 
barriers will need to occur in parallel to drug development in order for the potential for these 
compounds to be fully realized in the clinic.  
1.2   Heating and Therapeutic Transport 
1.2.1 History 
The use of heating in cancer therapy dates back to ancient times when it was described in 
Egyptian, Indian, and Greek civilizations as a method for treating ailments such as breast cancer. 
In the nineteenth century, fever therapy gained in prominence after Dr. William Coley and others 
administered bacterial toxins from Streptococcus pyogenes and Serratia marcescens to induce 
fever and observed tumor regression in their patients. It was not until the 1970s, however, that 
formal clinical trials and pre-clinical studies began to address the utility and molecular 
mechanisms of heating in cancer therapy. Trials thus far have investigated heating in the context 
of ovarian cancer, head and neck cancer, breast cancer, melanoma, esophageal cancer, gastric 
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cancer, cervical cancer, colorectal cancer, and soft tissue sarcoma.[91-108] Collectively, the 
randomized clinical trials to date have shown mixed results, with some trials demonstrating 
improved tumor responses and survival benefit while others not showing a significant difference 
from control groups.  
While heat itself exerts direct cytotoxic effects on tumor cells, most trials have examined 
the combined effects of heating with existing therapeutic modalities including radiation therapy 
and chemotherapy. Because mild heating in the range of 40-43°C enhances blood flow and 
oxygenation in tumors, it has been shown to radiosensitize tumors to radiation therapy, which 
relies on the generation of oxygen free radicals for its antitumor effects. The clinical 
effectiveness of radiosensitization by localized heating has been examined for superficial tumors 
including head and neck, melanoma, sarcoma, and breast tumors in trials comparing radiotherapy 
and local heating to radiotherapy alone. While the patient cohorts and clinical endpoints varied 
between these trials, about half of the trials demonstrated an improved response with combined 
radiotherapy and heating, but the majority did not demonstrate a survival benefit. [95, 97, 99, 
102-106] 
Non-specific, whole-body heating approaches have been shown to alter the systemic 
pharmacokinetics and metabolism of chemotherapeutics due to altered metabolism and filtration 
in the liver and kidney, respectively. The effect of systemic heating on the functioning of healthy 
organs has made these approaches less predictable in terms of their therapeutic benefit to 
patients. Because heating in the liver may delay drug metabolism by several hours, 
considerations of the relative timing between drug administration and induction of heating may 
be important for developing an optimized protocol, although most current studies support 
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synchronous administration of chemotherapy and heating. The biological basis for heat-based 
chemosensitization has been described primarily as an effect of pharmacodynamic enhancement. 
Many studies have reported that tumor cells from multiple lineages and tissues are more sensitive 
to elevated temperatures relative to normal, non-tumorigenic cells owing to genetic aberrations 
present within the cells that render them more vulnerable to undergoing apoptotic or necrotic cell 
death. At higher temperatures in excess of 50°C, heat has been used as a single modality 
approach for direct ablation of tumor tissue. Acting in combination with cytotoxic or cytostatic 
chemotherapies, mild heating can promote greater frequency of cell death. As a result, studies 
have looked at mild heating in the range of 40-43°C as a mechanism for chemosensitization. 
However, in addition to its pharmacodynamic effects directly on tumor cells, heating also exerts 
pharmacokinetic effects through modulation of the tumor microenvironment.  
1.2.2 Role in Transport 
There has been significant previous work on understanding the role of mild heating, or 
hyperthermia, in helping chemotherapeutics overcome the major transport barriers present in 
solid tumors. These studies have focused on the impact of mild heating on the endothelium in 
particular, as this tissue serves as the interface between the systemic circulation and the tumor 
cells. Systemically administered therapeutics of diverse sizes, electrostatic charge, 
hydrophobicity, and molecular composition must traverse the endothelium in order to reach their 
target cells within the tumor, and for many of these therapeutics, transport across this endothelial 
layer is the rate limiting step of the entire process. Using pre-clinical glioma tumor models, 
investigators demonstrated that heating using a water bath led to a four-fold enhancement in the 
delivery of therapeutic monoclonal antibodies into tumors. [109]Similar results have been 
demonstrated for liposomes, large molecular weight dextrans, and iron oxide ‘nanoworm’ 
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formulations, suggesting a generalized approach for enhancing therapeutic delivery.[110-112] 
Various mechanisms have been proposed to account for the enhancement in delivery induced by 
heating, including thermally-induced endothelial cell contraction, release of vasoactive mediators 
and inflammatory cytokines, direct injury to the endothelium, increased rates of transcytosis 
across the endothelium, and enhanced blood flow and interstitial diffusivity.[111] 
Studies investigating the role of heating in therapeutic transport have focused almost 
exclusively on the effects of single heat exposures on the tumor vasculature. In clinical settings, 
however, chemotherapy regimens typically include multiple rounds of administration spanning 
periods of days to months. As heating methods are considered as adjuncts to chemotherapy 
regimens, there is surprisingly little known about the efficacy of multiple heat exposures on the 
tumor vasculature in the context of therapeutic delivery. Much more has been studied about the 
effects of repeated thermal stress on cells grown in culture. In particular, an effect known as 
thermotolerance has been described that effectively renders cells more resilient to thermal stress 
if the cells were previously exposed to a sub-lethal thermal stress. 
1.2.3 Heat Shock Response and Thermotolerance 
The mechanistic details of thermotolerance have focused on the involvement of the heat 
shock response. An evolutionarily conserved pathway shared by yeast, plants, and mammals, the 
heat shock response consists of a coordinated cellular response that enables cells to survive a 
variety of physical and chemical stresses including elevated temperature, toxins, heavy metals, 
and oxidative stress.[113] In vertebrates, the master regulator of the heat shock response is the 
transcription factor Heat Shock Factor 1 (HSF1). In the unstressed state, HSF1 exists in the 
cytoplasm in an inactive monomeric form; upon cellular stress, HSF1 proteins form 
homotrimers, translocate to the nucleus, and initiate transcription of target genes involved in a 
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variety of cellular processes that collectively help the cell survive during periods of stress.[113] 
HSF1 is recruited to target genes by DNA sequences called heat-shock elements (HSEs).[114-
116] The classical genes induced by HSF1 include the family of heat shock proteins (HSPs), 
which act as chaperones to help stabilize and refold denatured proteins during thermal or other 
stresses. Certain heat shock proteins including HSP27 have been implicated in increasing the 
stability of actin filaments during heating.[117-119] However, while some studies have observed 
vascular thermotolerance develop within tumors, this phenomenon has not been extensively 
investigated in the setting of drug delivery across the tumor endothelium.[110] 
From a therapeutic standpoint, because many tumors rely on HSF1 activity during 
periods of rapid growth and protein synthesis, inhibitors of HSF1 may have utility in the clinic in 
combination with chemotherapy or other existing therapeutic strategies. Studies have 
demonstrated that deletion of HSF1 in cells and animal models is tolerated, suggesting that 
selective HSF1 inhibitors, if identified, could have a moderate therapeutic index.[120]  Recently, 
a compound called rocaglamide A was identified in a high-throughput small molecule screen as a 
potent inhibitor of translation and HSF1 activation.[121] In cell lines highly dependent on HSF1 
activation, rocaglamide A and its structural analog with enhanced potency RHT significantly 
decreased the levels of mRNA transcripts associated with the heat shock response including 
HSP70 and HSP40 and exhibited a pronounced effect on cell viability.[121] While there is 
enthusiasm for HSF1 inhibition as a tumor-specific therapeutic strategy, its inhibition in the 
tumor microenvironment to diminish vascular thermotolerance may have complementary effects 
in the context of drug delivery to solid tumors.  
1.2.4 Technologies in the Clinic 
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Technologies to induce elevated temperatures can be divided into whole body, regional, 
and local approaches. Whole body hyperthermia (WBH) systems have been utilized for patients 
with metastatic disease and can safely elevate the body temperature to approximately 42°C 
without significant systemic side effects. WBH systems consist of moisture-controlled chambers 
that emit NIR radiation, which is absorbed in the patient’s skin to depths of several 
millimeters.[122] This heat is transferred into the systemic circulation and within a period of 1-2 
hours the body temperature can reach 42°C. Clinical challenges of WBH approaches include the 
need for deep sedation or anesthesia, continuous skin temperature monitoring, frequent fluid 
replacement, and the possibility of hematological and cardiovascular side effects including 
cardiac arrhythmias and disseminated coagulation.[123, 124] The most positive outcomes for 
WBH trials have combined WBH with systemic chemotherapy in patients with sarcoma and 
ovarian cancer, but the complex implementation and systemic toxicities of WBH in comparison 
to local or regional methods has slowed the further development of these approaches.  
Regional approaches utilize antenna arrays to generate electromagnetic energy over a 
defined anatomic region. These systems may be particularly useful for simultaneously treating 
multiple tumors confined to a specific anatomic compartment such as the peritoneum. Using 
antenna arrays has allowed clinicians to develop more precise patterns of energy deposition 
because the spatial location, emitted frequency, and number of the antennas can be modulated to 
deposit energy more specifically at sites of disease. One group has combined a regional heating 
system with real-time thermometry by magnetic resonance-based imaging techniques, which 
provides a way to monitor temperature both in tumors and in adjacent healthy tissue.[125] 
Regional perfusion of limbs has a longer history of clinical use. In regional perfusion 
approaches, blood from a major artery is removed from the body, heated outside of the body, and 
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returned through a large vein in the same limb. Regional perfusion is considerably safer than 
WBH approaches and allows for greater concentrations of chemotherapy to be administered 
compared with systemic administration.[126-128] 
Several approaches to locally increase the temperature in a tumor include radiowaves and 
microwaves, high intensity focused ultrasound (HIFU), and laser-induced interstitial 
therapy.[128, 129] These approaches have found the greatest utility for superficial tumors and 
tumors present in the liver due to metastatic spread that are not surgically resectable. For tumors 
located close to the skin surface, applicators emitting microwaves and radiowaves can be placed 
on the skin and linked to a thermal monitoring device placed within the target tumor tissue for 
continuous monitoring and feedback control.[130] While these devices may cover relatively 
large areas up to 15 cm in diameter, the energy penetration depth is limited to only 3 cm, which 
diminishes their utility for deeper tumors.[128] A variety of implanted applicators have been 
developed to be placed directly within isolated tumors or hollow organ structures such as the 
esophagus, rectum, and urethra. These devices can emit radiowaves, microwaves, ultrasound, or 
laser-generated energy to directly heat tumor tissue less than 5 cm in diameter.[128, 129] While 
these locally applied ablative procedures are typically not curative, they can nevertheless reduce 
disease morbidity significantly and allow patients to experience an improved quality of life. 
One challenge has been developing methods to locally heat tumor tissue disseminated 
over a wide region without damaging adjacent healthy tissue. This is particularly true for 
advanced ovarian cancer because tumors disseminated in the peritoneum are situated amongst 
temperature-sensitive tissues such as the intestine. Methods to locally and specifically heat 
ovarian tumors in this setting may have therapeutic advantages compared with non-specific 
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heating methods such as HIPEC. Furthermore, with radiofrequency, microwave, or HIFU 
approaches, the heating localization is dependent on the location and placement of the 
transducer, which requires knowledge of the location of tumors prior to the intervention.  
1.3   Optically Active Nanomaterials 
Over the past two decades, a wide array of nanoparticles and nanomaterials have been 
engineered for applications ranging from electronics to energy storage to medicine. These 
particles and materials vary widely in terms of their chemical compositions, geometries, surface 
modifications, and electrostatic charges, but share the common feature of having at least two 
dimensions measuring between 1 and 1,000 nanometers.[131] The impact of nanomaterials on 
the field of medicine is already being realized with at least forty distinct nanomaterial 
formulations having received FDA approval or currently being assessed in clinical trials.[132] 
Many more nanomaterials are under development and being evaluated in pre-clinical studies. 
Nanomaterials for medical applications are typically composed of lipids (Doxil liposomes, 
micelles), proteins (Abraxane), polymers (dendrimers, block copolymer micelles), and inorganic 
materials such as metals (gold and silver nanoparticles, iron oxide).[131] Carbon-based 
nanomaterials including carbon nanotubes have also garnered increasing interest particularly for 
their non-invasive imaging capabilities.[33] In the setting of cancer, nanomaterials are being 
investigated as new classes of imaging agents to help detect disease at an earlier stage, detect 
biomarkers at greater sensitivity than with traditional assays, deliver chemotherapeutics more 
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efficiently and selectively to tumors, and physically modify tumors for therapeutic benefit. 
 
1.3.1 Plasmonic Nanomaterials 
One class of materials that has shown great utility for biomedical applications are 
plasmonic nanomaterials. Plasmonic materials are composed of noble metals such as gold and 
silver that have unique optical properties including strong scattering and absorption due to their 
electronic structure.[133-138] When these particles are exposed to electromagnetic fields, free 
electrons on the surfaces of these particles undergo collective oscillations along the axis of the 
particles.[134] This effect is known as surface plasmon resonance (SPR) and has been utilized 
for a diverse array of applications including diagnostic biosensing, imaging, and therapy. The 
energy of the electronic oscillations can either dissipate into the environment as scattered light or 
be absorbed by the metallic lattice to generate localized heating. Of particular relevance to in 
 
Figure 1.6. Design parameters of nanomaterials for medical applications. Controlling 
geometric parameters including particle size and shape, as well as incorporating targeting 
ligands, influences pharmacokinetics and pharmacodynamics. Elemental composition of 
nanomaterials embeds certain functions into material, including the ability to generate heat or 
emit fluorescence.  
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vivo applications, the resonant frequency of plasmonic nanomaterials is inversely proportional to 
the geometric aspect ratio of the particle. This property has allowed for the design of plasmonic 
nanostructures that exhibit localized SPR in the NIR regime at wavelengths with improved tissue 
penetrance relative to visible light.[112, 139-141] Biocompatible formulations of gold nanorods 
(PEG-NRs) coated in polyethylene glycol (PEG) polymers have been developed to increase 
circulation half-life, diminish systemic clearance by the reticuloendothelial system, and enhance 
intratumoral accumulation.  
1.3.2 Single-walled Carbon Nanotubes 
The carbon nanotube is a second type of optically active nanomaterial that has generated 
considerable interest for its potential biomedical applications including optical imaging. Carbon 
nanotubes consist of graphene sheets that are rolled into hollow cylinders. The chirality of these 
materials dictates whether they have metallic or semiconducting electronic properties, as well as 
the excitation and emission spectral characteristics. Semiconducting carbon nanotubes emit light 
in the second near-infrared window between wavelengths of 950-1400 nanometers.[26, 33, 36] 
Because these long wavelengths are significantly more transparent to tissue than the NIR or 
visible regimes, there is hope that novel imaging probes containing carbon nanotubes can be 
developed for non-invasive imaging applications.  
1.3.3 Enhanced Permeability and Retention (EPR) Effect 
The ability of systemically administered nanomaterials to reach their intended disease 
sites is essential for their function and clinical utility. Delivery of nanomaterials into tumors is 
governed in part by a phenomenon known as the enhanced permeability and retention (EPR) 
effect.[131, 142-146] Studies have demonstrated that permeable angiogenic tumor vasculature 
coupled with defective clearance by tumor lymphatic vessels facilitates the accumulation and 
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retention of nanomaterials in certain tumor microenvironments. EPR-mediated passive targeting 
of nanomaterials requires plasma half-lives on the order of hours to avoid rapid clearance by 
renal filtration and the reticuloendothelial (RES) system in the liver and spleen. To prolong the 
plasma half-life of nanomaterials, ‘stealth’ approaches involving the addition of biocompatible 
PEG polymers to particle surfaces have been developed successfully.[132, 147] PEG-coated 
nanomaterials with longer plasma half-lives can accumulate in tumors at higher concentrations. 
However, the addition of PEG polymers on nanomaterials can increase the particle diameter and 
diminish transvascular transport within tumors.[132]  
While many studies describing the EPR effect have relied on subcutaneous xenograft 
models, it is becoming increasingly clear that the relative contribution of the EPR effect on 
nanomaterial accumulation is dependent on cell-autonomous and non-autonomous factors 
including the tumor model, site of implantation, growth kinetics, and stromal characteristics such 
as interstitial fluid pressure, vascular and lymphatic density, and infiltrating immune cell 
populations. For example, the presence of adjacent healthy tissue, vascular architecture, and 
other stromal elements in genetically engineered mouse models (GEMMs) can be very different 
from subcutaneous models and therefore the significance of the EPR effect in GEMMs does not 
immediately follow from similar studies in xenografts.[148-150] These stromal variations, which 
can lead to tumor-dependent differences in nanotherapeutic transport, may explain in part why 
some promising nanoparticle therapeutics to emerge from pre-clinical studies have failed to show 
therapeutic utility in human patient populations. In one study of 17 patients with locally 
advanced cancer, the pharmacokinetics of radiolabeled pegylated liposomes was measured by 
scintigraphy on a gamma camera.[151] Liposome accumulation varied based on the site and size 
of the tumors; head and neck tumors displayed the highest accumulation (33% ID/kg), lung 
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tumors showed intermediate accumulation (18.3% ID/kg), and breast tumors displayed the 
lowest accumulation (5.3% ID/kg). Accumulation varied inversely with tumor size, as smaller 
tumors in the head and neck displayed greater accumulation than larger tumors in the breast and 
lung. While the EPR effect is a widely acknowledged mechanism of nanomaterial accumulation 
in solid tumors, the magnitude of its effect in different tumor models remains an important 
consideration for effective clinical translation.  
1.3.4 Diagnostic Applications – Biosensing and Imaging 
Plasmonic nanomaterials are strongly scattering at their SPR wavelength, and this 
property has been developed for an array of solution-based biosensing applications.[135, 138, 
152-171] The majority of these methods take advantage of small local surface plasmon 
resonance (LSPR) spectral shifts that occur upon binding of an analyte from a biofluid such as 
blood or cerebrospinal fluid to a capture probe in the vicinity of the plasmonic material. The 
degree of spectral shift in the plasmon resonance frequency is proportional to the concentration 
of analyte present in the local environment, and the sensitivity of plasmonic biosensors can be 
modulated by varying the particle geometry. Surface-enhanced Raman spectroscopy (SERS) has 
been applied to detect single molecules, as well as many biological analytes from clinical 
specimens. Plasmonic nanoparticles have been functionalized to facilitate antibody-antigen, 
lectin-saccharide, and biotin-streptavidin interactions for analyte detection. Plasmonic scattering-
based biosensors have been shown to detect glucose concentration from biofluids, amyloid beta 
from blood and cerebrospinal fluids for Alzheimer’s disease, and human papilloma virus DNA 
detection.[155, 159] These applications are highly sensitive, do not require prohibitively costly 
equipment, and have wide applicability in diverse fields of clinical medicine. Other studies have 
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used cancer-targeted plasmonic materials to perform imaging and have observed spectral shifts 
corresponding to cellular binding and particle uptake. 
1.3.5 Therapeutic Applications – Heating and Drug Delivery 
Plasmonic nanomaterials can also absorb the energy of the surface electron oscillations 
into the metallic lattice during the process of photothermal heating. The localized heat generated 
in these materials can be efficiently transmitted to the surrounding environment. This effect has 
been harnessed to create localized heating within specific tissues such as solid tumors.[141, 172-
179] In these approaches, plasmonic nanomaterials accumulate passively in tumors by the EPR 
effect or by active targeting with antibodies, peptides, or other targeting ligands. Exposure of 
tissues to laser irradiation at the particle’s SPR wavelength causes the particles to convert benign 
NIR light into heat locally within the tumor environment.    
Applications involving photothermal ablation have relied on gold nanoparticles of 
varying geometries, principally gold-coated silica nanoshells and gold nanorods. Surface 
plasmon absorption peaks in the NIR regime have made these particles attractive for biomedical 
applications requiring heat delivery to deeper tissue structures. Preclinical studies have focused 
on subcutaneous or genetically engineered tumors just beneath the skin. This approach has been 
used to selectively ablate tumors by heating to 50°C or higher.[141, 179] Most studies utilize 
passive targeting to deliver gold nanoparticles into tumor environments via the EPR effect. 
Additionally, there has been effort to incorporate targeting ligands to selectively deliver gold 
nanoparticles to lymphocytes and atherosclerotic plaques for photothermal ablation and imaging 
in non-tumor settings.[180, 181] However, NIR penetration depth remains a limiting factor for 
disease processes not occurring near the skin surface and strategies to deliver NIR light more 
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efficiently could create new applications for plasmonic nanomaterials involving photothermal 
ablation.  
Therapeutic applications of mild photothermal therapy in the range of 40-43°C have 
focused on utilizing plasmonically-active gold and silver nanoparticles to modulate a variety of 
temperature-sensitive polymers and hydrogels containing therapeutic cargoes.[141, 178, 182-
191] Nanomaterials are either embedded within or co-administered with heat-sensitive carriers to 
induce local burst-release of therapies in a spatially-controlled manner. Other studies have shown 
that localized heating in the tumor microenvironment can create novel binding targets for 
subsequent delivery of therapeutic payloads. In addition, a limited group of studies have 
investigated antimicrobial applications of sub-ablative photothermal therapy. As with 
photothermal ablation, NIR light delivery remains an important barrier for many clinical 
applications of sub-ablative photothermal therapy.  
1.4   Thesis Aims 
The clinical challenges related to disease detection and monitoring, surgical resection, 
and delivery of therapeutics are well-suited to be addressed by novel nanomaterials and related 
technologies that can be engineered to target tumors, fluoresce, and locally deposit energy.[3, 6, 
15-18] For ovarian cancer management, limitations related to diagnostic imaging, local heating, 
and therapeutic delivery represent significant barriers and therefore promising areas to address 
with nanotechnologies (Fig. 1.7). Towards this end, the overall goal of this thesis is to harness 
optically-active nanomaterials to (1) non-invasively image, (2) locally heat, and (3) enhance 
therapeutic delivery to ovarian tumors. 
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1.4.1 Non-invasive Imaging 
In Chapter 2, a novel nanomaterial-based method for non-invasive imaging of 
disseminated ovarian tumor nodules is described (Fig. 1.8). We characterize an ovarian tumor-
targeted imaging probe consisting of M13 virus-stabilized single-walled carbon nanotubes 
(SWNTs). The fluorescence emission spectra of SWNTs resides in the second near-infrared 
window (950-1400 nm), permitting deep-tissue imaging and superior signal-to-noise ratios 
compared to comparable probes in the NIR and visible regimes. We assess the probe’s stability, 
fluorescence, and pharmacokinetics in physiological environments both in vitro and in vivo. We 
demonstrate that the SWNT probe binds to ovarian tumors embedded on the intestine, liver, and 
spleen with high tumor-to-background ratios and use histopathological analysis to confirm the 
probe’s tumor sensitivity. To illustrate the utility of this approach for clinical applications, we 
 
Figure 1.7. Overall summary of Aims. This thesis describes the development and application 
of optically-active nanomaterials for advancing three aspects of ovarian cancer management. 
Specifically, technologies for non-invasive tumor imaging, localized heating, and enhanced 
drug transport are addressed.  
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demonstrate that SWNT image guidance led to improved detection and excision of ovarian 
tumors during cytoreductive surgery performed by a gynecological surgeon.  
 
1.4.2 Localized Heating 
1.4.2.1 Photothermal ablation in GEMM 
Chapter 3 describes the development of a therapeutic protocol for PEG-NR-mediated 
photothermal ablation in a genetically engineered mouse model (GEMM) of soft tissue sarcoma. 
While plasmonic nanomaterials are being evaluated for the clinical management of diverse 
cancer types, pre-clinical studies have utilized tumor xenograft models that fail to recapitulate 
important stromal and parenchymal features of human tumors such as vascularity, blood flow, 
and mutational landscape. We investigate the EPR-mediated passive accumulation of PEG-NRs 
within GEMM tumors and develop a therapeutic photothermal ablation protocol that 
demonstrates significant antitumor effect and enhanced survival. We also describe non-specific 
heating effects of photothermal ablation that are not observed in tumor xenograft models, 
illustrating an added advantage of the GEMM model. Collectively, this Chapter validates the 
effectiveness of PEG-NR-mediated photothermal ablation in a more representative model of 
 
Figure 1.8. Schematic for Chapter 2. Tumor-targeted single-walled carbon nanotubes 
(SWNTs) are developed to selectively bind to deep ovarian tumors. Imaging in the second 
near-infrared window permits highly sensitive, non-invasive imaging of tumor nodules for 
surgical guidance and may assist diagnostic tumor staging and monitoring progression after 
therapy.  
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human cancer, providing further rationale for studying the utility of plasmonic nanomaterials in 
clinical settings.  
1.4.2.2 Implanted NIR Source 
In Chapter 4, we explore a nanomaterial-based strategy for the localized heating of 
deeply-seated and disseminated ovarian tumors (Fig. 1.9). Because biological tissues such as 
skin, blood, and fat attenuate NIR light and limit its penetration depth, studies utilizing 
plasmonic nanomaterials have traditionally focused on extracorporeal energy sources directed 
upon isolated subcutaneous tumors. By combining systemically-delivered PEG-NRs with an 
implanted NIR source, we describe a novel approach for achieving localized heating for deeper 
tumors. In this Chapter, we characterize a series of implanted NIR light sources by 
computational modeling, fluence and thermographic measurements, and in vivo functionality. In 
orthotopic ovarian tumor xenograft models, we observe selective, localized heating of ovarian 
tumors and correlate this with enhanced accumulation of diagnostic and therapeutic cargoes. 
This work highlights how the combination of optically-active nanomaterials and implanted NIR 
sources can lead to effective photothermal therapy in complex anatomic environments.  
 
 
Figure 1.9. Schematic for Chapter 4. Localized heating of deep ovarian tumors is described 
using a combination of systemically-administered PEG-NRs and implanted NIR sources.  
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1.4.3 Enhanced Therapeutic Delivery 
Chapter 5 addresses a role for PEG-NR heating to enhance the delivery of diagnostic and 
therapeutic cargoes to ovarian tumors (Fig. 1.10). Because chemotherapeutic regimens in the 
clinic are often administered as multiple cycles spanning weeks to months, we specifically 
focused on the effects of single exposures versus re-exposure to PEG-NR heating on tumor 
transport. We observed a transient resistance to therapeutic cargo accumulation termed 
‘thermotolerance’ after an initial PEG-NR heat exposure and implicated the endothelial heat 
shock response as a contributor to this phenomenon. This work reveals an endothelial adaptation 
to nanomaterial-mediated heat exposure known as vascular thermotolerance and highlights a 
functional consequence on the delivery of diagnostic and therapeutic cargoes in tumors. 
 
 
Figure 1.10. Schematic for Chapter 5. The effects of PEG-NR heating on tumor transport are 
explored. Following an enhancement in tumor transport after an initial PEG-NR heat exposure, 
the tumor endothelium, mediated by the heat shock response and Hsf1, develops 
thermotolerance, leading to decreased tumor transport upon re-exposure to heating. We explore 
this effect using a combination of in vivo accumulation studies, in vitro microfluidic vessel 
models, cytoskeletal dynamics, intravital microscopy of the tumor environment, and genetic 
models to elucidate the role of the heat shock response. We apply the kinetic and mechanistic 
details to evaluate therapeutic protocols involving diffusion-limited chemotherapeutic 
compounds. 
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CHAPTER 2. NANOMATERIALS FOR NON-INVASIVE TUMOR 
IMAGING  
2.0   Abstract:  
Highly sensitive, non-invasive detection of small, deep tumors for early diagnosis and 
surgical interventions remains a challenge for conventional imaging modalities. Second window 
near-infrared light (NIR2: 950-1400 nm) is promising for in vivo fluorescence imaging due to 
deep tissue penetration and low tissue autofluorescence. With their intrinsic fluorescence in the 
NIR2 regime and lack of photobleaching, single-walled carbon nanotubes (SWNTs) are highly 
attractive contrast agents to detect tumors. Here, targeted M13 virus-stabilized SWNTs are used 
to non-invasively visualize deep, disseminated tumors in vivo. This nanoprobe demonstrates 
excellent tumor-to-background uptake and exhibits higher signal-to-noise performance compared 
to visible and near-infrared (NIR1) dyes for delineating tumor nodules. Detection and excision of 
tumors by a gynecological surgeon improved with SWNT image guidance and led to the 
identification of sub-millimeter tumors. Collectively, these findings demonstrate the promise of 
targeted SWNT nanoprobes for non-invasive disease monitoring and guided surgery. 
2.1   Introduction:  
In clinical oncology, in vivo fluorescence imaging has emerged as a valuable tool for 
improving diagnosis, staging tumors, monitoring response to therapy, and detecting recurrent or 
residual disease. Compared to existing imaging modalities, fluorescence imaging offers a low 
cost, portable and safe alternative (i.e. non-ionizing radiation), with key advantages including 
real-time imaging, superior resolution, and high specificity for small tumor nodules during 
diagnostic and intraoperative surgical procedures.[192, 193] While efforts have focused on using 
visible and short near-infrared (NIR1: 650 nm – 900 nm) wavelength fluorescent dyes as contrast 
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agents for delineating tumor margins in both pre-clinical cancer models [193, 194] and human 
patients[27], these agents are suboptimal for non-invasive, reflectance-based imaging due to 
limited penetration depth (3-5 mm) and high tissue autofluorescence. During intraoperative 
surgery, these dyes may additionally undergo photobleaching, thereby reducing the ability of the 
surgeon to readily locate and resect tumors. Alternative approaches to specifically permit non-
invasive imaging and limited photobleaching would be highly desirable for diagnostic and 
surgical applications.  
Single-walled carbon nanotubes (SWNTs) hold great promise as fluorescence imaging 
agents due to the large interband difference between their excitation and emission wavelengths, 
resulting in minimal spectral overlap and tissue autofluorescence. In particular, the low tissue 
autofluorescence observed with SWNTs greatly enhances target-to-background ratios necessary 
for improved detection of small tumor nodules in confined anatomic regions. SWNT emission at 
longer wavelengths in the near-infrared second window (NIR2: 950-1400 nm) results in less 
optical scattering and deeper tissue penetration compared to shorter wavelength visible and NIR1 
imaging agents. Simulations and experimental results suggest greatest tissue penetration depth is 
achieved in the NIR2 regime, which further highlights using SWNTs for biological imaging 
applications.[30, 195] Additionally, unlike visible and near-infrared dyes, well-functionalized 
SWNTs are less susceptible to photobleaching or quenching effects, which make them attractive 
for continuous, long-term imaging required during many surgical procedures.[196] Previously, 
we have demonstrated that M13 bacteriophage-stabilized SWNTs can target subcutaneous 
prostate tumors in pre-clinical models for fluorescence imaging in the second near-infrared 
window.[36] SWNTs have also been utilized for vascular and deep tissue fluorescence 
imaging.[33, 197] To date, however, there has been no report of a molecularly-targeted, 
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fluorescence imaging agent capable of non-invasive imaging and guiding diagnosis for surgical 
resection.  
Here we report an M13-stabilized SWNT probe that selectively targets SPARC (Secreted 
Protein, Acidic and Rich in Cysteines)-expressing tumor nodules in an orthotopic mouse model 
of human ovarian cancer. Ovarian cancer remains a major health care problem for women. 
Annually, 225,000 women worldwide are diagnosed with epithelial ovarian cancer (EOC) and 
approximately 140,000 women die from it.[198] While women with early stage ovarian cancer 
(FIGO stage I/II) can be cured, advanced stage ovarian cancer (FIGO III/IV) remains 
considerably more difficult to treat. Unfortunately, eighty percent of women with EOC have 
metastatic disease at the time of diagnosis, and many undergo a treatment regimen of surgery and 
chemotherapy. Our study focused on ovarian cancer because clinical evidence indicates that 
optimal surgery can significantly prolong the median overall survival of patients as well as 
reduce disease morbidity.[45] Using the NIR2 emission of these fluorescence probes, we 
determine the detection limit of labeled tumors and their target-to-background ratios. We 
demonstrate that this SWNT-based probe detects tumors not observed with visible and NIR1 
dyes, thereby aiding the discovery of smaller tumors during surgery. Collectively, our results 
highlight the potential for molecularly-targeted NIR2 fluorescence probes to non-invasively 
monitor disease processes such as cancer with enhanced sensitivity compared to current state-of-
the-art optical probes. 
2.2   Materials and Methods:  
SBP-M13-SWNT Complexation 
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To prepare the starting SWNTs, non-acid treated HiPCO SWNTs (Unidym) were diluted 
in aqueous 2 wt% sodium cholate (SC). The solution was then homogenized for 1 hour, cup-horn 
sonicated for 10 minutes at 90% amplitude and then centrifuged at 30,000 rpm for 4 hours to 
disperse individual SWNTs. SWNT concentration was determined by measuring absorbance at 
632 nm and calculated using the extinction coefficient of HiPCO SWNT at 632 nm, 632 
nm=0.036 L/mg•cm. Complexation of M13 to SWNT was performed as previously 
described.[36] Briefly, the calculated amount of SWNT-binding phage solution was mixed with 
the calculated volume of SWNTs dispersed by 2 wt% SC in water to achieve a 1:1 stoichiometric 
ratio of phage-to-SWNT. The solution was placed in a dialysis membrane with MWCO 12,000-
14,000 and dialyzed against water (10 mM NaCl, pH =5.3) for 48 hours with frequent buffer 
exchange. pH of the dialyzing solution was increased to 10 after 48 hours of dialysis. After 
dialysis, the phage-SWNT complex was removed and placed in a conical tube. Prior to 
experiments, samples were resuspended in 1X PBS, vortexed and centrifuged at 6000 rpm for 5 
minutes. 
Cell Culture and Establishment of an Orthotopic Ovarian Cancer Model 
All animal studies and procedures were approved by the MIT Institutional Animal Care 
and Use Committee. This study used the established human ovarian epithelial carcinoma cell line 
OVCAR8, engineered to constitutively express firefly luciferase. OVCAR8 cells were grown in 
RPMI 1640 medium containing 10% fetal bovine serum, penicillin, and streptomycin. 
Approximately 2 x 106 OVCAR8 cells suspended in 200 µL DMEM (high glucose, phenol-red 
free) (Invitrogen) were implanted into the peritoneal cavity of athymic (nu/nu) mice to establish 
orthotopic ovarian tumor models. Mice were monitored by whole-animal bioluminescence 
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imaging to assess tumor burden. Imaging experiments were performed approximately 7-14 days 
following tumor cell injection based on the measured bioluminescence intensity.  
In vivo Fluorescence Imaging of SBP-M13-SWNTs 
SBP-M13-SWNTs were injected into the peritoneal cavity of tumor-bearing animals at 
≈200 µg/kg. Mice were anesthetized with isoflurane gas. Fluorescence images were obtained 
approximately 24 hours following injection with exposure times ranging from 0.01 to 1 second 
for each subject. Background images were subtracted from raw images to generate the final 
images. We constructed equivalent standardized regions of interest (ROIs) to determine tumor-
to-background ratios at various locations within the peritoneal cavity. For comparisons of SBP-
targeted and untargeted M13-SWNT probes, we compared NIR fluorescent intensities of excised 
tumor nodules with normal intestinal tissue. Image intensities were quantified with ImageJ 
software.  
Comparison of In vivo Non-Invasive Imaging between SBP-M13-SWNTs, Near-Infrared Dye, 
and Visible Dye 
To confirm improved signal-to-noise in the NIR2 regime, SBP-M13-SWNT was 
compared to an NIR1 dye, AlexaFluor 750 (AF750), and a visible dye, fluorescein 
isothiocyanate (FITC). Briefly, two-fold dilutions of SBP-M13-SWNT or SBP-M13 conjugated 
with either AF750 or FITC (designated SBP-M13-AF750 and SBP-M13-FITC) were prepared 
onto a microtiter plate and their fluorescence was measured using either the custom-built NIR2 
reflectance imager or an IVIS Spectrum, respectively. Samples were measured within the linear 
range of detection, set from 1,000 to 60,000 for each instrument. Images were acquired under 
various exposure times, from 0.01 seconds to 10 seconds. Fluorescence from SBP-M13-SWNT 
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was measured using the custom-built NIR2 reflectance imager at maximum aperture, with a laser 
power of ~100 mW/cm2 at 0.01, 0.05, 0.1, 0.5, and 1 second exposures. SBP-M13-AF750 or 
SBP-M13-FITC was measured using an IVIS Spectrum in epi-illumination mode, under highest 
power, with fstop1 or fstop2 aperture (maximum and second-highest aperture) at 0.5, 1, 2, 5, and 
10 second exposures. Regions of interest (ROIs) were drawn around microtiter wells and 
fluorescence counts were determined for samples in the linear range (i.e. 1,000 – 60,000) using 
ImageJ software. The limit of detection of the probe was determined to be the minimum 
concentration detectable by the imaging system within the linear range.  
To compare signal-to-noise ratios in vivo, probes were combined and administered in 
five-fold excess of their minimum detection limit to mice bearing disseminated intraperitoneal 
OVCAR8 tumors. Fluorescence images from SBP-M13-SWNT, SBP-M13-AF750, and SBP-
M13-FITC were acquired using the NIR2 imager and IVIS, respectively. Images obtained from 
the NIR2 imager were taken at 0.01, 0.05, 0.1, 0.5, and 1 second exposures. Images taken using 
the IVIS Spectrum were acquired at 0.5, 1, 2, 5, and 10 second exposures. All images were 
analyzed using ImageJ software. ROIs were drawn around the peritoneal cavity containing 
tumors, muscle, and image background. Fluorescence intensities were determined from the ROIs 
and tumor-to-muscle and tumor-to-background ratios were calculated. Samples were run with 
standard error (n = 3).  
SBP-M13-SWNT Imaging During Surgery 
Surgical studies were performed by a gynecologic surgeon. Animals were administered 
≈200 µg/kg SBP-M13-SWNTs approximately 24 hours prior to surgery. For comparisons of 
initial surgery with or without SWNT-guidance, animals were randomly assigned to one of these 
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cohorts, and NIR2 fluorescence images were obtained 2-4 hours prior to surgery for all animals. 
For animals assigned to the SWNT-guided cohort, the whole-abdomen NIR2 fluorescence 
images were assessed by the surgeon prior to and during the surgical procedure. Excised nodules 
were measured, photographed, and imaged for SWNT-based fluorescence. 
Genetic engineering of SPARC binding peptide (SBP) onto p3 of SWNT-binding M13 phage 
Genetic engineering of the SPARC binding peptide (designated as SBP) and SWNT-
binding peptide (designated as DSPH) was described previously.[36] Briefly, oligonucleotides 
encoding SPARC binding peptide (designated as SBP, SPPTGINGGG [199]), 5’(Phos)-GTA 
CCT TTC TAT TCT CAC TCT TCA CCA CCG ACT GGA ATT AAC GGA GGC GGG TC -
3’ and 5’(Phos)-GGC CGA CCC GCC TCC GTT AAT TCC AGT CGG TGG TGA AGA GTG 
AGA ATA GAA AG-3’ (IDT) were annealed and inserted into the EagI and Acc65I restriction 
endonuclease sites of double stranded M13 DNA for N-terminal display on p3. The M13-based 
cloning vector was isolated from the SWNT-binding phage using standard DNA isolation 
(QIAGEN). Ligations were transformed in electrocompetent XL-1 Blue cells (Agilent 
Technologies), plated in top agar and incubated at 37°C overnight. DNA was purified (Qiagen) 
from isolated blue plaques and sequenced to confirm the insertion of SBP on p3.  
Absorbance and PLE measurements 
Absorption measurements were taken with a DU800 spectrophotometer (Beckman 
Coulter). PL of SWNTs was measured with a FluoroMax spectrofluorometer (Horiba Jobin 
Yvon).  
Imager Setup 
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For fluorescence imaging in the second near-infrared window, an in-house in vivo imager 
was previously described[36]. A liquid nitrogen-cooled OMA V 2D InGaAs array detector 
(detection range: 800 – 1,700 nm) with a 256 × 320 pixel array (Princeton Instruments) was 
used. A NIR camera lens (SWIR-25, Navitar) was attached in front of the InGaAs detector. To 
reduce tissue autofluorescence and maximize the detection of fluorescence from SWNTs, two 
stacked long-pass filters with cut-off wavelength of 1,100 nm and OD >4 (EdmundOptics) were 
used. For excitation, an optical fiber coupled to an 808 nm diode laser (MDL-F-808, 
OptoEngines) was used and a laser line filter with center wavelength of 808 nm (EdmundOptics) 
was attached in front of the laser to remove unwanted excitation light. To minimize laser 
exposure to animals, a computer-controlled shutter was incorporated into the imaging system. 
The measured fluence on the mouse for in vivo imaging was ~120 mW/cm2. The acquisition time 
for in vivo imaging ranged from 0.01 seconds – 1 second. For white contrast images, the same 
detector was used but the mice were illuminated with white light.  
Blood and Ascites Stability and pH Measurements 
For blood stability measurements, 20 µg/mL SBP-M13-SWNT was diluted in two-fold 
dilutions with PBS and then diluted 1:1 volume with blood obtained from healthy mice 
(Research Blood Components) and incubated for 0, 1, 2, 4, and 24 hours. Samples were 
measured at the given time point using the NIR2 imager at 0.01 second exposure. For pH 
stability, SBP-M13-SWNT were calibrated to pH = 4.5, 5.5. 6.5, 7.5, or 8.5 and samples were 
incubated 0, 1, 2, 4, and 24 hours. Samples were measured using NIR2 imager at 0.01 second 
exposure and normalized to the baseline value. 
Cell Viability Assay 
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To confirm OVCAR8 viability in the presence of SBP-M13-SWNT, 5,000 cells were 
seeded into each well of a 96-well plate and incubated with 10, 5, 2.5, 1.25, 0.62, and 0 µg/mL 
SBP-M13-SWNT. 24 hours after probe incubation, Alamar Blue (Life Technologies) reagent 
was added and fluorescence was measured 4 hours post-addition, following manufacturer’s 
recommendations. Viability was normalized to blank control. Samples were run in quadruplicate.  
Depth of Detection Limit of Tumors Labeled with SBP-M13-SWNT 
Mice bearing OVCAR8 tumors were injected with ~200 µg/kg SBP-M13-SWNT. 
Twenty-four hours post-injection, tumors were excised. To determine the limit of detection by 
reflectance imaging, labeled tumors were cut into 1 mm diameter fragments and placed in a 
quartz capillary tube (Sutter Instruments). The quartz capillary tube was placed in an XFM-2 
phantom mouse (Caliper) with the same optical properties of human tissue at 0, 4.3, 7.0, 9.7, or 
18.2 mm depths. The fluorescence from the labeled tumor fragments was measured using the 
NIR2 imager at maximum aperture using 0.5 second exposure time. Background fluorescence 
images were also acquired before addition of labeled tumors. To quantify detection depth, 
background images were subtracted from acquired images of fluorescent tumors, and equivalent 
ROIs were drawn for images taken from each depth to calculated signal intensity. 
Immunohistochemistry and fluorescence  
Excised tissues were fixed in 10% formalin, embedded in paraffin, and sectioned for 
histology. Hematoxylin and eosin (H&E) staining was performed on tissue sections. For SPARC 
staining, rat anti-SPARC (1:40, R&D Systems) and rat isotype IgG (1:200, Abcam) were used 
with biotin-conjugated goat anti-rat antibody (Vector Labs, BA-9401), followed by the 
Vectastain ABC immunoperoxidase kit (Vector Labs, PA-6100) and DAB substrate (Vector 
49 
 
 
Labs, SK-4100) for detection and visualization. For immunofluorescence, AlexaFluor donkey 
anti-rat 488 secondary antibody (Life Technologies) was used on frozen tissue sections. To 
visualize SBP-M13-SWNT by fluorescence, AlexaFluor 750 carboxylic acid, succinimidyl ester 
(Life Technologies) was conjugated to SBP-M13-SWNT via primary amine linkage following 
manufacturer’s recommendations and excess dye was removed by extensive dialysis before 
usage. 
2.3   Results:  
2.3.1 Physicochemical Characterization of M13-Stabilized SWNT Probe  
The imaging probe (SBP-M13-SWNT) consists of three fundamental components: the 
SPARC binding peptide (SBP), M13 virus (M13), and single-walled carbon nanotubes (SWNTs) 
(Fig. 2.1). The filamentous M13 virus (6 nm diameter, 880 nm length) is genetically modifiable 
to incorporate peptides for display on the various coat proteins of the virus. M13 can display 
peptides with affinities to materials or biomolecules through iterative panning and selective 
enrichment for diverse applications including epitope mapping, ligand discovery against cells 
and tissues, and binding and nucleation of materials.[38, 200-202] The modularity of M13 can be 
further exploited to target various biomarkers in cancers, highlighting its attractiveness as a 
multifunctional probe. Previously, we used phage display to identify a peptide along the p8 
major coat protein of M13 that binds and stabilizes SWNTs, while retaining the optical and 
electronic properties of the nanotubes.[202] Because M13 is amenable to genetic modification 
for peptide display, we further engineered the p3 minor coat protein to display a targeting peptide 
that binds SPARC (for Secreted Protein, Acidic and Rich in Cysteine).[199] SPARC is a 
matricellular protein highly expressed in certain subtypes of breast, prostate, and ovarian cancer. 
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SPARC overexpression has been shown to enhance ovarian cancer cell proliferation, invasion 
and metastasis. High levels of SPARC expression have been associated with high stage of 
ovarian carcinoma and correlated with poor clinical prognosis, suggesting its relevance as a 
clinical biomarker.[203] Collectively, this genetically-engineered NIR2 probe enables the 
localization, detection, and surgical excision of ovarian tumors, as outlined in the schematic 
presented in Fig. 2.1.  
 
To ensure that our probe retained its functionality following its synthesis, we examined 
the optical properties of SBP-M13-SWNTs. Compared to unmodified starting SWNTs dispersed 
  
Figure 2.1. Schematic illustrating probe binding with ovarian tumor nodules for non-
invasive detection by NIR2 fluorescence and surgical excision.
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in sodium cholate, complexed SBP-M13-SWNTs exhibit similar optical absorbance (Fig. 2.2). 
Photoluminescence (fluorescence) mapping of the excitation and emission wavelengths of SBP-
M13-SWNT suggests M13-stabilized SWNTs retain their fluorescent properties; non-dispersed, 
aggregating or bundled SWNTs would quench and not fluoresce, and thus, not appear in the 
fluorescence mapping.  
 
To establish their use for in vivo applications, we validated the stability of SBP-M13-
SWNTs in blood and ascites and at different pH values by measuring the fluorescence over 24 
hours using a custom-built small animal NIR2 fluorescence imager developed in our 
laboratory.[36] SBP-M13-SWNTs retain fluorescence at various dilutions in the blood and 
ascites fluid from the peritoneal cavity (Fig. 2.3), and we did not observe quenching of the probe. 
Previous reports indicate that exposed SWNTs in solution will adsorb serum proteins on their 
sidewall and subsequently lose fluorescence.[36, 204] Here, we observe no loss of fluorescence 
intensity, indicating the probes are well solubilized by M13 and highly stable for in vivo imaging 
applications. In addition, the probe is fluorescently stable across a broad pH range, from 4.5 to 
 
Figure 2.2. Absorbance spectra of SWNTs in sodium cholate and as SBP-M13-SWNT probe. 
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8.5 (Fig. 2.3), suggesting the probes will be stable in the vascular and lymphatic systems, 
peritoneal cavity, and for cellular uptake. We also confirmed the targeted probes are well 
tolerated and non-cytotoxic to target OVCAR8 ovarian cell line (Fig. 2.3), which underscores 
their potential for in vivo imaging applications. 
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We next examined the sensitivity of the probe in terms of its capacity to target OVCAR8 
ovarian cancer cells in vitro. Serial ten-fold dilutions of OVCAR8 cells were incubated with 
SBP-M13-SWNT for 24 hours and cell lysates were collected. Measuring the fluorescence 
 
 Figure 2.3. Stability and cytotoxicity of SBP-M13-SWNTs. (a) Serial two-fold dilutions of 
SBP-M13-SWNTs were incubated in blood to assess detection range and stability of the 
imaging probe in an in vivo environment for periods up to 24 hours. NIR2 fluorescence 
measurements directly correlated with concentration of SBP-M13-SWNT, and the fluorescence 
remained stable for periods up to 24 hours. Dilutions were measured in duplicate. Error bars 
denote standard deviation. (b) Serial two-fold dilutions of SBP-M13-SWNTs were incubated 
in ascites harvested from a tumor-bearing mouse to assess stability and detection limit of the 
imaging probe for periods up to 28 hours. Fluorescent signal was directly proportional to 
concentration of SBP-M13-SWNT in ascites. Dilutions were measured in duplicate. Error bars 
denote standard deviation. (c) SBP-M13-SWNTs were incubated at pHs between 4.5 – 8.5 for 
periods up to 24 hours. NIR2 fluorescence measurements were unaffected by pH of the solution 
for periods up to 24 hours. Samples were measured in duplicate. Error bars denote standard 
error. (d) OVCAR-8 cells incubated in the presence of SBP-M13-SWNTs remain viable at 
[SBP-M13-SWNT] between 0 - 10 ug/mL. Six samples were run for each experimental 
condition. Error bars denote standard error (n = 6). 
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intensity of the SBP-M13-SWNT incubated cells using our custom-built imaging system, we 
observed that as few as approximately 10,000 cells incubated with SBP-M13-SWNT exceeded 
the minimum level of detection (Fig. 2.4).   
To test SBP-M13-SWNT for risk of photobleaching, we exposed them to an 808 nm laser 
for a continuous, 30 minute period and measured fluorescence intensity in five minute intervals 
up to 30 minutes post-irradiation. No appreciable loss of fluorescence of M13-SBP-SWNTs was 
observed during this period. However, the intensity of fluorescein isothiocyanate (FITC), a 
fluorescein derivative that has been used to molecularly image and guide intraoperative resection 
of ovarian tumors in humans, exponentially decreased during the same light exposure kinetics 
(Fig. 2.4).[27] The observations that SWNTs do not photobleach and also maintain their optical 
properties illustrate that these particles have the potential to assist surgeons to visualize tumors 
during resection. 
Another potential advantage of SWNT-based imaging compared to FITC-based imaging 
is the potential to detect tumors located at greater depths in the body. To investigate the depth of 
detection that can be achieved with our probe, we harvested ovarian tumors that had been treated 
with SBP-M13-SWNTs and imaged the small tumor fragments (~1 mm diameter) at various 
depths within a tissue ‘phantom’ construct, which mimics the optical properties of human tissue. 
Using our NIR2 fluorescence reflectance imaging system, we could detect SWNT-containing 
tumors to depths as great as 9.7 to 18.2 mm (Fig. 2.4).[36] To our knowledge, this is the best-
reported quantifiable tumor depth using reflectance imaging, relative to previously reported 
values.[194] By permitting deeper imaging, SBP-M13-SWNT therefore offers the potential for 
non-invasive detection prior to surgery and improved resection of tumors during surgery.    
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Having demonstrated the in vitro stability and fluorescence of SBP-M13-SWNT, we 
proceeded to characterize the in vivo properties of the probe in an orthotopic model of ovarian 
cancer. OVCAR8 human cell line was used to create the orthotopic model, since it overexpresses 
the target SPARC, as confirmed by Oncomine analysis and immunohistochemistry (Fig. 2.5). 
[205]To compare routes of administration, tumor-bearing animals were injected intraperitoneally 
or intravenously and the circulating probe concentration was monitored via SWNT fluorescence 
in the blood. Intravenously administered SBP-M13-SWNT reached a peak concentration in the 
circulation approximately 10 minutes after injection, and circulating levels became negligible 
after 150 minutes (Fig. 2.5). Notably, SBP-M13-SWNT administered intraperitoneally led to 
negligible elevations in blood-borne SWNT fluorescence for at least 24 hours, suggesting that 
the majority of SBP-M13-SWNT remain in the peritoneum following injection (Fig. 2.5). This 
finding was verified by the observation that, following a transient increase in NIR2 fluorescence 
  
Figure 2.4. (a) In vitro sensitivity of SBP-M13-SWNT fluorescence in ovarian cancer cell 
culture. (b) Photobleaching fluorescence decay of FITC and SBP-M13-SWNTs under 
continuous excitation. (c) Depth of detection of tumors labeled with SBP-M13-SWNTs. 
Tumors containing SBP-M13-SWNTs were excised from mice into 1 mm diameter fragments 
and placed within a tissue phantom at varying known depths (0, 4.3, 7.0, 9.7, or 18.2 mm). 
Samples were imaged using a custom-built fluorescence imager at 0.5 s exposure. Samples 
were detectable to depths as great as 9.7 to 18.2 mm in the tissue phantom. Five samples were 
measured per condition. Error bars denote standard deviation (n = 5).
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in the peritoneum, the overall intensity in this location stabilizes for periods up to 24 hours 
following injection (Fig. 2.6).  
 
 
Figure 2.5. (a) SPARC Expression in OVCAR-8 Tumors. OVCAR-8 subcutaneous xenografts 
(left top; isotype control shown on left bottom) and orthotopic tumors (right) were processed 
for immunohistochemistry and examined for expression of SPARC. Both subcutaneous and 
orthotopic OVCAR-8 tumors express SPARC protein. Enhanced SPARC expression observed 
in the viable tumor rim of the orthotopic nodule (N, expression indicated by black arrow) seeded 
on liver (L). Scale bars: 100 µm (left top, bottom), .1 mm (right) (b) Pharmacokinetic circulation 
study of SBP-M13-SWNT administered intravenously (IV) and intraperitoneally (IP). 
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2.3.2 Improved Signal-to-Noise Performance In vivo Using SBP-M13-SWNT in NIR2 
Wavelength Regime  
Signal-to-noise behavior is a critical parameter for sensitive detection of tumors. To 
directly compare the signal-to-noise ratios between SWNTs and dyes in the NIR1 or visible 
regimes, SBP-M13 viruses were either complexed to SWNTs or conjugated with AlexaFluor750 
dye (SBP-M13-AF750) or FITC (SBP-M13-FITC). Probes were then combined and added in 
five-fold excess of their minimum detection limits to mice bearing disseminated tumors. Images 
were acquired (Fig. 2.7) and fluorescence intensities from tumors in the peritoneal cavity, muscle 
and background were determined. The tumor-to-muscle ratio of SBP-M13-SWNTs was 5.5 ± 1.2 
(mean ± s.d), which was significantly higher than ratios calculated for SBP-M13-AF750 (3.1 ± 
0.42) and SBP-M13-FITC (0.96 ± 0.10) (Fig. 2.7). The tumor-to-background ratio (i.e., intensity 
of tumor to image background) achieved using SBP-M13-SWNTs was 134.9 ± 21.0, which was 
 
Figure 2.6. (a) Representative whole abdomen NIR2 imaging series following intraperitoneal 
administration of SBP-M13-SWNTs. Inset (far right): Surgically excised tumor nodule 
(denoted by red arrow) observed 24 hours post-injection of SBP-M13-SWNTs. (b) NIR2 
fluorescence intensity in the abdomen of tumor-bearing animals following IP administration of 
SBP-M13-SWNTs up to 24 hours post-injection. (n = 5)   
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a 24- and 28-fold improvement over SBP-M13-AF750 and SBP-M13-FITC, respectively (Fig. 
2.7). Importantly, as highlighted by the arrows in Fig. 2.7, tumor nodules not observed in the 
visible and NIR1 channels were detectable in the NIR2 regime with SBP-M13-SWNTs, which 
highlights the sensitivity of SWNT probe and imaging system.   
 
  
Figure 2.7. (a) Non-invasive imaging of ovarian tumors using SBP-M13 conjugated to SWNTs 
(NIR2) , AlexaFluor750 (NIR1), and FITC (Visible) (top to bottom) Arrows in SWNT panel 
denote nodules visible only by SWNTs. (n=3 animals) (b-c), Tumor-to-muscle ratio and tumor-
to-background ratio from non-invasive images obtained with SWNTs, AF750, and FITC. (n=3 
per group; ***P <0.001; *P<0.05; one-way ANOVA and Tukey post tests.) Error bars, s.d. 
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2.3.3 Selective and Molecular Targeting of SBP-M13-SWNT to Ovarian Tumors In vivo  
Because many tumor nodules are implanted on the surfaces of peritoneal organs in this 
model, we also computed organ-specific TBRs for tumor nodules on the liver, intestine, and 
spleen. Representative photographs of organs containing tumor implants on their surface with 
their corresponding NIR2 fluorescent images are shown in Fig. 2.8. The TBRs (i.e., ratio of 
surface tumor nodule fluorescence relative to that observed in its underlying organ) calculated 
for the liver, intestine, and spleen were 4.6, 8.0, and 3.1, respectively (Fig. 2.8), highlighting the 
specificity of the probe towards tumor nodules compared to its underlying organs. 
The in vivo sensitivity of targeting conferred by the SPARC-binding peptide (SBP) was 
assessed by injecting tumor-bearing animals with M13-SWNTs expressing SBP or untargeted 
M13-SWNTs. The NIR2 intensities of excised tumor nodules and intestinal tissue of the same 
animal were used to compute target-to-background ratios (TBR) for the targeted and untargeted 
probes. SBP-M13-SWNTs showed significant, ten-fold higher TBR than untargeted M13-
SWNTs, likely due to a combination of improved targeting and reduced tissue autofluorescence 
in the second near-infrared window (Fig. 2.8).   
To verify the molecular specificity of SBP-M13-SWNTs, we assessed the SWNT-
positive tumor nodules by immunohistochemistry. Standard hematoxylin and eosin (H&E) 
staining of SWNT-positive tumor sections revealed histopathological features consistent with 
ovarian tumor nodules, including a high nuclear-to-cytoplasmic ratio, cellular crowding, a 
necrotic core, and a distinct architecture from underlying organs (Fig. 2.8). Interestingly, the 
liver displayed a fluorescent signal where no tumor nodule was visible by eye, and after biopsy 
of the indicated area, H&E staining indicated pathology consistent with a tumor nodule located 
on the liver (Fig. 2.8). Additionally, immunohistochemical staining revealed an enrichment of 
60 
 
 
SPARC expression along the periphery of the SWNT-positive tumor nodules (Fig. 2.8). Finally, 
to assess whether our probe specifically co-localizes with SPARC-expressing regions of the 
tumor nodules, we administered SBP-M13-SWNTs conjugated with AlexaFluor 750 to tumor-
bearing mice and analyzed the excised tumor nodules by immunofluorescence. In multiple 
nodules, SPARC was widely expressed, with particularly strong expression at the tumor 
periphery (Fig. 2.8) in a pattern consistent with our immunohistochemical staining described in 
Fig. 2.5. The AF750-labeled SBP-M13-SWNTs were similarly enriched at the tumor periphery 
(Fig. 2.8). These patterns are consistent with an outside-in diffusion model limited both by the 
hydrodynamic radius and ligand interactions of SBP-M13-SWNTs with the tumor nodule. 
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Figure 2.8. (a) Photographs and NIR2 fluorescence (10-50 ms exposure) of tumor 
nodules implanted on several peritoneal organs. (b) Quantification of nodule and organ-specific 
background for nodules present on the liver, intestine, and spleen. (n=8-11 nodules per organ) (c) 
Tumor to intestine ratio for targeted and untargeted M13-SWNT probes. Intestinal tissue used for 
background intensity. (+SBP, n=6; -SBP, n=13)  (d) Representative NIR2 fluorescence and H&E 
staining of a positive nodule revealing characteristic tumor histology. (e) Immunofluorescence 
staining reveals co-localization of M13-SBP-SWNTs conjugated to AlexaFluor750 dye with 
SPARC expression in an NIR2-positive nodule. Scale bars: 10 mm (a), 10 mm (d, NIR2), 250 
um (d, H&E Liver nodule), 125 um (d, H&E Nodules), 5 mm (e, NIR2), 2.5 mm (e, SPARC, 
AF750-M13) 
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Figure 2.8. (Continued).   
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2.3.4 Image Guidance Using SBP-M13-SWNT Improves Surgical Resection of Tumors  
To assess the potential clinical utility of SBP-M13-SWNTs for reduction of tumor 
burden, a gynecological surgeon performed surgeries on orthotopic models of ovarian cancer that 
were imaged at various points during the surgical procedures. Approximately 15-25 minutes 
were spent on procedures in each experiment, and tumor implants were predominantly 
distributed in the bowel mesentery, peritoneal wall, subdiaphragmatic surfaces, and surfaces of 
organs including the liver, spleen, pancreas, and within the pelvic cavity. H&E stained tissue 
sections were prepared from all excised nodules and assessed by a pathologist. With the 
exception of two non-tumor containing mesenteric lymph nodes, all tissues examined (n = 197) 
were positive for ovarian tumor tissue indicating an accuracy of 98.9% of our probe for ovarian 
tumors. Surgery was first performed with pre-operative image guidance to assess whether this 
was beneficial to the procedure based on the distribution of excised tumor nodule sizes. A 
comparative analysis of excised tumors revealed that a significantly higher number of sub-
millimeter tumor nodules were discovered in the image-guided cohorts versus the non-image 
guided cohorts (12 and 0 nodules, respectively, Fig. 2.9). Using image guidance, there were also 
greater numbers of excised tumors from 1.3 to 3 mm; however, there was no appreciable 
difference for larger tumors (> 3 mm) between image-guided and non-guided cohorts. We 
additionally assessed the impact of performing surgery in a serial manner, with an initial round 
of non-image guided surgery, followed by image acquisition and a second round of image-
guided surgery (Fig. 2.10). We observed reduction of tumor burden from non-image guided 
surgery to image-guided surgery (Fig. 2.10). We determined TBR of overall tumor burden to 
background muscle by region of interest analysis and confirmed reduction of overall tumor 
burden due to image-guided reduction (Fig. 2.10). Using both non-invasive SWNT imaging (Fig. 
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2.10) and quantification of excised tumor nodule diameters, we observed a greater number of 
sub-millimeter excised tumors in the groups assisted by SWNT image guidance (30 versus 4 
nodules, Fig. 2.10). Overall, significantly more, smaller diameter tumors were excised using 
SWNT-based image guidance as opposed to unguided surgeries (Fig. 2.10). 
 
  
 
Figure 2.9. Comparison of SWNT-Guided and Unguided Cytoreduction. Tumor-bearing animals 
were randomized to receive SWNT-guided or unguided cytoreduction. Excised tumors were 
measured along their maximum diameters prior to tissue fixation. Tumor diameters for each 
treatment group are plotted as a histogram. (n = 43 nodules, SWNT-guided; n = 24, unguided) 
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Figure 2.10. (a) Schematic of serial surgical procedure. (b) Representative whole-abdomen 
NIR2 images prior to injection of SBP-M13-SWNT, prior to surgery, after an initial, unguided 
surgery, and after subsequent SBP-M13-SWNT-guided surgery. White arrow indicates a 
SWNT-positive nodule detected only during image-guided surgery. (c) Non-invasive target-to-
background ratios during surgery. Muscle from hind limb used for background. (d) Photographs 
and NIR2 images of excised tumor nodules following unguided and SWNT-guided surgery. (e) 
Histogram of tumor diameters removed with and without guidance. (f) Dot plot of individual 
tumor nodule diameters excised with and without SWNT-guidance. (Guided, n=74; Unguided, 
n=146) Scale bars: 1 cm (b), 1 cm (c, photograph), 1 cm (c, NIR2) 
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2.4   Conclusions: 
This study describes the development and use of a single fluorescence imaging agent for 
high contrast, non-invasive detection and guidance for surgical removal of disseminated ovarian 
tumors. NIR2 emitting SWNT probes offer significantly improved signal-to-noise performance 
compared to visible and near infrared dyes and detect tumors not visualized using the optical 
dyes. These targeted, M13-stabilized SWNT probes assist surgical removal of ovarian tumors 
with excellent sensitivity as confirmed by subsequent pathological examination. The probe is 
sensitive for identifying tumor nodules located on several abdominal viscera, the peritoneal wall, 
and the bowel mesentery. Importantly, compared to fluorescent probes in the visible or NIR1 
regimes, the fluorescence of SWNTs is not limited by quenching, allowing for long-term, 
continuous imaging. Consequently, with the development of advanced imaging platforms, 
surgeons will be able to visualize tumors both before and throughout surgical procedures, 
thereby significantly improving fluorescence-guided tumor resection. This study demonstrates 
that surgery accompanied by image guidance leads to identification and removal of smaller 
tumor nodules. While NIR2 images could not provide three-dimensional localization of the 
tumor implants, they provided information about the sites of disease burden requiring closer 
surgical examination. Imaging of regions in which the surgeon was initially reluctant to explore 
in an effort to minimize morbidity such as excessive blood loss, but later revealed a positive 
NIR2 signal, often led to the identification and excision of additional tumor nodules missed on 
non-image guided approaches. While we did not investigate longitudinal survival rates after 
image-guided surgery in our animal models, the majority of clinical evidence suggests that 
optimal surgery, currently defined as the removal of tumors with diameters of 1 cm or larger, is 
correlated with improved overall survival rates.[45] SWNT-based molecular probes could 
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greatly aid in surgical planning and resection in order to help achieve a reduction in mortality 
rates in the future. 
 We achieve detection of sub-millimeter tumors with excellent target-to-background ratios 
using M13-stabilized SWNTs, in part due to properties of the particles that lead to low tissue 
scattering and minimal tissue autofluorescence in the NIR2 optical window. In comparing 
excised tumors with unaffected intestinal tissues as a background measurement, we observed 
high TBRs of ~112 using our SPARC-targeted M13-SWNT probes. Following intraperitoneal 
administration, some uptake is observed using non-targeted SWNT probes, which is most likely 
due to non-specific binding interactions or convective flow patterns present within the peritoneal 
cavity. Fluorescence imaging in the second optical window offers the promise of imaging at 
greater penetration depths (>3-5 mm) with reduced optical scattering within the tissue.  In 
comparing the performance of visible, NIR1 and NIR2 probes, the M13-SWNT probe achieved 
the highest tumor-to-muscle and tumor-to-background ratios, most likely due to less tissue 
absorbance and autofluorescence in NIR2 regime. In addition, we were able to see tumors not 
observed in the visible and NIR channels, highlighting the improved tissue penetration and 
detection in the NIR2 regime. Using our reflectance imaging system, we can detect 1 mm 
diameter tumors up to a maximal depth between 9.7 and 18.2 mm. To our knowledge, this 
represents the highest reported depth of detection using fluorescence reflectance, and is also 
higher than previous reports that detected mammary tumors labeled with activatable Cy5 
probes.[194] Future work to enhance the fluorescence of M13-SWNTs using plasmonic 
nanomaterials and molecular targeting using other ligand-receptor interactions including the 
folate receptor may offer further improvements on current limits of detection and resolution.[27, 
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206] These longer wavelength emitting probes will greatly aid in locating ovarian tumors 
confined to deep anatomical regions.  
SBP-M13-SWNT injected intraperitoneally co-localized with stromal SPARC expression 
on the periphery of the ovarian tumor nodules. Tumor nodules labeled with the probes exhibited 
high signal with low background in the surrounding healthy tissues, including liver, spleen, and 
intestine. These high organ-specific TBRs in part assisted with more accurate surgical resection 
of tumor nodules localized to the organ surfaces. Because our probes can visualize the tumor 
margins, they have potential to assist the surgeon in delineating tumors from healthy tissue for 
improved resection of other solid tumors, as also demonstrated by approaches using activatable 
peptides and dyes, fluorescein conjugates, and multimodal nanoparticles.[27, 193, 194, 207, 208]    
M13-SWNT molecular probes exhibit long-term stability and fluorescence for at least 24 
hours for in vivo imaging applications. Since the probe retains its optical properties under various 
pH and physiological environments and under constant excitation, it is an attractive candidate for 
long-term imaging for non-invasive detection and fluorescence-guided surgery. The safety of 
M13 in the clinic has been shown in a Phase I clinical trial to identify patient-specific ligands. 
The virus possessed a low toxicity profile, elicited a “submaximal” humoral immune response, 
and patients demonstrated no adverse allergic responses.[209] Similarly, recent work has 
confirmed the non-cytotoxicity of well-functionalized, short length SWNTs administered in vivo 
through histology and serum chemistry.[32, 210, 211] While further studies are required to 
conclusively establish the safety and pharmacokinetics of M13 and SWNTs, these initial findings 
support the potential use of these nanomaterials in a clinical setting.  
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While in this study we use SWNTs for fluorescence imaging, others have demonstrated 
their utility as carriers for therapeutic cargoes or genes (reviewed in [212]) as well as 
photothermal ablative therapy.[213] We have begun to explore the potential utility of SBP-M13-
SWNTs for in vivo heating of the local tumor microenvironment to assess their potential as 
sensitizing agents to chemotherapeutic agents and multimodal imaging and therapeutic agents.  
To advance our findings closer to clinical translation, new instrumentation will be 
required to allow for intraoperative surgical guidance in real-time, and three-dimensional 
tomography for quantitative analysis and more accurate localization of tumors. Simulations 
suggest that at near-infrared wavelengths that define the second near-infrared window, SWNT-
based probes may be detectable at depths up to 10 cm on improved imaging platforms, 
highlighting the potential utility of these particles in human subjects.[214] This new platform 
would allow for real-time, non-invasive imaging and processing for accurate visualization of 
tumors during tumor staging, pre-surgical planning, and during procedures. Coupling improved 
instrumentation with probe development will greatly improve the ability to detect tumors at 
earlier stages and possibly detect micrometastases. The ability to detect tumors of smaller sizes 
at earlier time points may also provide fundamental insights into tumorigenesis and disease 
progression, as well as allow clinicians to better monitor therapeutic responses and recurrence of 
disease. The modular nature of the M13 platform, which can incorporate patient-specific 
targeting peptides or antibodies, will enable the development of “personalized imaging” tailored 
to the unique tumor microenvironments present within individual patients.  
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CHAPTER 3. NANOMATERIALS FOR PHOTOTHERMAL ABLATION 
IN GENETICALLY-ENGINEERED TUMOR MODEL 
3.0   Abstract:  
Plasmonic nanomaterials are poised to impact the clinical management of cancer through 
their ability to convert externally applied energy into localized heat at sites of diseased tissue. 
However, characterization of plasmonic nanomaterials as cancer therapeutics has been limited to 
xenograft models, creating a need to extend these findings to more clinically relevant models of 
cancer.  Here, we evaluate the method of photothermal ablation therapy in a genetically 
engineered mouse model (GEMM) of sarcoma, which more accurately recapitulates the human 
disease in terms of structure and biology than subcutaneous xenograft models.  Using 
polyethylene glycol (PEG)-coated gold nanorods (PEG-NRs), we quantitatively evaluate the 
ability of nanoparticles to penetrate and accumulate in sarcomas through passive targeting 
mechanisms.  We demonstrate that PEG-NR-mediated photothermal heating results in significant 
delays in tumor growth with no progression in some instances. Lastly, by evaluating our 
photothermal ablation protocol in a GEMM, we observe off-target heating effects that are not 
detectable in xenograft models and which may be of future clinical interest. 
3.1   Introduction:  
In the last decade, nanoparticles and nanomaterials have been engineered for a wide array 
of biomedical applications. The clinical management of cancer stands to benefit greatly from 
nanoparticles that can more directly and selectively target tumors for diagnosis, imaging, and 
therapy. Noble metal nanomaterials are especially promising diagnostic, imaging and therapeutic 
tools because they exhibit strong optical absorption and scattering properties due to an effect 
known as surface plasmon resonance.  Gold nanoparticles are plasmonic materials which are 
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characterized by facile synthesis and bioconjugation and low cytotoxicity,[141, 179, 215-220]  
and which have demonstrated potential as multimodal diagnostic and therapeutic agents in 
vivo.[139, 141, 221]  As diagnostic agents, gold nanoparticles enable imaging by optical 
coherence tomography (OCT), photoacoustic tomography, two-photon luminescence, X-ray 
computed tomography (CT), and surface-enhanced Raman spectroscopy.[218, 222-225]   
Therapeutically, strategies employing gold nanoparticles have harnessed their ability to 
selectively heat tumor tissue through the localized conversion of light into thermal energy.  By 
varying their geometrical properties, gold nanoparticles including nanoshells and nanorods can 
be tuned to absorb specific near infrared wavelengths, at which biological tissue exhibits 
relatively low extinction coefficients. Gold nanoparticle-mediated photothermal ablation has 
shown considerable efficacy in the treatment of cancer, leading to complete resolution of 
irradiated tumor xenografts in some cases.[141, 219, 220] Gold nanoparticle-induced heating has 
also been combined with other therapeutic modalities to leverage synergies between heat and 
radiation or chemotherapy, thereby sensitizing tumors to treatment.[112, 226] Finally, 
nanoparticle-induced heating has been used as a photothermal trigger in heat-responsive drug 
delivery systems.[227, 228]  
Despite the therapeutic promise of gold nanoparticles, translation to the clinic requires 
that their effectiveness be validated in physiologically relevant models of human cancer.  To 
date, delivery of gold nanoparticles has been studied in subcutaneous xenograft tumors, and the 
accumulation of nanoparticles within xenografts has largely relied on passive targeting 
mechanisms.  However, because subcutaneous xenografts fail to recapitulate important structural 
features of more clinically representative GEMMs, the degree to which passive accumulation 
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plays a role in tumor-targeting within genetic models remains to be determined.[148, 149, 229]  
In particular, there is increasing evidence that tumor interstitial fluid pressure is model–
dependent and site-specific; therefore, pressure variations between subcutaneous xenografts, 
orthotopic models, and GEMMs may directly influence the extravasation across the vessel wall, 
the physical and biological entrapment of nanoparticles in the interstitium, and the intratumoral 
distribution of gold nanoparticles.[230] Differences in the anatomical location and geometry of 
the tumor in different mouse models may further affect the ability to focus NIR light, induce 
specific versus off-target heating, and lethally ablate the tumor.  Demonstrating the penetration 
and accumulation of gold nanoparticles, as well as their ability to induce site-specific 
photothermal ablation in GEMMs, is therefore an important step as these particles are evaluated 
for their utility in the clinic.  
Here, we sought to directly compare the effectiveness of a PEG-NR ablative therapeutic 
protocol in a genetically-engineered mouse model to previous results obtained in subcutaneous 
xenografts.[141, 219, 220] To assess the impact of PEG-NR ablative therapy, we selected a 
model of sarcoma harboring conditional mutations in Kras and Trp53 and resembling human 
sarcoma both in microscopic structure and by immunohistochemistry.[231] Our lab has 
previously developed polyethylene glycol (PEG)-coated gold nanorods which exhibit high 
stability in circulation (t½ ~ 17 hours) and a high optical absorption coefficient.[141] Leveraging 
this technology, we show that intravenously injected PEG-NRs passively accumulate in both 
subcutaneous xenografts and the sarcoma GEMM.  Additionally, near-infrared laser irradiation 
(NIR) results in rapid, sarcoma-specific heating and ablation, leading to significant delays in 
tumor growth.  We further show loss of extremity function due to non-specific heating of the 
sarcoma, an effect only observed in the GEMM. Collectively, these studies demonstrate that 
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passively-targeted PEG-NRs are capable of serving as highly-absorbing antennas in a clinically 
relevant model of cancer, and suggest that an optimal combination of PEG-NR delivery and 
appropriate ablation protocol could be translated to clinical utility. 
3.2   Materials and Methods: 
Preparation of PEG-coated Gold Nanorods 
Gold nanorods were prepared as described previously.[141]  Briefly, ~ 10 x 40 nm 
cetyltrimethylammonium bromide (CTAB)-coated gold NRs with longitudinal plasmon 
resonance at 810 (Nanopartz Inc.) were centrifuged at 16,000 rcf to concentrate and resuspended 
in 100 µM of 5-kDa methyl-PEG-thiol (Layson Bio, Inc.).  The solution of 5-kDa methyl-PEG-
thiol and CTAB-coated gold NRs was mixed and dialyzed overnight against ultrapure water (18 
MΩ cm-1) using cellulose ester membrane dialysis (Spectrapor).  Dialyzed samples were washed 
and filtered through 100-kDa filters (Millipore) to remove excess polymer, re-suspended in PBS, 
and stored at 4°C. 
Generation of Soft Tissue Sarcomas 
The mouse model of sarcoma was described previously by Kirsch, et. al.[231]  The 129 
S4/SvJae mouse strain was bred and used for the generation of transgenic sarcoma mice.  These 
mice harbor the following conditional mutations: LSL-KrasG12D/+ and p53Fl/Fl.  Soft tissue 
sarcomas were generated by intramuscular injection of 2.4 x 107 pfu of adenovirus (Ad-Cre) 
expressing Cre-recombinase (Gene Vector Transfer Core, University of Iowa) in the lower 
extremity. All animal studies and procedures were approved by the MIT and MGH Institutional 
Animal Care and Use Committees.  
Generation of HT-1080 Xenografts 
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To generate subcutaneous xenograft models, nude mice (Jackson Labs) were injected 
bilaterally in the hind flanks with ~ 5 x 106 HT-1080 cells suspended in 200 µL DMEM.  
Silver Enhancement Staining 
Paraffin-embedded tissue sections were dewaxed and rinsed with double-distilled water 
for up to 30 seconds. Silver enhancement was performed using the Silver Enhancer Kit for 
Membranes (Cytodiagnostics). Equal volumes of Silver Enhancer Solution A and Silver 
Enhancer Solution B were mixed, and 50-100 µL was added to tissue sections, ensuring that the 
entire tissue was covered. Several dilutions of Solution A/Solution B mixtures in double-distilled 
water were tested. To determine the optimal enhancement time, representative 20X fields were 
imaged every 10 minutes for up to 80 minutes (Nikon ECLIPSE Ti). After incubation in silver 
enhancement solution, tissues were rinsed well with double-distilled water for up to 60 seconds. 
Samples were counterstained with hematoxylin, dehydrated, and mounted using standard 
protocols.  
Quantification of silver deposits was performed using ImageJ software. To generate particle 
counts, the Analyze Particles command was applied to each contrast-enhanced, 8-bit, thresholded 
image. The same thresholding values were applied to all images included in the analysis.  
ICP-MS 
Samples for inductively coupled plasma mass spectrometry, or ICP-MS analysis, were 
frozen, lyophilized, and dissolved in aqua regia, prepared by adding 100 µL of nitric acid to 300 
µL of 37% hydrochloric acid for 72 hours to dissolve gold particles. Then, samples were diluted 
to 10 mL with 9.6-mL 2% HNO3 and analyzed via ICP-MS against standards (Thermo-Scientific 
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Finnigan ELEMENT2). Control saline and organ samples with exogenously added PEG-NRs 
were used for calibration. 
In vivo Photothermal Therapy 
Approximately ninety days after injection of Ad-Cre, mice bearing sarcomas between 
150-200 mm3 were randomized into one of three groups: PEG-NR + NIR, PEG-NR only, and 
NIR only (n = 4-5 mice per group).  Mice were then injected through the tail vein with PEG-NRs 
in PBS (40 mg Au/kg).  After allowing 72 hours for vascular clearance of PEG-NRs, the mice 
were anaesthetized with ketamine/xylazine and sarcomas were irradiated with a near-infrared 
laser (~0.5 W/cm2, 810 nm, ~1 cm beam diameter).  Prior to irradiation, the area around the 
tumor was shaved to remove excess hair.  To monitor surface temperature during irradiation, an 
infrared thermographic camera (FLIR, Thermacam S60) was used.  To assess tumor growth 
following treatment, tumors were measured every two to three days using digital calipers. Mice 
were euthanized when tumors exceeded 15 mm in any single dimension. 
Immunohistochemistry 
Immunohistochemistry was performed as described previously.[232]  Briefly, 
immunostaining was performed on formalin-fixed paraffin embedded sections following antigen 
retrieval (10 mM citrate buffer (pH~6.0) at 95º C for 20 minutes; 22º C for 20 minutes). Primary 
antibodies rat anti-mouse CD31 (1:100, Pharmingen) and mouse anti-PCNA (1:500, PC-10; 
Santa Cruz Biotechnology) were applied to tissue sections for 1 hour at room temperature.  
Secondary antibodies were applied for 30 minutes at room temperature: biotinylated rabbit anti-
rat IgG (1:1000, Vector Laboratories) or biotinylated horse anti-mouse IgG (1:1000, Vector 
Laboratories).  Sections were then incubated for 30 minutes with ABC reagent (Vector 
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Laboratories), rinsed with PBS-T, and incubated in DAB chromagen reagent (Vector 
Laboratories).  The sections were rinsed under running tap water for 5 minutes and 
counterstained in Mayer’s Hematoxylin (Sigma), dehydrated, and mounted using Permount 
(Fisher Scientific).  Standard hematoxylin and eosin staining was performed on tissue sections. 
3.3   Results:  
3.3.1 Sarcoma Treatment and Experimental Schedule 
Sarcoma-bearing mice were injected with either PEG-NRs or PBS control and subjected 
to the photothermal ablation protocol (Fig. 3.1). Following irradiation, mice in the treatment trial 
were regularly monitored for tumor burden. A second group of mice were sacrificed either 24- or 
72-hours after ablation to assess the short-term histopathological effects of ablation. We verified 
the uniform structure of PEG-NRs by transmission electron microscopy (Fig. 3.1) and 
demonstrated the capacity of PEG-NRs to specifically and significantly heat sarcomas exposed 
to NIR irradiation (Fig. 3.1). A representative photograph of the sarcoma (Fig. 3.1) provides 
perspective on the challenges of locally specific ablation and the potential source for non-
specific heating effects (Fig. 3.1). 
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3.3.2 Comparison of PEG-NR Accumulation in GEMM and Xenograft Models of Sarcoma 
To confirm the presence of PEG-NR accumulation in the tumor interstitium of both the 
GEMM and xenograft, we performed silver enhancement staining on tumor sections to visualize 
PEG-NR microdistribution within the tumors.  Both the GEMMs and HT-1080 xenografts 
displayed comparable PEG-NR microdistributions, with PEG-NRs appearing throughout the 
tumor tissue (Fig. 3.2), while control samples displayed little to no detectable background staining 
(Fig. 3.2). Quantification of silver-enhanced PEG-NRs in histological sections revealed a greater 
number of particles accumulating in the HT-1080 xenografts compared to the GEMM; further, 
both the HT-1080 xenografts and GEMMs exhibited significant accumulation of particles relative 
 
Figure 3.1.  Schematic of PEG-NR heating with NIR laser irradiation in a GEMM of 
sarcoma. (A) Timeline of sarcoma generation and photothermal ablation procedure. (B) 
TEM image of PEG-NRs. Scale bar represents 50 nm. (C-E) Bright field (C) and IR 
thermographic images of mice with NIR irradiation only (D) and PEG-NR + NIR irradiation 
(E). 
 
B. 
C. 
A. 
D. E. 
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to uninjected tumor controls (Fig. 3.2). Additionally, we did not detect significant silver deposits 
in surrounding tissues, including skeletal muscle, indicating that PEG-NRs accumulated 
preferentially in sarcomas.   ICP-MS confirmed the presence of gold in the GEMMs (6.60 %ID/g) 
in amounts comparable to those seen in the HT-1080 xenografts (11.32 %ID/g) (Fig. 3.2). These 
results directly confirm that PEG-NRs are able to penetrate and accumulate in sarcoma GEMMs 
in amounts sufficient for photothermal ablation protocols. 
  
80 
 
 
 
 
Figure 3.2. Accumulation of PEG-NRs in GEMM and subcutaneous xenograft.  Representative 
silver enhancement staining of PEG-NRs in a GEMM of sarcoma (A) and HT-1080 xenograft 
(B).  Representative silver enhancement staining in an uninjected GEMM of sarcoma (C) and 
HT-1080 xenograft (D). Scale bar represents 50 μm. (E) Quantification of silver enhanced 
spots. Contrast-enhanced images captured at 20x magnification were analyzed on ImageJ 
software (n = 9 per group). (F) ICP-MS quantification of PEG-NR deposition in GEMM of 
sarcoma and HT-1080 xenografts 72 hrs after i.v. administration. 
E.                                                 F. 
D. C. 
B. A. 
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3.3.3 Immunohistochemistry of Tumors Following Photothermal Ablation 
Examination of H&E-stained paraffin sections revealed regions of gross necrosis at 24- 
and 72-hours post-irradiation. These sections were characterized by loss of tumor architecture, 
cellularly hypodense regions, lymphocytic infiltrates, and irregular nuclear staining patterns (Fig. 
3.3). These regions likely correspond to the portions of the tumor receiving the majority of 
photothermal energy during the ablation procedure.  
To assess cellular proliferation, we immunohistochemically stained the sarcoma sections 
for proliferating cell nuclear antigen (PCNA). Consistent with the H&E results, we observed wide 
regions of absent PCNA staining throughout the tumors at 24- and 72-hours following ablation 
(Fig. 3.3). Interestingly, we identified isolated regions located exclusively at sites of the tumor 
most distal from the skin surface that stained positively for PCNA.  These areas of viable tissue 
account for anywhere between zero to approximately 20% of the area of some tissue sections (Fig. 
3.3), suggesting that portions of the tumor did not receive sufficient photothermal energy during 
the ablation procedure.   
Finally, to understand how photothermal ablation influences the distribution of blood 
vessels in the sarcoma, we measured expression of CD31, an endothelial cell marker commonly 
used to identify blood vessels. Necrotic regions exhibited diffuse, non-specific staining patterns 
bearing no resemblance to the blood vessels observed in untreated control tissue. Thus, in regions 
of tumor receiving sufficient irradiative heat to induce necrosis, the tumor-associated vasculature 
is also ablated. 
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3.3.4 Therapeutic Assessment of Photothermal Ablation in a Transgenic Sarcoma Model 
To test the ability of a single dose of PEG-NRs to significantly delay tumor growth 
following one session of near-IR irradiation, genetically-modified 129 S4/SvJae mice bearing 
 
 
 
Figure 3.3. Immunohistochemical analysis of short-term heating effects on GEMM of sarcoma.
(A) H&E and PCNA staining of sarcoma 72 hours after heating versus an unheated control. Scale
bar represents 100 μm. Contrast-enhanced images captured at 10x magnification.  (B) Schematic
of sarcoma cross-section following heating.  (C) Photograph of PEG-NR + NIR treated sarcoma
prior to excision, 72 hours post heating. 
A. B. 
C. 
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induced soft tissue sarcomas were injected with PEG-NRs.  Mice were randomized to one of three 
cohorts (PEG-NRs + NIR, PEG-NRs only, NIR only).  After plasma clearance of PEG-NRs, 
tumors in the PEG-NRs + NIR and NIR only groups were irradiated for 5 minutes (~0.5 W/cm2, 
810 nm) and tumor volume was measured over time (Fig. 3.4). Mice receiving the PEG-NRs + 
NIR treatment experienced significant tumor growth delay and extended lifespan compared to 
control treatment groups.  During the post-ablation observation period, all mice in the PEG-NR 
only and NIR only groups developed substantial tumor burdens requiring euthanization by day 16, 
whereas mice receiving PEG-NRs + NIR survived until day 30 or longer (Fig. 3.4). At the end of 
the study period, the two remaining mice had tumor volumes < 150 mm3 (Fig. 3.4). Notably, 4 of 
the 5 mice receiving PEG-NR + NIR lost lower extremity function after the ablation procedure. 
Additionally, in a repeat therapeutic trial, we observed delayed progression of sarcoma consistent 
with our initial results.  
 
Figure 3.4.  Photothermal ablation of GEMM of sarcoma using PEG-NRs. (A) Volumetric 
changes in tumor volume are plotted over time (n = 4-5). Error bars represent standard 
deviations. PEG-NR is statistically different from NIR and PEG-NR from day seven onwards 
with p < 0.0001 based on analysis of variance. (B) Survival of mice over time (n = 4-5). 
A. B. 
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3.4   Conclusions:  
Surgery, chemotherapy, and radiation have remained the standard of care in cancer therapy 
for decades. Novel approaches harnessing the unique properties of nanomaterials have been 
proposed to improve cancer therapy in the future. To date, numerous therapeutic protocols, 
involving a variety of nanomaterials, have been described in xenograft mouse models. While 
xenograft models offer a straightforward and reliable method for quantitatively assessing tumor 
burden, studies in more physiologic tumor microenvironments, such as those that occur in 
genetically-engineered mouse models (GEMMs), may be more accurate predictors of therapeutic 
efficacy.[233]  For these reasons, GEMMs are gaining favor in the pharmaceutical industry and 
will almost certainly find utility in assessing the clinical validity of nanomaterial-based therapeutic 
protocols as well. 
This study represents the first demonstration of a therapeutic, nanoparticle-mediated 
thermal ablation protocol in a GEMM. We have demonstrated that PEG-coated gold nanorods 
(PEG-NRs) accumulate in the sarcomas at levels comparable to those in subcutaneous HT-1080 
xenografts. Deposition of PEG-NRs is sufficient to facilitate photothermal ablation of the sarcomas 
upon localized administration of near-infrared irradiation. 
While numerous lines of evidence support the notion that passively targeted 
nanotherapeutics can penetrate and accumulate in human tumors, this phenomenon has not been 
well-characterized in a clinical setting.[145, 150]  Routinely used xenograft models fail to capture 
important characteristics of human disease that may impact the effectiveness of passive targeting 
mechanisms.[149]  This uncertainty is significant as many nanotherapeutic approaches rely on 
passive targeting to varying degrees in order for the therapeutic payload to accumulate at the site 
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of disease. Our demonstration of untargeted PEG-NR accumulation in a GEMM of sarcoma 
provides evidence that passive targeting is indeed sufficient for PEG-NRs to accumulate in a 
physiologic tumor microenvironment.  
The considerable heterogeneity of human cancers is an important factor for PEG-NR-based 
therapies. It is not anticipated that a “one-size-fits-all” therapy will be identified, but rather that 
therapeutic protocols must be tailored to each type of cancer. Features including grade, stage, tissue 
of origin, anatomical location, and metastatic progression will influence if, and to what extent, 
PEG-NR-based therapies will have a place in the clinic.[231, 234, 235] For example, because of 
constraints related to depth of near-infrared irradiation into tissues, tumors that develop close to 
the skin surface, such as some soft-tissue sarcomas, would be better candidates for PEG-NR-based 
therapies than tumors that develop at sites more distant from the skin surface. Interestingly, in our 
GEMM, a portion of the sarcoma developed closer to the surface while the remainder developed 
deeper within surrounding skeletal muscle. In contrast to HT-1080 xenograft models which 
replicate superficial truncal tumors, our GEMM replicates a deep extremity sarcoma, which 
represents the majority of human sarcomas. We propose that this spatial heterogeneity contributed 
to the differential success in ablative therapy that we observed.  Additionally, tumors that are 
identified at earlier stages may be better candidates for PEG-NR-therapies than tumors identified 
at late stages, such as pancreatic adenocarcinoma,[236] because of the increased challenge of 
optimally irradiating multiple metastatic lesions. 
Notably, a significant proportion of mice to undergo photothermal ablation lost function in 
the irradiated limb following treatment. Because the sarcomas invade surrounding skeletal muscle, 
the thermal energy generated within the sarcoma damaged the skeletal muscle as well as the sciatic 
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and femoral nerves in the leg. We believe this observation is important in two respects. First, it 
suggests that improvements are required in the irradiation protocol to provide more precise thermal 
ablation at cellular resolution. Pulsed laser sources represent one possibility for improving the 
localization of photothermal ablation. Second, this unwanted side effect of the therapy could only 
be detected and fully appreciated in a GEMM, where the sarcoma’s anatomical location closely 
mimics that of human extremity soft tissue sarcomas. While a subcutaneous xenograft model can 
provide important information such as tumor burden in response to treatment, only in a GEMM 
can these realistic clinical consequences be detected and assessed. 
The ability of mouse models to accurately recapitulate human cancers and yield clinically 
insightful results is critical to the continuing development of nanotechnology for therapy and 
diagnostics.  Our work highlights the therapeutic efficacy and potential challenges of PEG-NR-
mediated photothermal ablation therapy in a GEMM of sarcoma. We anticipate that our findings 
will enable the development of improved therapeutic protocols as PEG-NRs and other 
nanotherapeutics advance closer to clinical use. 
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CHAPTER 4. NANOMATERIALS AND IMPLANTED NIR SOURCES FOR 
LOCALIZED HEATING OF DEEP TUMORS  
4.0   Abstract:  
Plasmonic nanomaterials including gold nanorods are effective agents for inducing 
heating in tumors. Because near-infrared (NIR) light has traditionally been delivered using 
extracorporeal sources, most applications of plasmonic photothermal therapy have focused on 
isolated subcutaneous tumors. For more complex models of disease such as advanced ovarian 
cancer, one of the primary barriers to gold nanorod-based strategies is the adequate delivery of 
NIR light to tumors located at varying depths within the body. To address this limitation, a series 
of implanted NIR illumination sources are described for the specific heating of gold nanorod-
containing tissues. Through computational modeling and ex vivo studies, a candidate device is 
identified and validated in a model of orthotopic ovarian cancer. As the therapeutic, imaging, and 
diagnostic applications of plasmonic nanomaterials progress, effective methods for NIR light 
delivery to challenging anatomical regions will complement ongoing efforts to advance 
plasmonic photothermal therapy towards clinical use. 
4.1   Introduction:  
The unique optical and electromagnetic properties of plasmonic nanomaterials have 
generated interest in using these materials for a variety of applications in medicine ranging from 
clinical diagnostics and imaging to targeted tumor therapy.[160, 178, 237-239] The strong 
scattering and absorption properties of plasmonic nanomaterials have led to the development of 
highly sensitive plasmonic biosensors for detecting glucose from biofluids, epidermal growth 
factor receptors (EGFR) on human cancer cells, amyloid beta from blood and cerebrospinal fluid 
in Alzheimer’s Disease, and human papilloma virus DNA.[154, 157, 159, 161, 168, 169] For 
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therapeutic applications, the ability of plasmonic nanomaterials to absorb specific wavelengths of 
light and efficiently generate heat through the surface plasmon resonance (SPR) effect has been 
exploited for localized ablation of solid tumors, as well as for milder sub-ablative heating to 
transiently damage non-tumor endothelial cells or enhance delivery of therapeutic cargoes.[141, 
179, 180, 183, 240, 241] Collectively, these studies have demonstrated the potential for 
plasmonic photothermal therapy to impact a variety of pathophysiological processes such as 
tumor growth and angiogenesis. The advantages of polyethylene glycol-coated gold nanorods 
(PEG-NRs) in particular include their long term stability, minimal cytotoxicity, and ability to be 
geometrically tuned to absorb specific wavelengths of NIR light.[139, 141, 215, 217-219, 241] In 
preclinical models, PEG-NRs passively accumulate in tumors, efficiently absorb NIR light, and 
generate localized heat through the SPR effect. To date, the therapeutic potential of PEG-NR-
mediated photothermal ablation as well as sub-ablative heating for recruitment of therapeutic 
cargoes has been demonstrated in both genetically engineered and xenograft animal models.[139, 
141, 172, 179, 219, 241] 
One limitation of approaches involving NIR light delivered by an external device is the 
limited penetration depth of NIR light due to the optical absorption and scattering properties of 
biological tissue, which has restricted therapeutic studies to superficial tumors located near the 
skin surface.[242] For solid tumors positioned in deeper, more anatomically challenging regions 
and distributed over larger areas, such as advanced ovarian cancer, it would be advantageous to 
have NIR light delivery systems capable of providing sufficient energy to elicit the SPR effect 
within these deeper and spatially distributed tumor environments. Several efforts to deliver light 
internally for applications such as photodynamic therapy have focused on optical fiber 
technologies, which direct a point source of light upon target tissues.[242-245] For laser-induced 
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interstitial therapy (LITT) protocols, surface- and volume-scattering applicators have been 
developed to homogeneously scatter light after catheter-guided insertion directly into individual 
tumors.[246-248] By contrast, for scenarios requiring broader NIR illumination of multiple 
target tissues simultaneously, including tissues that may not be visible to the human eye or 
accessible by catheter, a source providing contiguous illumination over a larger surface area 
would be beneficial.     
In this study, a potential strategy combining systemically-delivered plasmonic 
nanomaterials with locally implanted NIR illumination sources is described. A series of 
biocompatible, implanted illumination devices are characterized through computational 
modeling, ex vivo fluence rate and thermographic measurements, and in vivo thermographic 
profiling. Two illumination devices were capable of heating solutions of PEG-NRs in a dose-
dependent manner, and one of these devices was further validated by in vivo imaging and 
thermography. In animal models of orthotopic ovarian cancer pre-treated with PEG-NRs, 
delivery of NIR light via the implanted device selectively elevated the temperature of ovarian 
tumors relative to background tissue without generating irreversible tissue damage and enhanced 
the delivery of diagnostic and therapeutic agents. Collectively, these data illustrate that synergies 
between plasmonic nanomaterials and novel NIR illumination methods can achieve selective and 
tolerable photothermal effects in complex anatomical environments. 
4.2   Materials and Methods:  
Synthesis of PEG-NRs 
Gold nanorods (PEG-NRs) coated in PEG were prepared as described previously.[141, 
241] Briefly, 41 nm x 10 nm cetyltrimethylammonium (CTAB)-coated PEG-NRs (Nanopartz) 
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were concentrated ~100-fold by centrifugation at 15,000 rcf for 30 minutes, incubated with 5-
kDa methyl-PEG-thiol (Laysan Bio, Inc.) to 100 µM, and dialyzed for at least 24 hours against 
distilled, deionized water in 3,500 MWCO Slide-A-Lyzer cassettes (Thermo Scientific). 
Dialyzed samples were washed in ultrapure water, filtered through 100-kDa filters (Millipore), 
and resuspended in PBS. PEG-NR solutions were stored at 4˚C.  
Device design and construction 
Implanted devices consisted of silica rods and fiber optic meshes (Rogers Sciences, Inc.). 
Silica rods were treated by an optomechanical scoring process to create varying illumination 
patterns and light-dispersive coatings. Light emission was incoherent with an exitance of ~2π 
steradians at each illumination surface. Fiber optic meshes were encased in medical-grade 
silicone to provide adhesion, flexibility, and biocompatibility. Meshes were treated in an array 
format by an optomechanical scoring process to allow approximately uniform light emission 
from the top surface.  
Computational modeling 
An approximate anatomical model of the mouse was developed including liver, intestine, 
kidney, stomach, spleen, lungs, vertebrae, and skin using a nude mouse (female) atlas as a guide 
(Xenogen). Tissue layers were assigned indices of refraction, scattering coefficients, and 
absorption coefficients. Implanted NIR devices (silica rod, flexible mesh) were simulated in this 
three-dimensional anatomical model using Zemax and TracePro software. Each simulation 
performed consisted of 1 x 104 distinct ray tracings. NIR illumination from the silica rod was 
modeled as 1 x 104 ray tracings across the device’s entire length and diameter, while illumination 
from the fiber optic mesh was modeled as 1 x 104 ray tracings emitted from the top and bottom 
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surfaces of the mesh. The surfaces for both devices were modeled with a lambertian reflectance 
profile (1 W, 808 nm). 
Fluence rate measurements 
Implanted NIR devices were directly coupled to an 810 nm continuous diode laser source 
(Visotek) through an SMA-threaded glass fiber optic cable (0.4 mm diameter). Fluence rate 
measurements were recorded on an optical power and energy meter with an S121C silicon 
photodiode power sensor (400-1100 nm, 500 mW) (Thorlabs). Measurements were obtained at 
808 nm at multiple distances and input currents.  
Ex vivo thermographic profiling 
Solutions of PEG-NRs (0, 1, 10, and 100 µg/mL) were irradiated by implanted NIR 
devices for three minutes. Maximal surface temperatures of PEG-NR solutions were monitored 
continuously by infrared thermography (Thermacam S60, FLIR). Each concentration of PEG-
NRs was identically exposed to the 810 nm laser illumination. All conditions reported were 
measured in triplicate.  
In vivo imaging 
All animal studies were approved by the MIT Committee on Animal Care. Computed 
tomographic (CT) imaging on animals with implanted NIR devices was performed on an 
eXplore CT120-whole mouse MicroCT system (GE Healthcare). Image analysis for anatomic 
measurements and three-dimensional rendering was performed with MicroView software (GE 
Healthcare).  
In vivo thermographic profiling 
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Female NCR nude mice at ~4 weeks of age (Taconic) received an intraperitoneal 
injection of ~5 x 105 OVCAR8 human ovarian cancer cells expressing firefly luciferase. At 4-6 
weeks following implantation, establishment of tumors was confirmed on the whole-animal IVIS 
Spectrum-bioluminescence and fluorescence imaging system (Xenogen). Tumor-bearing animals 
received either an intravenous injection of PEG-NRs (100 µL; ~14 mg Au/kg) or no injection for 
the control group; after vascular clearance (~48 hours), animals were anesthetized and a midline 
incision through the skin and abdominal wall was made for implantation of the silica rod NIR 
device under study. To assess tissue-specific heating properties, the implanted NIR device was 
independently positioned in proximity to the liver, intestine, and ovarian tumors within the 
peritoneal cavity. K-type fiberglass thermocouples (National Instruments) were placed adjacent 
to each tissue and equidistantly from the NIR device (~0.3-0.5 cm) to minimize non-specific 
direct heating effects from the device. Implanted devices were connected via fiber optic cable to 
a continuous 810 nm laser source (Visotek) during a five minute heating period per tissue. 
Thermocouple temperature signals were integrated on a portable DAQ thermocouple module (NI 
USB-9211A, National Instruments) and recorded at 2 Hz with NI-DAQmx and LabView 
software during the five minute heating window. Thermographic profiles were assembled and 
statistically analyzed with Prism 5 software (GraphPad).  
Histology 
Harvested tissues were fixed in 4% paraformaldehyde overnight at 4˚C prior to paraffin 
embedding. Standard hematoxylin and eosin (H&E) staining was performed on sections of 
tumor, liver, and intestine. Immunohistochemical staining for the cell proliferation protein Ki67 
was performed with primary antibody rabbit anti-human Ki67 (1:100, EMD Millipore). IHC with 
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antigen retrieval was performed on the LabVision Autostainer 360 Immunohistochemical Stainer 
(Thermo Scientific).  
In vivo quantification of cargo 
Tumor-bearing animals received an intravenous co-injection of doxorubicin-loaded 
liposomes (8 mg Dox/kg) and AngioSPARK750 (100 µL in PBS) (Perkin Elmer). The silica rod 
was implanted as described and positioned in proximity to multiple tumor nodules within a 
specified quadrant of the abdomen. Each animal received continuous NIR light irradiation (810 
nm) for 30 minutes and the abdominal wall and skin were sutured prior to recovery. Three hours 
after the procedure, tumors were harvested and AS750 fluorescence within whole tumors was 
imaged on an NIR imaging system (LICOR Odyssey). Tumors were weighed and homogenized 
in 1.0 mL of extraction buffer (70% EtOH, 0.3N HCl) using an automated tissue homogenizer 
(gentleMACS Octo Dissociator, Miltenyi Biotec). Supernatants were measured on LICOR 
platform for AS750 and a fluorescence microplate reader (Molecular Devices, SpectraMAX 
GeminiEM) for doxorubicin fluorescence. For each group, the fluorescence of 12 individual 
tumor supernatants obtained from three mice per group was normalized by tissue weight prior to 
analysis. 
4.3   Results:  
4.3.1 Development and Validation of Computational Model for Intraperitoneal NIR Light 
Delivery 
PEG-NRs were prepared from stock CTAB-coated gold nanorods to minimize toxicity 
and extend particle circulation time as previously described. (Fig. 4.1, left)[141, 241] 
Transmission electron microscopy (TEM) images revealed the PEG-NR dimensions to be 41 nm 
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in length and 10 nm in width for an aspect ratio of 4.1 (Fig. 4.1, left). The surface plasmon 
resonance (SPR) peak absorbance of PEG-NRs was 808 nm in accordance with previously 
observed measurements (Fig. 4.1, left). Implanted NIR illumination devices were composed of 
silica rods and fiber optic meshes (Fig. 4.1, center). Silica rods were designed with varying 
geometric parameters such as diameter, length, and tip tapering, treated to have uniform surface 
diffusivity along the rod, and joined with an SMA fiber-optic connector to interface with a 
continuous 810 nm NIR laser source. To provide a flexible alternative to the silica rods, fiber 
optic meshes consisting of sub-millimeter fibers encased in adhesive medical-grade silicone were 
prepared. Fibers were treated by an optomechanical scoring process prior to encasement to alter 
the total internal reflection at distinct locations and thereby permit NIR light emission along the 
length of the fibers. For each device, fluence rate-distance relationships were computed for input 
currents ranging from 9.0–13.0A (Fig. 4.1, center). The combination of systemic PEG-NRs and 
implanted NIR devices was investigated as a strategy to achieve photothermal heating in deep 
tumor nodules (Fig. 4.1, right).  
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The abdominal cavity consists of organs and biological tissues with varying optical and 
geometric properties contained within a confined anatomical compartment. To develop a 
quantitative framework for understanding NIR illumination in the peritoneal cavity and thereby 
assess the feasibility of the implanted NIR devices, a three-dimensional solid model 
incorporating the liver, spleen, stomach, kidney, large and small intestine, and skin was 
developed (Fig. 4.2). For modeling simulations, abdominal organs were assigned approximate 
indices of refraction, scattering coefficients, and absorption coefficients based on values obtained 
from the literature. Previous computational models developed in our lab applied finite element 
simulations to approximate photothermal heating of gold nanorod-containing subcutaneous 
tumors using the bio-heat transfer equation.[141] While the current model describes NIR light 
distribution in non-tumor tissues within the peritoneal cavity, future models incorporating tumor 
tissue elements, absorption coefficients dependent on gold nanorod tissue content, and 
Figure 4.1. First component for plasmonic photothermal heating of intraperitoneal tumors 
consists of polyethylene glycol-coated gold nanorods (PEG-NRs), which are characterized by 
TEM imaging and optical absorbance. (Left panel) PEG-NRs with an aspect ratio of 4.1 display 
a peak surface plasmon resonance (SPR) at 808 nm. Scale bar: 20 nm. (Center panel) Classes 
of implanted NIR devices include silica rods and flexible meshes encased in silicone. 
Generalized fluence rate-distance relationship for several input currents (Io) of an implanted 
NIR device. (Right panel) The combination of systemically-administered PEG-NRs and 
implanted NIR illumination permits plasmonic photothermal therapy for intraperitoneal tumors. 
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biophysical heat transfer equations will be useful for providing a more detailed description of 
plasmonic photothermal heating in the peritoneal cavity. The current deterministic model 
predicts that most of the emitted NIR light focuses on regions containing the intestine, liver, and 
spleen within the peritoneal cavity with lambertian, or diffusely reflected, illumination along the 
silica rod (Fig. 4.2, Fig. 4.3). In comparison, with a lambertian profile along the flexible mesh, 
the model predicts an enhanced, more uniform transmittance within the peritoneal cavity due to 
increased surface area relative to the silica rod (Fig. 4.3). Importantly, simulations using this 
anatomically based model predicted the limitations of NIR light penetration due to tissue 
absorption and scattering. For example, at the interface of the silica rod and abdominal organs 
with an input power of 1 W along the device, the model predicts a peak fluence rate of 1.35 x 103 
W/m2, while at a distance 8 mm deep to the device, the peak fluence rate decays to 5.9 x 102 
W/m2 (Fig. 4.3). Similarly, at the interface of the flexible mesh and abdominal organs, the peak 
fluence rate is estimated to be 3.0 x 103 W/m2, and the peak fluence rate decays to 7.3 x 102 
W/m2 at a depth of 8 mm (Fig. 4.3). The depth-dependent decay observed is consistent with 
tissue absorption and scattering and suggests that the model parameters approximate to a first 
order the in vivo environment. 
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To validate and refine model predictions for the silica rods and flexible mesh, fluence 
rate was calculated at multiple distances and input currents for six distinct implanted NIR 
devices (Fig. 4.3). Consistent with the model, fluence rate decreased approximately as the square 
of the distance between the device and detector plate when measured in an air medium (Fig. 4.3). 
As the input current from the laser was increased, a linear increase in fluence rate was observed 
at the surface of each implanted device, highlighting the ability to precisely tune the NIR 
 
Figure 4.2. Anatomic models of abdominal cavity used in fluence rate simulations. (a) 
Reference atlas overlay on tumor-bearing, female nude mouse from side, dorsal, and ventral 
orientations. (L, liver; J, jejunum (intestine); C, cecum (intestine); I, ileum (intestine); St, 
stomach; Sp, spleen; K, kidney; V, vertebral body) (b) Approximate anatomic model developed 
for simulations. Each tissue assigned optical coefficients for refraction, scattering, and 
absorption. (c) Models depicting implanted silica rod (top) and fiber optic mesh (bottom). 
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emission from the devices to achieve the desired level of photothermal heating in vivo (Fig. 4.3). 
In contrast to the model predictions, the peak fluence rate measured for the flexible mesh surface 
(~500 W/m2) did not reach the maximal surface fluence rate of 3.0 x 103 W/m2 predicted by the 
model. Limitations related to the material properties and device fabrication likely contributed to 
the difference and suggest that future models could be refined by incorporating specific physical 
properties of the device in addition to tissue properties. Finally, surface fluence rate was highly 
dependent on the geometry of the device and spanned several orders of magnitude (4 x 103 W/m2 
to 2 x 10-1 W/m2) (Fig. 4.3).  
 
 
Figure 4.3. (a) Fluence rate simulation in abdominal cavity with two implanted NIR devices at 
up to 8 mm depth from skin surface. (b) Photographs of implanted NIR devices investigated 
include silica rods (devices 1-5) and mesh (c) Fluence rates from representative silica rod device 
for variable input currents ranging from 9.0-13.0 A and distances from source ranging from 0-
4 cm. (d) Fluence rate-distance curves obtained at 13.0A input current for multiple models 
(devices 1-5; mesh) and spatial orientations of implanted NIR devices. 
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4.3.2 Efficiency and Specificity of Plasmonic Nanomaterial Heating by Implanted NIR Sources 
Based on the surface fluence rate measurements, we next assessed whether our devices 
possessed differing capacities to photothermally heat PEG-NRs. In an ex vivo setting, multiple 
concentrations of PEG-NRs in PBS were subjected to continuous NIR laser irradiation (810 nm) 
dispersed by each implanted device, and the temperature of PEG-NR solutions was continuously 
monitored via infrared thermography (Fig. 4.4). Several distinct patterns of photothermal heating 
were observed, which are denoted as: (1) non-specific, (2) PEG-NR-dependent, and (3) 
inefficient. Due to elements of device construction that resulted in a greater localized 
concentration of laser energy at the device tip (device 3), non-specific devices led to temperature 
elevations in both PEG-NR- and PBS control solutions (Fig. 4.4, Fig. 4.5). Conversely, devices 
with inefficient heating failed to yield an appreciable rise in temperature of PEG-NR solutions at 
approximately physiologic PEG-NR concentrations (Fig. 4.4, Fig. 4.5). A subset of implanted 
devices investigated, however, was observed to selectively elevate the temperature of PEG-NR 
solutions in a concentration-dependent manner while failing to significantly heat PBS control 
solutions (Fig. 4.4, Fig. 4.5). After three minutes of NIR irradiation, one PEG-NR-dependent 
heater (device 2) elevated a 100 µg/mL PEG-NR solution by 20.53˚C±0.68˚C, a 10 µg/mL PEG-
NR solution by 11.90˚C±0.44˚C, a 1 µg/mL PEG-NR solution by 4.43˚C±0.47˚C, and a PBS 
control solution by 2.57˚C±0.79˚C. Collectively, this ex vivo characterization helped identify a 
subset of implanted NIR light sources to evaluate in an in vivo context.  
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Figure 4.4. (a) Images of implanted NIR devices 2, 3, 5, and 6 (top to bottom). Infrared 
thermographic images of PEG-NR and PBS solutions after NIR exposure with implanted NIR 
devices. Scale bar: 1 cm (b) Representative thermographic timecourse for device 2, illustrating 
selective heating of PEG-NRs. (c) PEG-NR heating for implanted NIR devices 2, 3, 5, and 6 
(left to right) (n=3 per group). Error bars, s.e.m. (d) Maximal temperature elevation for multiple 
PEG-NR concentrations. (n=3 per group; ***P<0.001; one-way ANOVA and Tukey post 
tests.) Error bars, s.e.m. 
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Figure 4.5. Ex vivo thermographic profiles for implantable devices. Images show devices 2, 3, 
5, and 6 in solutions of PEG-NRs or control PBS. (a) Devices 2 and 5 demonstrate PEG-NR-
dependent heating; (b) Device 3 demonstrates non-specific heating; (c) and Device 6 
demonstrates inefficient heating. 
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The ex vivo fluence rate and PEG-NR photothermal heating measurements, coupled with 
computational models for two generic device geometries (i.e., silica rod and flexible mesh sheet) 
allowed for progressive down-selection of candidate devices prior to attempting plasmonic 
photothermal therapy in an animal model. Despite comparable fluence rate modeling predictions 
between the rod and mesh sheet, the various silica rod designs were pursued further because their 
material properties and construction proved able to sustain input powers in the anticipated range 
necessary for in vivo photothermal heating. The six-fold lower measured surface fluence rate 
compared to the model prediction illustrated that incorporation of physical properties of the 
device would be advantageous for future simulations, and also that future iterations of the 
flexible mesh should include design parameters that can sustain the necessary power 
requirements for plasmonic photothermal heating.   
Of the silica rod devices with the highest measured fluence rates, only a subset was able 
to heat PEG-NR solutions in a selective and dose-dependent manner. Those devices which failed 
to achieve PEG-NR-specific heating likely did so due to a combination of suboptimal geometric 
design and the incorporation of highly absorptive elements. Suboptimal geometries such as the 
long, narrow cylindrical design may have resulted in poorly diffused incoming NIR light with 
inhomogeneous emission to the surrounding environment. Such geometric constraints have been 
previously observed in the related field of laser-induced interstitial therapy, where NIR scattering 
from implanted laser applicators in part determines the volume of tissue susceptible to heating 
therapy.[249, 250] While the power required for this ablative therapeutic modality is 
substantially higher than that required for plasmonic photothermal therapy, the ability of the 
implanted device to scatter NIR light isotropically and minimize heat conduction at the tissue-
device interface is highly dependent on geometric and material design parameters and is 
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important for ensuring broad tissue coverage. Incorporating a metallic cap at the device tip led to 
heating of both PEG-NR and control solutions non-selectively, suggesting that the metallic cap 
absorbed the incident NIR light to generate heat within the device itself. Such designs are not 
suitable for implantation into the peritoneal cavity due to reduced, inhomogeneous light 
emission, as well as local coagulation of tissues in the vicinity of the device tip.[250] Limiting 
the incorporation of absorptive elements and improving light scattering from the device surface 
would help reduce the non-specific heating observed here. The optimal implanted NIR device 
based on fluence rate and selective PEG-NR heating had a tapered tip design and a length of ~3 
cm, which was among the shortest of the candidate devices investigated. Future iterations on 
silica- or fiber optic mesh-based implanted NIR devices will focus on improved flexibility, 
isotropic NIR emission from the device surface, and improved materials able to sustain a broader 
range of powers and thereby reduce the time required to reach the desired temperature range for 
plasmonic photothermal therapy.  
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4.3.3 Localized In vivo Plasmonic Heating to Enhance Therapeutic Delivery to Ovarian Tumors 
The function of a silica rod from the PEG-NR-dependent activator group was next 
assessed in an orthotopic mouse model of ovarian cancer. The device was implanted into the 
peritoneal cavity through an approximately 1 cm midline incision on the ventral surface and 
connected to the laser source via fiber optic cable (Fig. 4.7). To visualize the device inside the 
peritoneal cavity, computed tomography (CT) imaging was performed. CT images clearly 
delineated the implanted device and revealed its placement relative to abdominal structures 
 
 Figure 4.6. (a) Images of explanted ovarian tumors from the peritoneal cavity grouped by size 
(maximum diameter) (b-c) Tissue sections stained for CD31 were quantified with ImageJ 
software and correlated with total tissue area. Vascular density was found to correlate closely 
with total tissue area. (r = 0.842) Tumors < 4 mm positive for CD31 suggest that intraperitoneal 
tumors across a range of sizes are well-vascularized. (n = 56 tumors) 
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including intestine, abdominal wall, and vertebral bodies (Fig. 4.7, Fig. 4.8). To investigate the 
capability and specificity of the device to photothermally heat various tissues, the device was 
implanted into the peritoneal cavity of animals pre-treated with PEG-NRs or control animals 
lacking PEG-NRs, and the temperature of ovarian tumor tissue, intestine, and liver was 
continuously monitored with thermocouples placed at approximately equal distances (0.3-0.5cm) 
from the implanted device within each of these tissues (Fig. 4.8). Thermal profiling revealed a 
more efficient heating process in ovarian tumors, intestines, and livers of PEG-NR-treated 
animals relative to control animals lacking PEG-NRs (Fig. 4.8). Modest temperature changes 
between 2.4-3.0°C observed in tissues lacking PEG-NRs may be attributed to heat non-
specifically conducted from the device itself. In contrast, temperature elevations observed within 
the first minute of NIR exposure rose significantly steeper for tumors and liver in animals pre-
treated with PEG-NRs, while the trend was also increased but not significant for the intestine. 
For tissues in the PEG-NR group, the maximum temperature changes for tumor, liver, and 
intestine were 6.27°C±2.47°C, 6.51°C±1.47°C, and 4.66°C±2.49°C respectively (Fig. 4.8).  
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Figure 4.7. (a) Measured distances between implanted device and anatomic landmarks. (b) 
Landmarks include vertebrae, ventral and dorsal surfaces measured at multiple locations along 
body length by microCT image analysis. (c) Measured distances between implanted device and 
thermocouple. Representative images of implanted glass rod device (R), ovarian tumors (T), 
intestine (Int), liver (L), and thermocouple (TC). (d) Distances between implanted glass rod 
device and thermocouples for each tissue in presence or absence of PEG-NRs. (one-way 
ANOVA and Tukey’s post tests, n=4 for liver, intestine; n=2-3 for tumors). Error bars, s.d. 
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Figure 4.8. (a) Placement of implanted NIR device in a tumor-bearing animal shown 
macroscopically, by axial CT scan (R, rod; I, intestine; V, vertebrate; dashed line outlining body 
cavity), and 3D-rendered CT scanning. (b-d)  Thermal profiling in presence or absence of PEG-
NRs in (b) ovarian tumors, (c) intestine, and (d) liver. (n=3-5 per group) (e-g) Initial temperature 
change after 50 seconds of direct implanted NIR illumination in (e) tumors, (f) intestine, and 
(g) liver in PEG-NR-treated animals and controls. Red bar denotes mean value per group. (n=3-
5, *P<0.05, unpaired t-test) (h) Maximal temperature change for tumor, liver, and intestine of 
PEG-NR-treated animals (n=5 per tissue). Error bars, s.e.m. 
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Following PEG-NR photothermal heating, tissue sections were prepared to assess tissue 
viability and any resulting histological changes consistent with inflammatory or necrotic tissue 
damage. Importantly, normal tissue histology was observed for intestine, tumor, and liver by 
H&E staining (Fig. 4.9). Furthermore, Ki67-positive immunohistochemical staining confirmed 
that these tissues remained actively proliferative after photothermal heating (Fig. 4.9). Evidence 
of mild bleeding and coagulation at the device incision site, however, was noted in some animals 
investigated. These studies therefore establish that an implanted NIR device shown to selectively 
heat PEG-NR solutions in an ex vivo setting can likewise heat tissues containing PEG-NRs deep 
within the peritoneal cavity while not inducing irreversible damage in these organs.  
 
Plasmonic photothermal therapy and other modalities to heat tumors in the sub-ablative 
range (~41-45˚C) have been shown in subcutaneous models to alter the flow and permeability of 
tumor vessels and enhance accumulation of diffusion-limited therapeutic cargoes.[110, 112, 251-
253] To investigate whether NIR irradiation from the implanted silica rod similarly drove 
accumulation of therapeutic cargoes in an orthotopic site, tumors from NIR-treated and control 
animals were studied following administration of doxorubicin-loaded liposomes and the 
 
Figure 4.9. Histology and Ki-67 immunohistochemical staining of tissues following PEG-NR 
therapy with implanted NIR device. Scale: 100 µm. 
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diagnostic imaging agent AngioSPARK750 (AS750; core diameter: 20-50 nm). We observed 
from prior studies that the lower third of the silica rod dispersed NIR light with high intensity, so 
this region was used to induce heating in tumors in this proof-of-principle study. Intraperitoneal 
tumors from the quadrant receiving NIR illumination and harvested three hours after receiving 
AS750 and PEG-NR/implanted NIR heating demonstrated elevated macroscopic accumulation 
of AS750 (Fig. 4.10). Significantly elevated fold enhancements of 3.27 and 11.2 for 
doxorubicin-loaded liposomes and AS750 respectively were measured in homogenized tumor 
samples from the PEG-NR/implanted NIR group relative to control tumors from animals 
receiving no PEG-NR/implanted NIR therapy (Fig. 4.10). These data suggest that plasmonic-
based enhancement of therapeutic cargoes previously observed in subcutaneous tumor 
models[112] may also have utility for delivering cargoes to tumors in the peritoneal cavity.  
 
 
Figure 4.10.  (a) Whole-tumor fluorescence of AngioSPARK750 and (b) quantification of 
doxorubicin-loaded liposomes and AngioSPARK750 in tumor homogenates from tissues 
harvested 3 hours after injection and PEG-NR/Implant NIR therapy or injection only. (n=11-
12 tumors, 3 animals per group, **P<0.01, ****P<0.0001, Mann-Whitney test) Error bars, 
s.e.m.  
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For in vivo thermographic studies, the liver and intestine were studied in addition to 
tumors for several reasons. First, previous work on the biodistribution of PEG-NRs has 
demonstrated a significant accumulation of PEG-NRs in the liver (~14 %ID/g).[141] Because of 
its high PEG-NR concentration, large size, and proximity to orthotopic ovarian tumor nodules, 
the liver poses a challenge for tumor-specific photothermal heating in the peritoneal cavity. The 
temperature elevations observed in the liver were anticipated and importantly, they relaxed to 
baseline temperatures within several minutes after the procedures. The intestine, while 
accumulating fewer PEG-NRs than the liver, has been shown to be sensitive to broad elevations 
in temperature. This has been observed most notably during investigations with heated 
chemotherapy administered directly into the peritoneal cavity for ovarian cancer patients.[48] In 
this study, elevations in intestinal temperature were detected, but no tissue damage or 
proliferative defects were observed, and the thermal effects were more modest than in ovarian 
tumors or the liver, which is perhaps representative of differing PEG-NR concentrations within 
each of these tissues. A key advantage of PEG-NRs and plasmonic nanomaterials more generally 
is the ability to ‘sensitize’ tumor tissue to incident NIR light relative to surrounding tissues 
containing fewer PEG-NRs. The ability to locally deposit heat in desired tissues using plasmonic 
nanomaterials stands in marked contrast to heated chemotherapy approaches which cause non-
specific temperature elevations throughout the entire peritoneal cavity and have been associated 
with high morbidity and even mortality.[48] In the future, strategies to both shield non-tumor, 
PEG-NR-rich tissues (e.g., liver) from implanted NIR light as well as spatially localize thermal 
gradients around PEG-NRs via pulsed laser sources could prove fruitful for mitigating any off-
target effects. 
4.4   Conclusions: 
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Plasmonic nanomaterial-based therapies that generate localized heating within tumors 
hold great promise for future clinical interventions in oncology, but novel methods of delivering 
NIR light to deeply located and distributed solid tumors are needed for tumors that do not reside 
superficially beneath the skin. Here, to overcome the optical limitations of external NIR 
irradiation, we propose a possible alternative strategy using a biocompatible, implanted NIR 
illumination device and assess its functionality through computational modeling, ex vivo 
characterization, and in vivo thermographic profiling of orthotopic ovarian tumors. Ray tracing 
analysis in a simulated mouse model approximated the degree of NIR light penetration 
influenced by tissue scattering and absorption from two general device designs, providing a 
framework for selecting candidates for further study. These modeling predictions were validated 
and further refined by ex vivo fluence rate and thermographic measurements, as well as in vivo 
plasmonic photothermal heating of PEG-NR-containing ovarian tumors and non-tumor tissues. 
We demonstrate that localized plasmonic heating of ovarian tumors by this method can enhance 
accumulation of diagnostic and therapeutic agents including doxorubicin liposomes in this 
orthotopic tumor model. In future studies, it will be valuable to investigate what therapeutic 
benefits may be attained in these deep-seated tumors and the degree to which they correlate with 
results obtained from related preclinical models as plasmonic nanomaterials advance closer to 
clinical use. 
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CHAPTER 5. NANOMATERIALS FOR ENHANCING THERAPEUTIC 
DELIVERY 
5.0   Abstract:  
The delivery of diagnostic and therapeutic agents to solid tumors is limited by physical 
transport barriers within tumors, and such restrictions directly contribute to decreased therapeutic 
efficacy and the emergence of drug resistance. While the biological effects of heating on tumors 
and tumor-associated vasculature have been explored previously, recent technological advances 
in the ability to achieve precise spatiotemporal control of tumor heating with nanomaterials have 
led to a renewed interest in understanding how these materials modulate the tumor vasculature, 
as well as the consequences of such interventions for therapeutic delivery in clinically 
meaningful contexts. Here, we investigated the effects of plasmonic nanoantennae on modulating 
tumor transport in a xenograft model of ovarian cancer. We observed a temperature-dependent 
increase in the transport of diagnostic nanoparticles into tumors, as well as a transient, reversible 
reduction in transport upon re-exposure to heating, which we term thermotolerance. Using a 
minimal microfluidic model of the endothelium, in vitro studies of the endothelial cytoskeleton, 
and chemical and genetic tools to inhibit the heat shock response (HSR), we identified the tumor 
endothelium and HSR as contributors to this ‘thermotolerance’ effect. Harnessing the 
understanding of the kinetic, structural, and molecular parameters governing tumor transport, we 
designed an improved therapeutic protocol combining plasmonic nanoantennae with diffusion-
limited chemotherapies. This work therefore highlights the clinical relevance of cellular 
adaptations to nanomaterial-mediated perturbations and provides insight on molecular pathways 
whose modulation by emerging pharmacological agents could improve therapeutic tumor 
transport.  
115 
 
 
5.1   Introduction:  
With the emergence of molecularly targeted therapies and novel nanoparticle carrier 
formulations, the efficient delivery of such therapeutic cargoes to solid tumors remains a central 
challenge in oncology. Locally enhancing the concentration of these agents within tumors will 
provide opportunities to achieve greater therapeutic efficacy, minimize off-target toxicities, and 
limit the development of drug resistance. Current chemotherapeutic regimens must carefully 
balance the conflicting goals of achieving cure and limiting systemic and organ-specific 
toxicities. Many compounds which are highly lethal to cancer cells in vitro are rendered less 
effective in patients due to this narrow ‘therapeutic window’, a constraint well appreciated in 
clinical oncology.[254] To a large degree, it is the physical transport barriers within solid tumors 
that impose a bottleneck on the delivery of cytotoxic agents, targeted compounds, and 
nanoparticle formulations. These barriers include heterogenous blood flow, inefficient 
transvascular transport, and limited interstitial diffusion through the tumor stroma.[55-57] For a 
particular combination of tumor type and drug cargo, the extent to which each barrier is involved 
can be viewed as a complex interplay of tumor- and drug-specific factors, such as vessel 
perfusion, vessel surface area, stromal density, cargo size, and cargo surface chemistry which 
can modify a cargo’s electrostatic charge and pharmacokinetics.[59] Perturbing the tumor 
vasculature represents an attractive approach for enhancing therapeutic accumulation in solid 
tumors for at least two reasons. First, by dictating tumor blood flow and extravasation, the 
vasculature of solid tumors limits the delivery of a variety of therapeutic compounds spanning 
several orders of magnitude in size, including antibodies, nanoparticle carriers, and conventional 
chemotherapies.[56, 59, 60, 109, 110, 253] Secondly, solid tumors, independent of their tissue of 
origin or underlying mutational landscape, eventually become dependent on the host vasculature 
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for supplying nutrients and oxygen during angiogenesis, making the vasculature a general and 
genetically stable target for the majority of solid tumors.[255] 
Efforts thus far to modulate the tumor vasculature in the context of therapeutic delivery 
have focused on chemical, biophysical, and molecular targeting approaches. Molecules such as 
the anti-angiogenic antibodies trastuzumab, bevacizumab, and cediranib have been shown to 
normalize tumor vasculature by pruning poorly formed angiogenic vessels and thereby improve 
overall blood flow within the tumor.[65, 67, 68, 70] Extravasation across the endothelium 
through intercellular gaps has been facilitated by molecules such as vascular endothelial growth 
factor (VEGF), tumor necrosis factor alpha (TNFα), interleukin 1 (IL-1), vasoactive agents 
including histamine and bradykinin, and tumor-penetrating peptides.[63, 89, 256-259] Homing 
peptides identified by in vivo phage display have been conjugated to a variety of therapeutic and 
diagnostic nanocarriers to target specific proteins enriched in the tumor vasculature like αVβ3 
integrins.[260-262] Physical approaches using electromagnetic or acoustic energy have also been 
explored, most often in the context of ablative therapy.[263-267] These include radiofrequency 
ablation (RFA), microwave therapy, laser-induced thermotherapy, and high-intensity focused 
ultrasound (HIFU),[129, 268-271] but the high local temperatures achieved by these methods 
leads to coagulative necrosis rather than non-destructive, transient vascular perturbations.[265] 
For milder heating regimes, variations of these physical approaches have been combined with 
therapeutic cargoes such as temperature-sensitive liposomes containing chemotherapeutics to 
selectively trigger drug release by heating under real-time image guidance.[272, 273] Recent 
advances in nanomaterials have provided an opportunity to precisely control heating within 
tumor environments, and this has led to increased interest in understanding how such 
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nanomaterial-mediated heating regimens perturb the tumor vasculature and modulate tumor 
transport in clinical contexts.  
Here, we explore the effects of plasmonic nanoantennae called gold nanorods towards 
promoting the accumulation of therapeutic and diagnostic cargoes in solid tumors via transient 
modulation of the tumor vasculature. While an initial heat exposure with PEG-NRs enhanced 
tumor transport, tumors re-exposed to PEG-NR heating, as would occur in clinical protocols 
requiring repeated administration of chemotherapeutics over periods of days to weeks, developed 
thermotolerance with diminished tumor transport. Activation of the mammalian heat shock 
response (HSR) has been implicated in the development of thermotolerance in tumor cells, but 
its potential role in the endothelium is less clear. Using microfluidic endothelial permeability 
assays, in vitro analysis of the endothelial cytoskeleton, and intravital microscopy of the tumor 
vasculature, we identify the endothelium and the HSR as contributors to this thermotolerance 
effect. We preliminarily explore inhibition of the HSR as a remedy for thermotolerance using 
chemical and genetic approaches that diminish Hsf1 activity. Lastly, we demonstrate that PEG-
NR regimens which establish thermotolerance lead to reduced delivery of doxorubicin-loaded 
liposomes and less effective therapeutic responses in ovarian tumor xenograft models. 
Collectively, this work describes a thermal adaptation made by solid tumors in response to 
nanomaterial-generated heat stress, an effect with functional consequences for chemotherapeutic 
delivery and relevance to designing optimized treatment schedules.     
5.2   Materials and Methods:  
Animal models and cell lines:  
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All studies involving animal models were approved by the MIT Committee on Animal 
Care. Epithelial ovarian cancer models were established by unilateral or bilateral subcutaneous 
injection of ~1-2e6 CP70 human ovarian cancer cells into the rear flanks of 4-5-week-old 
athymic nude mice (Charles River). HSF1-null and HGL models expressing GFP and Luciferase 
driven by HSE A6 promoter were generated in the Lindquist Laboratory. 
Rag1tm1MomTg(Tie2GFP)287Sato/J mice expressing GFP in endothelial cells were used for 
vessel permeability studies (Jackson Laboratory). Tumor growth was monitored for 
approximately 10-20 days prior to injection of PEG-NRs. CP70 and OVCAR-8 cells were 
cultured in RPMI 1640 with L-glutamine (Invitrogen) supplemented with 10% fetal bovine 
serum (FBS) and penicillin/streptomycin. B16 cells were cultured in DMEM supplemented with 
10% fetal bovine serum (FBS) and penicillin/streptomycin. Primary HUVEC cells were cultured 
in media prepared from the EGM-2 BulletKit (Lonza).  
PEG-NR Synthesis:  
Concentrated cetyltrimethylammonium (CTAB)-coated gold nanorods (Nanopartz, Inc.) 
with dimensions of 41 nm x 10 nm were incubated with 5 kDa methyl-PEG-thiol (Laysan Bio, 
Inc.) to a final concentration of 100 μM as described previously.[241] After gentle mixing for 60 
minutes, solutions were dialyzed for at least 24 hours in 3,500 MWCO Slide-A-Lyzer cassettes 
(Thermo Scientific) in deionized, distilled water. Solutions were transferred to 100 kDa filter 
tubes (Millipore) and filtered with ultrapure water for five cycles of centrifugation (3,000g, 10 
minutes). PEG-NR solutions were resuspended in sterile PBS to an optical density of ~100 OD 
and stored at 4°C prior to administration in animal models.    
Intratumoral accumulation studies:  
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Animals bearing bilateral CP70 ovarian tumors were administered intravenous injections 
of PEG-NRs (100 μL; 100-150 OD). After 48-72 hours to allow PEG-NR clearance from 
circulation, animals received an intravenous injection of AngioSpark750 (AS750) (Perkin Elmer) 
(50 μL in PBS; stock solution) and one flank tumor received 808nm near-infrared irradiation for 
up to 30 minutes using a continuous 808nm diode laser source (Visotek). Tumor temperature 
was monitored continuously with an infrared thermal camera (FLIR T650sc) and tumor 
temperature was maintained at 40-43°C for the laser irradiation period. At multiple time points 
between 10 minutes and 48 hours after PEG-NR heating, tumor near-infrared fluorescence was 
acquired on the whole-animal IVIS Spectrum-bioluminescent and fluorescent imaging system 
(Xenogen). Quantification of relative AS750 accumulation in PEG-NR-heated tumors compared 
to contralateral unheated tumors was performed using Living Image analysis software (v4.3.1). 
Tumors harvested from animals were rinsed in PBS and whole-tumor AS750 fluorescence was 
detected using a near-infrared imaging system (LICOR Odyssey). Tumor homogenates were 
prepared by incubating tumor samples in tissue extraction buffer (70% EtOH, 0.3N HCl) and 
lysing samples on an automated homogenizer (gentleMACS Octo Dissociator, Miltenyi Biotec). 
Samples were centrifuged (1,000 rpm, 5 minutes), extracted overnight at 4°C, and supernatant 
fluorescence was measured in microplates on the LICOR imaging system. 
Intravital imaging:  
Intravital tumor imaging was performed on an Olympus FV1000 multiphoton laser 
scanning confocal microscope with a 25X, N.A. 1.05 objective lens. For vessel permeability 
experiments, animals were anesthetized by isoflurane and administered an intravenous bolus of 
fluorescein dextran (70,000 MW; Invitrogen), tetramethylrhodamine (TMR) dextran (2,000,000 
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MW; Invitrogen), or Texas Red dextran (70,000 MW; Invitrogen) (2–2.5 mg/mL). Immediately 
following injection of vascular dyes, tumors were positioned and immobilized on the stage for 
the duration of the experiment. For heat shock induction experiments, dorsal window chambers 
were surgically implanted or skin-flap models were prepared on HGL models and induction of 
the heat shock response as measured by GFP expression in vessels and surrounding tissue was 
monitored up to 24 hours post-heating. For intratumoral cellular uptake studies, Rag1-Tie2GFP 
mice bearing unilateral subcutaneous CP70 xenograft tumors were intravenously administered 
TR-dextran to visualize the vessel lumen and interstitial cells and imaged with a 25X, N.A. 1.05 
objective lens and 4X digital zoom (100X total magnification) within 1-2 hours following PEG-
NR heating. 
Microfluidic in vitro permeability studies:  
 Microfluidic devices were fabricated as described previously.[274] Briefly, 400 µm 
stainless steel needles were withdrawn from polymerized collagen hydrogels to create cylindrical 
voids that were then seeded with HUVECs. The endothelialized channels were exposed to 
continuously applied shear stress at magnitudes between 0.1 and 0.2 Pa for 12-18 hours to 
facilitate formation of tight junctions. Channels were placed in a temperature-controlled chamber 
(Air-Therm ATX, World Precision Instruments) on an epifluorescence microscope (Nikon 
Eclipse TI, Nikon Instruments). Saline solutions containing 70 kDa FITC-Dextran and 
Rhodamine-Dextran (Sigma) were continuously perfused through channels at flow rates of 5 
µL/min. Temperature within the heated chamber was continuously monitored for the duration of 
each experiment. Fluorescence and brightfield images were acquired with a 10X objective lens at 
the start and conclusion of each heating period. MetaMorph software (v7.7.3.0) was used for 
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image acquisition. Channels receiving multiple heat exposures were returned to a 37ºC incubator 
between the initial and subsequent imaging sessions, and again exposed to fluid shear stress. 
Dextran diffusion was quantified by tracking the movement of the dye front as a function of 
time. Image analysis, quantification of dye front displacement, and statistical analysis were 
performed with ImageJ software and GraphPad Prism software (v6.02).   
Cytoskeletal stability studies: 
Human umbilical vein endothelial cells (HUVEC) were seeded into μ-slide 8 well 
standard bottom dishes (ibidi) at 4.5e3 cells per well and allowed to adhere for 24 hours. The 
culture medium was then exchanged for fresh medium containing rAVCMV-LifeAct-TagGFP2 
(MOI: 100) (ibidi). After overnight incubation at 37°C, HUVECs either received a heating pre-
treatment (45°C, 30 minutes) or were maintained at 37°C. Following a 24 hour recovery period 
at 37°C, all cells then received a heat shock (45°C, 1 hour). Images were acquired using a 20X 
objective lens on a fluorescence microscope (Nikon Eclipse Ti) prior to and 0, 1, 2, 4, and 6 
hours after the final heat treatment. Images were obtained from 6–8 distinct wells per condition 
and time point. An investigator blinded to the experimental conditions scored cells contained 
visible actin filaments connecting opposing sides of the cell membrane, as well as the total 
number of cells per field. A total of 13,583 cells were scored (1,072–1,213 cells per condition) 
and statistical analysis was performed using GraphPad Prism software.  
Cell viability studies: 
HUVECs were seeded at 5e3 cells per well in 96-well black glass-bottom plates (Grenier) 
and allowed to adhere for 24 hours. Cells were pretreated by incubation at 45°C for 30 minutes, 
allowed to recover for 24 hours at 37°C, then incubated at 45°C for an additional 1 hour. Cells 
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were allowed to recover at 37°C for 30 hours. Cell viability was assayed using Alamar Blue 
(Invitrogen) prior to and 0, 6, and 30 hours after the final heat treatment. 
Tumor volume and survival studies:  
For longitudinal survival studies, nude mice were implanted with ~1-2e6 CP70 human 
ovarian cancer cells in the hind flanks. Tumor treatments consisted of administration of PEG-
NRs, doxorubicin-loaded liposomes (5 mg/kg) (Encapsula), and NIR irradiation with appropriate 
controls. Briefly, 48-72 hours post PEG-NR administration, animals received NIR laser 
irradiation (~41-43°C, 30 minutes) under continuous temperature monitoring using an infrared 
camera (FLIR T650sc). 24 hours later, animals underwent a second round of NIR laser 
irradiation in combination with intravenously administered doxorubicin-loaded liposomes. 
Longitudinal studies lasted ~4-5 weeks from initial treatment with tumor volumes measured 
approximately every 3-4 days using digital calipers by investigators who were blinded to the 
experimental groups. Animals were euthanized when the tumor burden exceeded 500 mm3. Plots 
and statistical analysis of tumor volume growth and Kaplan-Meier survival curves were 
performed using GraphPad Prism.  
Heat shock induction in vivo:  
HGL mice were implanted with 2e5 B16 melanoma cells in the hind flank. After 2-3 
weeks, animals were injected with PEG-NRs intravenously and received an initial round of NIR 
irradiation 48-72 hours later. Animals were injected subcutaneously with RHT (1.2 mg/kg) in 
cyclodextran or vehicle control twenty minutes prior to NIR irradiation. 24 hours after NIR 
irradiation, animals were injected subcutaneously with D-Luciferin (9 mg/mL in PBS) (Gold 
Biotech) and imaged on the IVIS Spectrum system for bioluminescence. The procedure was 
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repeated for a second round of NIR irradiation and RHT administration, with bioluminescence 
imaging performed 24 hours later. Image analysis was performed on Living Imaging software.  
Immunohistochemistry: 
Tumors were harvested and fixed in a 4% paraformaldehyde solution overnight at 4ºC. 
Tissues were transferred to cassettes and placed in 70% ethanol solution at room temperature 
until paraffin embedding. Antibodies used included a rabbit polyclonal CD31 antibody (1:75, 
Abcam), rabbit monoclonal HSP70 (1:50, Cell Signaling), and rat HSF1 (4B4) (1:500, Thermo 
Scientific). Slides were counterstained with standard Hematoxylin & Eosin (H&E). LabVision 
Autostainer 360 Immunohistochemical Stainer (Thermo Scientific) was used to perform IHC 
with antigen retrieval.  
Nanoparticle circulation time:  
AS750 and FITC-Dextran were intravenously administered to animals, and blood was 
collected by retro-orbital sampling at several times following injection using heparin-coated 
microcapillary tubes (VWR). Samples were rapidly transferred to a 5 mM EDTA solution to 
prevent coagulation. Blood samples were spun on a tabletop centrifuge for 30-60 seconds to 
separate plasma and erythrocyte fractions. Plasma fractions were transferred to 96-well plates 
and read on a fluorescence microplate reader (Molecular Devices) and near-infrared imaging 
system (LICOR).  
Nanoparticle in vitro stability:  
AS750 nanoparticles were serially diluted in solutions of distilled water, PBS, 10% (v/v) 
FBS in PBS, and 50% (v/v) FBS in PBS to a lowest concentration of 1:100,000 of the stock 
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concentration. Nanoparticle fluorescence was measured on the IVIS Spectrum-bioluminescent 
and fluorescent imaging system (Xenogen) and the Odyssey near-infrared scanner (LICOR). 
Image analysis and quantification was performed using ImageJ software. 
5.3   Results:  
5.3.1 PEG-NR heating enhances tumor transport followed by development of thermotolerance  
Mild heating of tumors with PEG-NRs and other methods has previously been shown to 
enhance the accumulation of diagnostic and therapeutic agents in tumors.[109, 110, 112] In order 
to study the impact of nanomaterial-driven heating on tumor transport, mice with ovarian 
xenograft flank tumors were administered PEG-NRs several days prior to heating. At various 
times, tumor transport was assessed by quantifying delivery of pegylated fluorescent 
nanoparticles (AS750) as a model of diffusion-limited cargo. AS750 is composed of an iron 
oxide core coated with polyethylene glycol (PEG) and near-infrared fluorophores; its circulation 
time (t1/2: 283 minutes), particle size (~35 nm), and spectral characteristics (Ex/Em: 750/775 nm) 
make it a good model for clinical nanoparticle formulations and for in vivo monitoring (Fig. S1). 
Consistent with previous studies, tumors receiving a single exposure to PEG-NR heating 
accumulated AS750 in 2.1-fold excess compared to unheated tumors on the contralateral flanks 
(Fig. 5.1). Because in clinical settings many therapeutic agents are administered as multiple 
cycles spanning periods of days to weeks, we explored the consequences of repeated PEG-NR 
heating on tumor transport. Ovarian tumor xenografts received repeated exposure to PEG-NR 
heating with intervals between heating ranging from 8 hours to 1 week, defined as delta T. In 
these experiments, tumor transport was characterized at the time of the second heat exposure by 
administration of AS750. The results show that delta T of 8 hours still resulted in an increase in 
tumor transport of 1.4-fold over untreated tumors, however the enhancement was reduced as 
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compared to that after the first heat exposure (Fig. 5.1). At longer delta T of 24 and 48 h, tumor 
transport was no longer enhanced over untreated controls (0.9- and 1.0-fold respectively) (Fig. 
5.1). We term this loss of heat-responsiveness ‘thermotolerance’. At longer delta T, we noted a 
recovery of heat-responsiveness, beginning at 96 h and increasing back to >2-fold by a delta T of 
one week (Fig. 5.1). Fluorescence of explanted tumors displayed a similar trend, with shorter 
delta T between PEG-NR heat exposures correlating with reduced tumor transport (Fig. S2). 
This data demonstrates that PEG-NR heating increases tumor transport but also induces a 
thermotolerance to subsequent heating that peaks at 24-48 h and reverts after one week. In 
subsequent experiments, we establish a delta T of 8 or 24 h to further investigate the 
thermotolerance phenomena. 
 
 
Figure 5.1. Heat-induced transport enhancement is followed by a period of thermotolerance 
wherein tumors are resistant to subsequent heating. (a) Experimental time course includes 
administration of gold nanorods (PEG-NR), an initial exposure of laser heating (heat), and an 
interval delta T varying from 0 to 7 days prior to re-exposure (heat). Tumor transport is probed 
at the end of delta T via administration of AS750 imaging nanoparticles and tumor 
accumulation is quantified via in vivo fluorescence imaging. (b) Tumor transport as visualized 
by AS750 nanoparticle fluorescence in heated versus unheated tumors for increasing delta T. 
Note the increase in tumor transport after heat exposure is absent upon repeat exposure after 
24-48 h (‘thermotolerance’) but begins to recover at 96 h. (c) Tumor transport (ratio of AS750 
for heated versus unheated tumors) (n = 8-12 per group from two independent experiments, 
**P<0.01, ***P<0.001, one-way ANOVA and Tukey’s post-tests.) Error bars, s.e.m. 
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To explore the dynamics of heat-enhanced tumor transport, animals received either a 
single or double exposure to PEG-NR heating and tumor transport was assessed by offsetting the 
administration of AS750 by either 1 or 6 h after heating. (Fig. 5.2). Tumors receiving a single 
exposure of PEG-NR heating displayed a 2-2.7-fold increase in accumulation when AS750 was 
administered within 1 hour of PEG-NR heating and no relative enhancement in accumulation 
when AS750 was administered 6 hours after PEG-NR heating (Fig. 5.2). This data suggests that 
a single exposure of PEG-NR heating established a 6 hour ‘window’ where nanoparticles could 
preferentially accumulate within heated tumors. Interestingly, in tumors receiving a repeated 
PEG-NR exposure after delta T of 8 h, we no longer observed an enhancement in accumulation 
when AS750 was administered 1 h following the second heat exposure. (Fig. 5.2). These results 
suggest that both the magnitude of the thermal response and the dynamics may be altered after 
repeated exposure to heat. Taken together, these data demonstrate an initial increase in tumor 
transport in response to heat that is followed by a transient, reversible loss in heat responsiveness 
(thermotolerance). Because the endothelium is a dynamic, heat-responsive interface between the 
systemic circulation and the tumor interstitium, we next assessed the potential role of the 
endothelium in mediating the observed thermotolerance.  
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5.3.2 Endothelial heat response is sufficient for transvascular transport and thermotolerance 
To study the specific contribution of the endothelium, we utilized a microfluidic device 
consisting of a cylindrical channel lined by a monolayer of endothelial cells encapsulated in type 
I collagen (Fig. 5.3).[274] The minimal components contained in this device represent to a first 
approximation the angiogenic vasculature of solid tumors, which consists of an endothelial 
monolayer with reduced pericyte coverage and surrounded by a network of collagen fibers, 
proteoglycans, and tumor cells.[255] A saline solution containing 70 kDa FITC-Dextran was 
perfused through the endothelial channel and permeability at various temperatures and heating 
regimens was measured over time as the displacement of the FITC-Dextran dye front (Fig. 5.3). 
We performed a temperature ramp spanning physiological body temperature of 37°C to 45°C to 
encompass the full range of temperatures achieved during in vivo PEG-NR heating experiments. 
For vessels subjected to a single exposure of heating, FITC-Dextran dye was retained within the 
Figure 5.2. Diminished window of tumor transport after re-exposure to PEG-NR heating. (a) 
Experimental time course includes an initial exposure to PEG-NR heating (heat), an interval 
delta T of 8 h, re-exposure to PEG-NR heating (heat), and AS750 administration offset from 
the second heating by 0, 1, or 6 h. Tumor accumulation is quantified via in vivo fluorescence 
imaging. (b) Representative in vivo fluorescence images demonstrating shortened window of 
tumor transport after re-exposure to PEG-NR heating. Red arrows indicate heated tumors. (c) 
Tumor transport (ratio of AS750 in heated versus unheated tumors) for each offset in AS750 
administration after re-exposure to heating. (n = 8 per group, **P<0.01, unpaired t-test, two-
tailed.) Error bars, s.e.m. 
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vessel lumen between 38°C and 42°C (Fig. 5.3). When the temperature reached 43°C, we 
observed significant displacement of the dye front into the surrounding collagen matrix, 
indicating disruption of the endothelial monolayer and increased transvascular permeability (Fig. 
5.3). Structural changes to the endothelium were observed, as the cells transitioned from a 
confluent, flow-aligned ‘cobblestone’ appearance prior to heating to a contracted state with 
increased frequency of interendothelial gaps (Fig. 5.3). 
Interestingly, when the same vessels were subjected to a second exposure of heating with 
a delta T of 8-24 h, the dye front displacement of FITC-Dextran was diminished. When heated 
channels were returned to physiological body temperature after an initial heating, the endothelial 
cells efficiently resealed to form an effective barrier to FITC-Dextran diffusion (data not shown). 
Compared to their initial heating exposure, re-heated vessels displayed 26.3- and 11.6-fold less 
dye front displacement at 42°C and 43°C, respectively (Fig. 5.3). To integrate the effect across 
temperature, we calculated the cumulative dye front displacement during single heating and re-
heating regimens. The cumulative displacement of FITC-Dextran from the lumen into the 
surrounding collagen matrix between 40°C and 43°C was reduced by 2.6-fold in doubly-heated 
channels relative to single heated channels (Fig. 5.3). The ability to recapitulate thermotolerance 
in a model containing minimal elements (i.e., endothelial cells and collagen) suggests that the 
endothelium itself can adapt to repeated thermal exposures and play an important role in 
modulating transvascular transport in vivo. 
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5.3.3 Cytoskeletal recovery of endothelial cells is enhanced after repeated heat exposure 
The morphological changes to endothelial cells observed in the microfluidic vascular 
model suggested that cytoskeletal disruption was contributing to the functional changes to 
permeability. To explore the response of the endothelial cytoskeleton to single versus double 
heat exposures, human umbilical vein endothelial cells (HUVECs) were infected with adenovirus 
Figure 5.3.  Endothelial heat response is sufficient for transvascular transport and 
thermotolerance. (a) Photograph and cross-section schematic of microfluidic endothelial 
channel. A cylindrical channel lined by an endothelial monolayer is established within type 1 
collagen gel. Saline solutions containing 70 kDa FITC-Dextran are flowed through the channel 
during controlled heating regimens to monitor temperature-dependent transport across 
endothelium. (b) Representative fluorescence and bright field images for pre- and post-heating. 
Prior to heating, FITC-Dextran is retained in the channel lumen and a confluent endothelial 
monolayer is observed. After heating, extravasation of FITC-Dextran is associated with 
contracted endothelial cells (ECs). Dye front displacement (δ) measured for each temperature. 
(c) FITC-Dextran accumulation outside of lumen during 43°C heating period in microfluidic 
channels subjected to a single (1X heat) or repeated (2X heat) heat exposure. (d) Dye front 
displacement versus temperature across physiological temperature range. (n = 3-6 channels per 
group) (e) Cumulative front displacement over time between 40–43°C. Channels were exposed 
to each temperature for 10 minutes excluding ramping intervals.
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expressing an F-actin-binding GFP fusion protein to dynamically monitor F-actin destabilization 
and structural recovery in living endothelial cells. HUVECs received either a single heat 
exposure (‘1X heat’) or second heat exposure with delta T of 24 h (‘2X heat’), and cytoskeletal 
structure was serially monitored by time-lapse fluorescence microscopy (Fig. 5.4). To quantify 
cytoskeletal structure, we defined the parameter membrane-spanning filaments to indicate cells 
with at least one visible F-actin filament connecting non-adjacent points along the cell membrane 
(F-Actin+), and an investigator blinded to the treatment groups scored individual cells across all 
conditions. These heating conditions intended to mimic the single and double PEG-NR heating 
regimens explored in vivo, and the heat exposures in the minimal microfluidic vasculature in 
vitro. At physiological temperatures, the majority of cells in the single heat exposure and re-heat 
exposure groups displayed numerous membrane-spanning F-actin filament networks (72.6% and 
62.9% cells with membrane-spanning F-actin filaments, respectively) (Fig. 5.4, Fig. S3). 
Immediately following heating, both single heated and re-heated cells displayed a collapsed F-
actin appearance, with re-heated cells exhibiting an elevated but insignificant percentage of cells 
with membrane-spanning filaments compared with single heated cells (16.9% and 4.1%). Time-
lapse microscopy revealed the kinetics of cytoskeletal recovery of single heated and re-heated 
cells following heat exposure. Re-heated endothelial cells exhibited efficient structural recovery 
1-2 hours after heat exposure (63.6%-75.9%) and remained stable at these levels for 4-6 hours 
after heat exposure (64.3%-72.4%). In contrast, single heated cells failed to exhibit recovery of 
the cytoskeleton 1-2 hours after heat exposure (3.0%-7.2%), which represented 21.3- and 10.6-
fold fewer cells with membrane-spanning filaments relative to re-heated cells at 1 and 2 hours 
after heat exposure, respectively. However, single heated cells did display a partial structural 
recovery of F-actin filaments by 6 hours after heat exposure (30.4%). Endothelial cell viability 
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was not significantly different between single heated and re-heated cells before heat exposure, 
immediately following heat exposure, and 30 hours following heat exposure, although a small 
decrease in viability in single heated cells was observed 6 hours after heat exposure (Fig. 5.4). 
Within the single heat exposure and re-exposure cell populations, the individual fields of view 
examined within each group displayed similar temporal patterns of cytoskeletal recovery (Fig. 
S4). In a separate experiment, we investigated the temperature dependence on cytoskeletal 
 
 Figure 5.4. Cytoskeletal recovery of endothelial cells is enhanced upon re-exposure to heating. 
(a) Experimental time courses for single heat exposure (1X heat) and re-exposure to heat (2X 
heat). (b) Representative fluorescence images of EC F-Actin filaments during recovery after 
heating. Images depict cytoskeletal collapse and subsequent recovery. For each regimen, the 
same cell is shown across multiple time points to demonstrate the kinetics of EC recovery. (c) 
Relative EC viability for cells in single exposure and re-exposure groups prior to, immediately 
after, 6 hours, and 30 hours after heating. Bars represent EC viability in the single exposure 
group relative to re-exposure group. (n = 5 per group, *P<0.05 one-way ANOVA and Tukey’s 
post-tests.) (d) Percentage of cells with visible membrane-spanning F-Actin filaments per field 
during the post-heating recovery period. (n = 1,072 – 1,213 cells from 6-8 fields of view per 
condition per time point, ****P<0.0001, two-way ANOVA and Bonferroni’s post-tests.) Error 
bars, s.e.m.               
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collapse between 37-42.3°C and observed a progressive increase in the frequency of cytoskeletal 
collapse with increasing temperature and duration of heating (Fig. S5). Collectively, this data 
demonstrates that subjecting endothelial cells to a previous heat treatment contributes to 
accelerated remodeling upon subsequent heat exposure, which is manifested by more efficient 
structural recovery of the F-actin cytoskeleton. Interestingly, the time scales for cytoskeletal 
recovery observed in single and re-heated endothelial cell populations were similar to the 
windows of cargo accumulation observed in tumors exposed to single and double PEG-NR 
heating regimens, respectively. 
5.3.4 Endothelial response to PEG-NR heat exposure in the tumor environment 
Having observed the effect of thermotolerance on tumor transport in vivo and on vascular 
permeability and endothelial cytoskeletal architecture in vitro, we next visualized endothelial 
barrier function in vivo. In particular, we sought to understand the size dependence of the 
permeability effects on potential cargos, as well as observe endothelial responses to single and 
double PEG-NR heating in the tumor environment. Mouse xenograft models received either a 
single PEG-NR heat exposure or double PEG-NR heat exposure with a delta T of 24 hours. 
Transvascular transport in tumors was probed by an intravenous bolus of 70 kDa FITC-Dextran 
immediately followed by intravital multiphoton microscopy. Unheated tumors displayed minimal 
extravasation of 70 kDa FITC-Dextran tracer dye, whereas tumors receiving a single PEG-NR 
heat exposure exhibited moderate vascular leakage into the interstitial space within an hour after 
heating (Fig. 5.5). 
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Consistent with bulk measurements in Fig. 5.1, tumors receiving a second exposure to PEG-NR 
heating displayed reduced extravasation of tracer dye into the interstitial space in the majority of 
fields examined. In unheated tissues, we also observed a clear size-dependence to extravasation, 
as 10 kDa FITC-Dextran readily diffused from the vascular compartment into the collagen-rich 
interstitial space whereas 2,000 kDa TMR-Dextran was retained in the vessel lumen (Fig. S6).   
Because increased vascular permeability via endothelial contractions would not 
necessarily lead to enhanced tumor accumulation due to ‘back-diffusion’ of cargoes into 
vessels[56], we sought to understand what could be driving the accumulation and retention in our 
 
 Figure 5.5. Transvascular transport in tumors after single exposure and re-exposure to PEG-
NR heating. Unheated and re-exposure (2X heat) tumor vessels display intravascular retention 
of 70 kDa FITC-Dextran, while a greater degree of extravasation of FITC-Dextran was 
observed during single exposures (1X heat) to PEG-NR heating. Collagen fibers (magenta) 
delineate the tumor interstitium and PEG-NRs appear in a punctate perivascular pattern in both 
channels. (n = 15-31 z-stacks from n = 3-7 animals per treatment group) Scale bar: 50 µm 
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model using high magnification intravital microscopy. To visualize extravasation in proximity to 
tumor vessels at higher resolution, we established tumors in a transgenic mouse model 
expressing the Tie2-GFP fusion protein to fluorescently label the tumor endothelium. 
Intravenous 70 kDa Texas Red dextran (TR-Dex) was administered and the intra- and 
extravascular distribution of TR-Dex was examined in response to different PEG-NR heating 
regimens (Fig. 5.6). In particular, we observed a significant number of perivascular phagocytic 
cells within tumors, likely representing macrophage or dendritic cell populations. We observed 
punctate spots of TR-Dex appearing within these perivascular cell populations consistent with 
endocytic uptake of TR-Dex. For each PEG-NR heating regimen, we quantified the frequency of 
TR-Dex-positive cells per volumetric image stack as a proxy for the degree of local extravasation 
occurring within each field. Unheated tumors displayed relatively few TR-Dex-positive cells 
(5.1±2.4 cells per field), whereas tumors receiving a single exposure to PEG-NR heating 
displayed a significant 3.9-fold greater frequency of TR-Dex positive cells (19.9±2.1 per field). 
In contrast, tumors re-exposed to PEG-NR heating with delta T of 24 h displayed a reduced 
frequency of TR-Dex-positive cells and only 1.6-fold higher than the unheated state (8.3±1.1 per 
field). For each condition, tumor blood flow was maintained during each imaging period 
suggesting that vaso-occlusion or thrombosis was not a major contributor to the diminished 
extravasation observed with repeated PEG-NR heating (data not shown). Additionally, elevated 
levels of vascular endothelial growth factor (VEGF) in the tumor microenvironment can enhance 
vascular permeability, with both increased inter-endothelial gap formation and increased 
transcytosis across endothelial cells. We did not observe significant differences in VEGF 
expression following each heating regimen in this study. (Fig. S7) 
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To corroborate these microscopic observations with bulk tumor accumulation, tumor 
homogenates were prepared from mice intravenously administered 70 kDa FITC-Dextran. 
Homogenates from tumors receiving a single exposure of PEG-NR heating accumulated 1.7-fold 
greater FITC-Dextran (8.6 versus 5.2 %ID/g), whereas homogenates from tumors receiving a 
double heat exposure accumulated FITC-Dextran to a similar degree as unheated tumors (4.6 
versus 5.2 %ID/g) (Fig. 5.6). Having established a role for the endothelium in mediating 
thermotolerance using both in vivo and in vitro models, we next sought to understand the 
relevant molecular pathways involved. 
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5.3.5 Heat shock response is induced by PEG-NR heat exposure and can be inhibited by RHT 
Because thermotolerance was shown to impact tumor transport, an understanding of the 
molecular pathways mediating thermotolerance could suggest approaches to overcome its 
undesirable effects on tumor transport. The mammalian heat shock response (HSR) is an ancient, 
evolutionarily conserved cellular signaling network that responds to a variety of stresses 
 Figure 5.6. Macromolecular accumulation in vivo after single or double PEG-NR heating 
exposures. (a) Intravital imaging of intra- and extravascular distribution of 70 kDa Texas Red 
dextran (TR-Dex) in ovarian xenografts with Tie2-GFP+ endothelium. Collagen fibers (purple) 
highlight the tumor interstitial space, GFP (green) highlights tumor endothelium, and TR-Dex 
(red) is distributed between vessel lumen, interstitial space, and perivascular cells. Scale bar: 
20 µm (b) Perivascular phagocytic cell residing in tumor interstitium (T) outside of tumor blood 
vessel (V). Yellow asterisk highlights uptake of TR-Dex cargo in putative endosome. (c) 
Quantification of TR-Dex-positive cells per tumor tissue volume measured by intravital 
imaging. (n = 15 – 23 fields of view from 3 mice per condition, ****P<0.0001, one-way 
ANOVA with Tukey’s post-tests.) Error bars, s.e.m. (d) Accumulation of 70 kDa FITC-Dextran 
in tumor homogenates from tumors receiving no heating, a single exposure, or double heat 
exposure. (n = 3-7 tumors per condition, *P<0.05, unpaired t-test, two-tailed.) Error bars, s.e.m.   
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including heat, oxidative stress, low pH, and heavy metals.[113] Previous studies have identified 
a role for the HSR in mediating thermotolerance in a variety of cells and organisms.[275-277] 
Although we use the term here to describe tumor transport effects, thermotolerance is classically 
defined as a cell-intrinsic adaptation to stress that promotes increased viability upon subsequent 
stress. Of interest to this study, however, classical thermotolerance has been shown to confer 
enhanced cytoskeletal stability to cells upon subsequent heat exposure.[117-119] To investigate 
whether nanomaterial-induced heat was activating genetic heat shock programs in our model, we 
performed intravital microscopy on immunocompetent tumor xenograft models expressing heat-
inducible GFP (HSE-GFP) and luciferase (HSE-Luc) under the heat shock element (HSE) A6 
promoter (HGL model) (Fig. 5.7). HGL mouse models bearing B16 melanoma xenografts 
received single exposures of PEG-NR heating. Unheated tumors displayed minimal GFP 
expression in vascular territories (Fig. 5.7). Because of their strong optical scattering properties, 
PEG-NRs were readily visualized in both heated and unheated tumors as punctate, perivascular 
signals in all emission channels (Fig. 5.7, Fig. S8).Tumors receiving a single PEG-NR heat 
exposure, however, displayed a marked and diffuse increase in GFP expression indicating robust 
induction of the HSR in response to PEG-NR heating. A cellular infiltrate appearing to 
concentrate the PEG-NRs in perivascular regions was also observed in PEG-NR heated tumors. 
Notably, several regions revealed strong perivascular GFP expression suggesting that the 
endothelium develops an active HSR within hours following heating (Fig. 5.7). 
Our results suggest that the thermotolerance we observed in tumors with delta T between 
8 – 24 h could be explained by induction of the HSR in the endothelium after an initial heat 
exposure. We hypothesized that inhibition of the HSR by either chemical or genetic approaches 
could mitigate thermotolerance. Recently, a family of natural product compounds called 
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rocaglates was shown to potently inhibit Heat Shock Factor 1 (Hsf1) via translational repression 
and release of Hsf1 from promoters of target genes including the heat shock proteins 
(HSPs).[121] To investigate whether pharmacological inhibition could diminish the HSR after 
PEG-NR heating, we administered RHT, a potent member of the rocaglate family, in 
combination with PEG-NR heating to HGL tumor xenograft models and monitored HSR 
induction by bioluminescence. For tumors receiving either a single or double PEG-NR heat 
exposure, RHT significantly inhibited HSR induction in the tumor stroma and surrounding tissue 
(Fig. 5.7). If thermotolerance is being driven by the HSR, then HSR inhibition via RHT might be 
expected to improve tumor transport in the setting of double heat exposure. While we did not 
observe an enhancement in AS750 accumulation in RHT-treated tumors, this may represent a 
pharmacodynamic limitation of the dosing regimen, as partial activity of Hsf1 may still be 
sufficient to induce thermotolerance. Taken together, these experiments establish that tumor-
localized heating by PEG-NRs and other means is sufficient to induce a robust HSR in the tumor 
endothelium and that pharmacologic agents can effectively counteract HSR induction due to 
PEG-NR heat exposure. 
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 Figure 5.7. Induction of heat shock response correlates with acquisition of thermotolerance. (a) 
Schematic of HGL transgenic model. Heat-inducible HSE promoter (A6) regulates expression of 
GFP and firefly luciferase, permitting visualization of the heat shock response in the tumor 
stroma including the endothelium. (b) Elevated GFP expression following PEG-NR heating in 
tumors indicates a robustly induced heat shock response. Tumor vasculature highlighted by 
intravenous TR-Dextran (TR-Dex). Intrinsic luminescence of PEG-NRs allows for direct 
detection of nanoparticles by multiphoton microscopy. (c-d) Intravital imaging reveals induction 
of endothelial heat shock response. Line histogram profiles of normalized GFP and TR-Dex 
fluorescence intensities at regularly-spaced intervals along vessel after heat exposure (n = 6 
equidistant positions along vessel). (e-f) Pharmacological inhibition of heat shock response in 
PEG-NR heated tumors pre-treated with RHT. Whole animal imaging of HSE-Luciferase (HSE-
Luc) expression and quantification in tumors receiving single or double PEG-NR heat exposures 
in the presence of RHT or control. (n = 6-7 mice per condition, *P<0.05, unpaired t-test, two-
tailed) Error bars, s.e.m. 
140 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. (Continued). 
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5.3.6 Inhibition of heat shock response enhances tumor transport upon re-exposure to heating  
Because chemical inhibition with RHT did not enhance tumor transport after re-exposure 
to PEG-NR heating, we next investigated whether a genetic approach having a more complete 
and sustained inhibition might enhance tumor transport. Tumor xenografts were established in 
immunocompromised mice harboring deletions in one or both alleles of Hsf1. Tumors received 
two PEG-NR heat exposures with a delta T of 24 h. As in Figs. 5.1 – 5.2, AS750 tumor 
accumulation was serially measured by in vivo fluorescence imaging. (Fig. 5.8). Because we 
observed the greatest thermotolerance with delta T of 24 h in earlier experiments, we selected 
this as our interval between PEG-NR heat exposures. Among the groups, animals with two 
functional alleles of Hsf1 displayed the least enhancement in AS750 accumulation, consistent 
with the development of thermotolerance observed earlier (Fig. 5.8). Interestingly, compared to 
Hsf1+/+ models, mice with one or two deleted Hsf1 alleles accumulated 2.6- and 6.0-fold greater 
concentrations of AS750, respectively, during the 24 h period following AS750 administration 
(Fig. 5.8).  
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At approximately 3 hours after re-exposure to PEG-NR heating, the intratumoral 
accumulation of AS750 from their baseline values increased by 43.7% in Hsf1-/- models, 
whereas it increased by only 16.3% in Hsf1+/+ models. To determine whether tumors with Hsf1-
 
 Figure 5.8. Inhibition of heat shock response enhances tumor transport after re-exposure to 
PEG-NR heating. (a) Ovarian tumor xenograft models either homozygous-null (-/-), 
heterozygous (+/-), or wild type (+/+) for Heat Shock Factor 1 (Hsf1) received an initial PEG-
NR heat exposure (heat), an interval delta T of 24 h, and a re-exposure to PEG-NR heating 
(heat). Tumor transport (AS750 fluorescence) was measured serially for 24 h by in vivo 
fluorescence imaging. (b) Tumor accumulation (AS750) for each genetic background up to 24 
h after treatment. (n = 3-6 per group) Error bars, s.e.m. (c) Relative AS750 fluorescence in 
tumors normalized to initial value after administration. (n = 3-6 per group) Error bars, s.e.m. 
(d) Representative in vivo fluorescence images in animals with Hsf1-/-, Hsf1+/-, and Hsf1+/+ 
backgrounds receiving double PEG-NR heat exposures. (e) Area under the curve from panel 
(b) for each genetic background demonstrating enhanced accumulation in Hsf1-/- animals. (n = 
3-6 per group, **P<0.01, one-way ANOVA and Tukey’s post-tests.) Error bars, s.e.m. 
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/- stroma were more prone to accumulate AS750 than Hsf1+/+ models due to intrinsic, non-
vascular structural differences, single exposures of PEG-NR heating were explored in Hsf1+/+ 
and Hsf1-/- models. With single exposure to PEG-NR heating, we observed no significant 
difference in the kinetics and cumulative amount of AS750 that accumulated within Hsf1+/+ and 
Hsf1-/- models (Fig. 5.9). 
  
Tumor sections revealed moderate Hsf1 expression in the tumor parenchyma independent 
of the host’s genetic background, but diminished Hsf1 expression in the tumor stroma, including 
CD31+ vasculature, of Hsf1-/- animals that received PEG-NR heating (Fig. S9). Collectively, 
these data suggest a model in which PEG-NR heating modulates the tumor endothelium in a 
transient, reversible manner, with consequences for cargo delivery and potentially for overall 
therapeutic efficacy (Fig. 5.10). 
 Figure 5.9. Cargo accumulation in tumors with Hsf1+/+ and Hsf1-/- stroma after single 
exposure to PEG-NR heating. Similar overall levels and kinetics of accumulation of AS750 
were observed for both groups. (n = 3 per group)   
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5.3.7 Rational design of PEG-NR therapeutic regimens for enhanced tumor transport and 
efficacy 
We next explored the relationship between PEG-NR heating schedules, chemotherapeutic 
accumulation in tumors, and overall therapeutic efficacy. Our results in tumor models and in 
vitro systems point to specific design criteria that could maximize the efficacy of combination 
therapeutic approaches involving PEG-NR heating and chemotherapy. In particular, we reasoned 
that the temporal relationship between heating and administration of therapy may be important, 
as re-exposure to PEG-NR heating with delta T of 24-48 h dampened the accumulation of cargos 
within tumors. Doxorubicin-loaded liposomes are a clinically-approved nanoparticle therapy for 
ovarian cancer, yet their relatively large particle diameter (~100 nm) limits their intratumoral 
 
 Figure 5.10. Model describing heat-induced tumor transport and development of 
thermotolerance. An initial exposure to PEG-NR heating alters the endothelial architecture via 
cytoskeletal remodeling, leading to enhanced tumor transport of nanoparticle cargoes. Over the 
next 24-48 h, the endothelium develops thermotolerance, mediated by the heat shock response 
and Hsf1, such that re-exposure to PEG-NR heating results in enhanced cytoskeletal recovery 
and diminished tumor transport. Restoration of heat-responsiveness occurs after approximately 
1 week from the initial heat exposure. 
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accumulation. Consistent with previous observations, a single exposure to PEG-NR heating led 
to a 2.7-fold higher concentration of doxorubicin liposomes in xenograft tumors relative to 
double heated tumors with delta T of 24 h (Fig. 5.11). Given the enhancement in intratumoral 
therapeutic concentrations, we then investigated the degree to which improved delivery 
influenced antitumor efficacy and animal survival. Cohorts of mice bearing ovarian tumor 
xenografts were randomized to receive either single exposures to PEG-NR heating and 
doxorubicin liposomes (1X Heat+Dox), double exposures to PEG-NR heating (delta T = 24 h) 
and doxorubicin liposomes administered during re-exposure to heat (2X Heat+Dox), doxorubicin 
liposomes alone (Dox), or no treatment (NT) (Fig. 5.11). We observed the greatest antitumor 
effect in the 1X Heat+Dox cohorts. While tumor growth was delayed in the 2X Heat+Dox cohort 
relative to untreated controls, tumors in the 1X Heat+Dox cohort grew significantly slower than 
those in the 2X Heat+Dox cohort. A similar trend was observed in a Kaplan-Meier survival 
analysis; untreated and Dox only cohorts survived between 16-20 days after initiation of 
treatment. While 2X Heat+Dox cohorts survived longer than either of these groups, the 1X 
Heat+Dox cohorts survived for the longest duration overall and significantly longer than the 2X 
Heat+Dox cohort (Fig. 5.11).  
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5.4   Conclusions: 
Delivering therapeutic compounds to solid tumors with improved efficiency and 
specificity has long been a major goal within the clinical community. In addition to molecular 
targeting approaches with monoclonal antibodies or peptides, physical stimuli such as acoustic 
and electromagnetic energy have garnered interest in part due to the notion that such vascular-
 Figure 5.11. Rational design of PEG-NR therapeutic regimens for enhanced drug delivery and 
efficacy. (a) Accumulation of doxorubicin liposomes in unheated, single heat exposure (1X 
heat), and re-exposure with delta T of 24 h (2X heat) groups. Bars normalized to unheated 
controls. (n = 5 mice per group, *P<0.05, Mann-Whitney test.) Error bars, s.e.m. (b) Time 
courses for each experimental group. Animals received 0, 1, or 2 exposures to PEG-NR heating 
with doxorubicin liposomes administered with the final heat exposure. Regimens were repeated 
weekly for the duration of the therapeutic trial period. (c-d) Tumor volume and Kaplan-Meier 
survival curves (n = 8–9 mice per group, *P<0.05, (c) unpaired t-test, two-tailed, Holm-Sidak 
method for multiple comparisons and (d) Log-rank Mantel-Cox test) Error bars, s.e.m. 
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modulating strategies would affect a conserved, genetically-stable component of solid tumors 
and therefore would be expected to have widespread utility for tumors of diverse tissue origins 
and genetic backgrounds. In addition, the technologies to generate intratumoral heating have 
significantly matured during the past decades, with nanomaterials such as gold nanorods offering 
the promise of more targeted, homogeneous, controlled, and efficient deposition of thermal 
energy within tumor tissue.[128]   
In this work, we characterize the effects of an optically-active, heat-inducible 
nanomaterial on modulating tumor transport in ovarian tumor models. Because many dosing 
schedules in the clinic require multiple rounds of administration, we explored the effects of re-
exposure to PEG-NR heating on tumor transport. Our data revealed a transient period of 
impaired tumor transport, which we term thermotolerance, in tumors re-exposed to PEG-NR 
heating within 24-48 h of an initial heat exposure. Restoration of heat-responsiveness was found 
to return after approximately 1 week in our model. Previous studies have elucidated a role for 
endothelial thermotolerance in regulating tumor blood flow, so the data presented here extend the 
effects of thermotolerance to transvascular transport, a second major barrier of cargo 
delivery.[278] The interaction between blood flow and transvascular transport in tumors requires 
further investigation, but it is feasible that these parameters may be functionally coupled in the 
context of therapeutic delivery.   
The well-defined role of the tumor endothelium in regulating cargo transport [56] led us 
to focus on its role in the thermotolerance that we observed. Using a minimal microfluidic model 
of the endothelium, we recapitulated the transport behavior observed in vivo, providing evidence 
that the endothelium was sufficient for the development of thermotolerance. Additionally, for 
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both single and double heat exposures, we linked the structural stability and recovery kinetics of 
the endothelium to the dynamics of the F-actin cytoskeleton. Finally, the endothelial adaptations 
suggested by these data were verified by intravital imaging studies that measured local 
transvascular transport within tumors. By observing similar heat-responsive kinetics at multiple 
biological scales – from individual cells to vessel models to the in vivo tumor environment – we 
suggest that subcellular processes in endothelial cells, particularly related to cytoskeletal 
stability, explain in part the macroscopic effects on tumor transport.  
While we focused on transvascular transport, PEG-NR-mediated heating almost certainly 
influences parameters related to overall blood flow or interstitial diffusion, two of the additional 
barriers to drug delivery in solid tumors. Indeed, studies in several models have demonstrated 
that increasing intratumoral temperature in the range of 41-43°C can modulate blood flow in a 
site- and tumor model-dependent manner.[73, 279] Modifications to blood flow or diffusion 
upon re-exposure to PEG-NR heating were not investigated here, but these may be relevant 
contributors to the effect described. For instance, because the heating regime explored is close to 
the blood coagulation threshold, local vascular damage, particularly in regions containing higher 
concentrations of PEG-NRs, may play a partial role in the initial development of transport 
resistance. In our model, however, we observed via intravital microscopy that tumor vasculature 
exposed to single or double exposures to PEG-NR heating remained functionally perfused with 
fluorescent tracer dyes for the duration of the experiments.  
While the development of thermotolerance is associated with induction of the HSR, less 
is known about the role of the HSR in governing endothelial properties in the context of cargo 
delivery. In this study, we demonstrated a role for the heat shock response by observing that 
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induction of the HSR in the endothelium temporally correlated with the development of 
thermotolerance. Furthermore, genetic deletion of Hsf1, the master regulator of the mammalian 
HSR, in the tumor vasculature was associated with improved intratumoral cargo accumulation 
following re-exposure to PEG-NR heating.   
Our focus in this study on the endothelial cell-intrinsic adaptations to heat exposure does 
not preclude other known mechanisms of vascular permeability from remaining operative in our 
model. In addition to thermally-induced cytoskeleton collapse, endothelial contraction in venules 
occurs in the presence of vasoactive agents such as histamine and bradykinin, as well as 
cytokines including tumor necrosis factor (TNF) and interferon-γ.[76]Mast cell activation in 
tumors upon PEG-NR heating may induce local release of histamine, which in turn may 
contribute to the early phases (< 1 hour) of enhanced nanoparticle delivery observed in our study. 
Additionally, direct endothelial injury, in regions with high concentrations of PEG-NRs for 
example, may induce an immediate sustained response in all tumor vessels lasting for several 
hours following PEG-NR heat exposure. Finally, vascular endothelial growth factor (VEGF) 
levels can influence the degree of vascular permeability in tumors[255], but we did not observe 
variations in VEGF between different heating regimens in this study. The kinetics of 
nanoparticle accumulation, including a 6 hour period of enhanced accumulation after heat 
exposure, suggest that PEG-NR-mediated heat exposure may be acting in concert with additional 
chemical mediators to promote vasodilation and increased vascular permeability in tumors.  
Lastly, building upon the cargo accumulation and structural data obtained from our in 
vitro and in vivo models, we could rationally design therapeutic dosing schedules involving 
PEG-NRs and chemotherapeutic agents. In particular, we observed that delivery of doxorubicin 
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liposomes was impaired after allowing thermotolerance to develop in tumors whereas therapeutic 
delivery was improved after single exposure to PEG-NR heating. In addition to its effect on the 
endothelium, heat may directly affect the tumor cells by chemosensitization mechanisms.[278] It 
is interesting to note that despite comparable therapeutic concentrations in the unheated and re-
exposure to PEG-NR heating groups, animals receiving doxorubicin liposomes in combination 
with PEG-NR heating demonstrated slower tumor growth rates, which could represent a 
synergistic interaction between heating and chemotherapy occurring within the parenchymal 
tumor cells. Nevertheless, these effects on tumor transport contributed to a stronger antitumor 
effect and improved overall survival in cohorts receiving weekly doxorubicin liposomes with 
single exposures to PEG-NR heating in comparison to cohorts receiving doxorubicin liposomes 
during re-exposure to PEG-NR heating.  
The biological mechanism linking the heat shock response to endothelial stability in the 
tumor microenvironment is intriguing, as previous reports have identified proteins regulated by 
Hsf1, such as heat shock protein Hsp27, as cytoskeletal stabilizers of F-actin stress fibers during 
thermal stress.[117-119] These studies revealed that cell lines with elevated expression of Hsp27 
had increased stability of stress fibers during multiple heat exposures. Cytoskeletal 
thermotolerance persisted for several days and contributed to the maintenance of both normal 
morphology and viability. Future studies may illuminate potential roles of Hsp27 and other 
components of the HSR in modulating transport across the endothelium.  
In summary, our findings point to a potential therapeutic consequence at the macroscale 
of an underlying endothelial cell adaptation to heating. Pharmacological strategies to render 
endothelial cells more heat-responsive while within the thermotolerance window would create 
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new opportunities to deliver chemotherapies more frequently and with improved efficacy. As 
nanomaterial-inspired approaches to enhance tumor transport in solid tumors are considered, this 
work anticipates one possible clinical challenge and suggests methods for achieving a maximal 
therapeutic response through rationally designed dosing schedules. Future studies investigating 
the mechanistic links between endothelial adaptations and therapeutic cargo accumulation in 
solid tumors will provide additional avenues for introducing nanoparticle-mediated heating into 
clinical practice. 
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CHAPTER 6. SUMMARY AND CONCLUSIONS 
6.0   Non-Invasive Imaging with Nanomaterials  
Optically-active nanomaterials offer tremendous promise for enhancing modern 
therapeutic and diagnostic approaches in oncology. This thesis demonstrates several applications 
of such nanomaterials in the context of ovarian cancer, but one could envision adaptations of 
these methods being broadly applicable to other solid malignancies as well. For example, our 
focus on using molecularly targeted single-walled carbon nanotubes (SWNTs) to guide 
cytoreduction of ovarian tumors could be extended to other disseminated peritoneal malignancies 
including colorectal and appendiceal adenocarcinomas, peritoneal mesothelioma, and fallopian 
tubal cancers. To advance this technology towards clinical implementation, a platform capable of 
providing real-time feedback to surgeons in an intraoperative setting would be desirable. Similar 
platforms have been described in human clinical trials for imaging probes in the visible 
spectrum.[27] The incorporation of tomographic imaging capabilities could further improve the 
sensitivity and accuracy of tumor detection, thereby allowing surgeons to more readily locate 
tumors during cytoreductive procedures.  
Efforts to enhance the instrumentation could be complemented by modifications to the 
imaging probe itself. Concerns about the biocompatibility and potential toxicities of both 
SWNTs and M13 bacteriophage have been raised. For SWNTs, several pre-clinical studies 
investigating the long-term fate of these nanomaterials have shed light on the potential issues that 
may arise should SWNTs be explored for human indications.[31, 211] Despite their retention in 
the liver and spleen for up to five months, no overt signs of systemic toxicity were observed in 
these studies, based on blood chemistry, histology, overall growth, and behavioral patterns.[211] 
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In our work, the use of M13 bacteriophage served at least three important roles: stabilization of 
SWNTs; targeting to ovarian tumors via expression of SPARC-binding peptide (SBP); and 
intraperitoneal retention due to a relatively large hydrodynamic radius. However, alternative 
strategies using non-biological scaffolds or nanomaterials may prove more feasible for clinical 
translation.  
As the intra- and inter-patient molecular heterogeneity of cancer is more fully cataloged 
by genomic and proteomic approaches, the ability to characterize the full compendium of 
biomarkers available for molecularly-targeted imaging will be essential for developing probes 
unique to a particular patient or even particular tumors within an individual patient. Here, the 
potential value of using a genetically-encodable scaffold like M13 becomes readily apparent. In 
the future, we might anticipate a clinical protocol as follows: a patient recently diagnosed with 
advanced ovarian cancer has a biopsy performed on one or more tumors; a genomic analysis 
reveals the unique biomarkers enriched in this patient’s tumors; over the following week, using a 
genetically-encodable scaffold such as M13, one could then rapidly prototype and construct a 
unique tumor-targeted imaging probe by expressing patient-specific peptide ligands; one could 
then investigate the utility of such tailored imaging probes compared to generic probes for both 
diagnostic and intraoperative applications. As the experience with personalized molecular 
therapies has demonstrated, the extent of tumor heterogeneity between patients and within a 
single patient will determine how feasible such personalized imaging approaches will be in the 
clinic.  
6.1   Tumor-Localized Heating with Nanomaterials 
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In addition to applications in diagnostic and intraoperative imaging, nanomaterials have 
been developed for an increasing number of therapeutic applications as well. Much research has 
gone into understanding the biological and physiological effects of heating on tumors and the 
tumor microenvironment, and thus the scientific rationale for incorporating heat-generating 
nanomaterials into existing cancer therapeutic protocols is encouraging. Ongoing efforts to 
understand the multifaceted role of the heat shock response in malignant cells continues to reveal 
how these cellular pathways facilitate survival and proliferation, as well as identify promising 
therapeutic targets.[116, 121] However, technological barriers involved in establishing localized 
heating in distributed, disease-specific sites at the anatomic scale of human patients has limited 
the utility of heating approaches in clinical practice. Focal radiofrequency and microwave 
ablation of primary and metastatic tumors in the liver are performed routinely in the clinic, but 
these procedures are often palliative rather than curative in effect.[280-282] Conversely, 
intraperitoneal heated chemotherapy represents a diffuse heating strategy, but is limited by off-
target toxicities, in part due to temperature-sensitive tissues such as the intestines. Tumor-
localizing nanomaterials including gold nanorods and novel NIR light delivery systems therefore 
provide an attractive approach to address this challenge.  
While our work highlights the feasibility of combining optically-active nanomaterials 
with implanted NIR sources, several important technological and clinical hurdles remain for its 
effective translation to humans. On the technological front, next-generation devices capable of 
providing deeper and more dispersed delivery of NIR energy at spatial scales relevant to human 
anatomy, perhaps by incorporating features enabling flexible conformity to bodily contours, 
would help advance this concept closer to the clinic. Secondly, the efficacy of such methods 
compared to or in combination with current surgical and chemotherapeutic approaches remains 
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to be established. In particular, the limited accumulation of gold nanorods in residual tumors 
where the EPR effect may be diminished or absent may represent a potential hurdle for 
demonstrating superior clinical efficacy. Delivery strategies that target non-vascular components 
of such early-stage, pre-angiogenic lesions, such as tumor-specific extracellular matrix (ECM) 
proteins or tumor cell surface antigens, may provide alternative approaches for delivering gold 
nanorods to residual tumors and micrometastases. The non-specific accumulation of gold 
nanorods in the liver and spleen poses an added challenge for tumor-specific heating in the 
peritoneal cavity; devices capable of providing customizable and programmable NIR emission 
patterns to avoid off-target heating effects in these nanoparticle-concentrating tissues may help 
broaden the therapeutic utility.  
Lastly, while we have focused on oncology applications in this work, optically-active 
nanomaterials such as plasmonic nanoparticles will likely have broader applications in medicine 
given their chemical stability, biocompatibility, and functional tuning to specific electromagnetic 
stimuli. For instance, the localized delivery of thermal energy using plasmonic nanomaterials 
may have dermatologic applications in managing common chronic ailments such as acne 
vulgaris. In addition, angiogenic vasculature has been documented not only in solid tumors, but 
in numerous inflammatory autoimmune disorders including psoriasis, rheumatoid arthritis, and 
inflammatory bowel disease. Should thermal exposure prove beneficial for treatment or 
alleviation of symptoms in any of these conditions, the angiogenic vasculature in disease-
associated lesions could provide a route for plasmonic nanomaterials to accumulate and exert 
beneficial functions.  
6.2   Enhancing Therapeutic Delivery with Nanomaterials 
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Nanomaterial-mediated heating of tumors in a specific and localized fashion is 
particularly relevant to applications of therapeutic delivery. The structural and physiological 
features of many tumors, including heterogeneous blood flow, tortuous vasculature, and dense 
stromal collagen and glycosaminoglycans, contributes to non-uniform and limited delivery of 
therapeutic compounds, which in turn contributes to incomplete tumor responses, the evolution 
of drug resistance, and disease progression. The development of nanocarrier formulations such as 
polyethylene glycol-coated liposomes to minimize renal excretion and clearance by the 
reticuloendothelial system has improved their pharmacokinetic profiles and therapeutic 
accumulation within tumors. However, the transport of these nanocarriers across the endothelium 
represents a significant bottleneck for efficient tumor penetration. Therefore, thermal 
perturbation to the tumor endothelium using optically-active nanomaterials represents a 
complementary strategy for achieving optimal responses with current chemotherapeutic agents.  
Heating must be viewed as a multifaceted modifier of the tumor microenvironment. 
While the final section of this thesis focused on the endothelial response to heating, approaches 
using gold nanorods likely influence diverse processes including immune cell trafficking, 
inflammation, cytokine signaling, interstitial pressure, blood flow, and direct effects on tumor 
cells. These processes can promote vascular changes and modify therapeutic transport properties 
within tumors independent of endothelial modifications. Going forward, it will be important to 
gain a better understanding of the effects of gold nanorod-mediated heating on these processes as 
well. For instance, we observed significant accumulation of both gold nanorods and therapeutic 
surrogates within perivascular phagocytic cells lining the tumor endothelium. If these cells are 
effectively scavenging nanomaterials and therapeutic agents that manage to cross the 
endothelium, it suggests an additional barrier for therapies to reach tumor cells. In addition, the 
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‘retention’ component of the EPR effect is commonly ascribed to defective or obstructed 
lymphatic channels; our results suggest that particle scavenging by perivascular phagocytes 
provides an alternative, complementary explanation for the observed retention of a variety of 
cargoes in tumors. Selective ablation of these cell types, perhaps by taking advantage of the 
natural accumulation of gold nanorods within this population of cells, prior to administration of 
chemotherapy may improve the overall distribution of therapy within tumors.   
One important conclusion from this thesis is that the temporal patterns between heating 
and therapeutic administration are directly relevant to the overall therapeutic efficacy. Defining 
the kinetics and temporal windows in which transport is enhanced by heating allowed for the 
rational design of therapeutic regimens. The observation of a functional resistance to heat-based 
transport across the endothelium can be linked with the development of thermotolerance and 
cytoskeletal stability within endothelial cells. However, the delayed tumor growth and improved 
survival rates we observe in single PEG-NR heat exposure versus heat re-exposures alongside 
chemotherapeutic cargo may be due to both these endothelial adaptations as well as 
thermotolerance induced in the tumor cells themselves. It will be important in future studies to 
sort out the relative contributions of these vascular and tumor adaptations, as this knowledge 
would suggest the applicability of nanomaterial-based heating regimens for other tumor types, 
sites of disease, and therapeutic cargoes.   
6.3   Nanomaterials and the Future of Medicine 
From the first documented cases in ancient civilizations to the modern era, great progress 
has been made in understanding the molecular underpinnings of cancer. This knowledge has in 
turn led to the discovery of new therapies, diagnostic tools, and surgical approaches to curtail 
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disease progression and in some cases provide cures for patients. However, modern medicine is 
far from eliminating cancer in the same way that vaccination has eradicated poliovirus or 
smallpox in the developed world. While the reasons for this are varied and complex, one 
recurring theme is that despite having an arsenal of highly potent and toxic chemotherapeutics, 
the selective delivery of such agents is fundamentally limited by the structural composition of 
solid tumors. These tumor structures – blood vessels, collagen fibers, immune cells, lymphatics, 
and more – are dynamic and capable of modulation for therapeutic benefit. Nanomaterials are 
providing an unprecedented ability to interface with the human body at the multiple scales of its 
functional elements – from vessels to cells to organelles to proteins and nucleotides – for far-
reaching applications ranging from diagnostic imaging to therapeutic drug delivery. While still 
the early days, there is considerable cause for hope that ‘going small’ with nanomaterials will 
usher in the next generation of therapeutic advances, enabling cancer patients to live longer and 
healthier lives. 
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SUPPLEMENTAL FIGURES 
 
 
 
 
 
 
 
 
 Figure S1.  Stability and pharmacokinetics of AS750 nanoparticles. Near-infrared (NIR) 
fluorescence is maintained in a dose-dependent manner in serial dilutions of AS750 incubated 
with PBS, water, and saline solutions containing 10% FBS and 50% FBS on (a) IVIS Spectrum 
and (b) LICOR Odyssey NIR imaging platforms. All measurements performed in triplicate. (c-
d) Concentration of AS750 in circulating blood for 24 hours following intravenous 
administration of 50 or 100 µL AS750. Normalized data for 50 uL AS750 shown in (d) and the 
circulation half-life is 283 minutes (for 50 µL AS750). (n = 4-5 animals per group) 
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 Figure S2. Tumor accumulation of AS750 after PEG-NR heat exposure with varying delta T. 
Tumor transport (ratio of AS750 for heated versus unheated tumors) and representative images 
of explanted tumors after PEG-NR heating with delta T ranging between 0 h to 1 week. (n = 4-
9 per group from two independent experiments, *P<0.05, one-way ANOVA and Tukey’s post-
tests.) Error bars, s.e.m. 
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 Figure S3.  Endothelial cell F-Actin dynamics during heat exposure and recovery. (a) 
Representative images of endothelial F-actin filaments prior to heat exposure and 0 – 6 hours 
following heating for the single exposure (1X) and re-exposure (2X) groups. Loss of filament 
structure after heat exposure was observed in both single heat exposure and re-exposure groups, 
with more efficient recovery of filament structure in the re-exposure group. The same fields 
were imaged at each time point to enable measurements of actin dynamics in the same cells 
over time. (b) Quantification of endothelial cells and F-actin structure. A total of 13,583 
individual cell measurements were scored for this analysis. 
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 Figure S4. Normalized F-Actin recovery in endothelial cells for single heat exposure and re-
exposure to heat. Each tracing represents the kinetics of cytoskeletal recovery for an individual 
field of view over time, normalized to its initial percentage of F-Actin+ cells prior to heat 
exposure. For re-heated cells (2X heat), the Pre-heat indicates the period between the first and 
second heat exposure. (n = 6-8 fields of view per condition)    
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 Figure S5. Temperature- and time-dependent collapse of the endothelial F-Actin cytoskeleton. 
(a) Cells were transfected with CellLight Actin-GFP to visualize actin filaments in living 
endothelial cells. Actin-GFP was present throughout the cell, with regions of concentrated 
signal along the cell borders consistent with cortical actin and focal adhesions (white arrow in 
37ºC). Cells were subjected to a temperature ramp spanning 37ºC–42.3ºC. Between 41 and 
42.3C the distributed Actin-GFP relocalized to perinuclear regions (white arrow in 42.3ºC) with 
a corresponding retraction of the cell membrane morphology was observed.  (b) Quantification 
of cells with collapsed, perinuclear F-Actin cytoskeleton pattern, normalized to cells at 37ºC. 
(n = 3,220 cells total) (c) Representative images of time-dependent cytoskeletal collapse during 
a 120 minute heat exposure. 
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 Figure S6. Size-dependent macromolecular extravasation from the unheated vasculature. 
Intravenous co-administration of (a) 10 kDa FITC-Dextran and (b) 2,000 kDa TMR-Dextran 
revealed greater extravasation of the smaller molecular-weight compound, which appeared to 
become sequestered in regions with dense collagen fibers as shown by the correspondence in 
relative intensities on line histograms computed for collagen and FITC-Dextran. Larger 
molecular weight TMR-Dextran was retained within the vessel lumen in the same field of view, 
revealing the size-dependence of extravasation in our model. 
166 
 
 
 
 
 
 
  
 
 Figure S7. Vascular endothelial growth factor (VEGF) expression in PEG-NR heated tumors. 
(a) Representative images illustrating VEGF expression in tumors either unheated or receiving 
a single exposure or re-exposure to PEG-NR heating. (b) Mean immunohistochemical staining 
intensity of large scan images of the tumor cross-sectional area. No significant differences were 
observed in VEGF intensity between the unheated, single, and repeat PEG-NR heated groups. 
(n = 4-6 tumors per group) 
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Figure S8. Visualizing PEG-NRs in the tumor microenvironment using multiphoton 
microscopy. (a) Fluorescence/luminescence intensities of PEG-NRs (yellow), FITC-Dextran 
(green), and TMR-Dextran (red) with three separate emission filter channels (425/30, 525/50, 
and 607/70 nm). An intense signal with a peak at ~400nm was observed for PEG-NRs in all 
three channels. FITC-Dextran was detected with the 525/50 filter and TMR-Dextran with the 
607/70 only. (b) Dose-dependent luminescence of PEG-NRs in each channel using 1:10 and 
1:100 dilutions from stock PEG-NR concentration (OD: 200). (c) Plot of peak intensity versus 
PEG-NR optical density with each emission filter. (d) Images of PEG-NRs, FITC-Dextran, and 
TMR-Dextran acquired by multiphoton microscopy. 
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 Figure S9. Hsf1 expression in tumor-associated vasculature following PEG-NR heating. 
Immunohistochemical staining of serial tissue sections for PECAM-1 (CD31) to label 
endothelial vessels and Hsf1, counterstained with H&E. CD31-positive endothelium in Hsf1+/+ 
models displays a strong nuclear Hsf1 staining pattern (red arrow), consistent with Hsf1 
activation and translocation to the nucleus with PEG-NR heating. CD31-positive endothelium 
in Hsf1-/- models displayed no observable Hsf1 staining pattern (red arrow). In both models, 
positive Hsf1 staining was detected in tumor parenchymal cells. 
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Figure 5.18. Temperature profiles for tumors in stromal Hsf1 accumulation study. Tumors 
receiving PEG-NR heating from each group (Hsf1+/+, Hsf1+/-, and Hsf1-/-) displayed similar 
temperature profiles during the 30 minute PEG-NR heating exposures. (2X Heat: n = 4-6 per 
group; 1X Heat: n = 3 per group) Error bars, s.e.m. 
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 Figure S11. Animal weights during PEG-NR and doxorubicin liposome therapeutic trial. 
Weights remained consistent among treatment groups during the trial period. (n = 8-9 per 
group) Error bars, s.e.m. 
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